Adverse events in people taking macrolide antibiotics versus placebo for any indication by Hansen, Malene Plejdrup et al.
Bond University
Research Repository
Adverse events in people taking macrolide antibiotics versus placebo for any indication
Hansen, Malene Plejdrup; Scott, Anna M; McCullough, Amanda; Thorning, Sarah; Aronson,
Jeffrey K; Beller, Elaine M; Glasziou, Paul P; Hoffmann, Tammy C; Clark, Justin; Del Mar,
Chris B
Published in:
Cochrane database of systematic reviews (Online)
DOI:
10.1002/14651858.CD011825.pub2
Published: 18/01/2019
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Hansen, M. P., Scott, A. M., McCullough, A., Thorning, S., Aronson, J. K., Beller, E. M., ... Del Mar, C. B. (2019).
Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane database of
systematic reviews (Online), 2019(1), CD011825. [CD011825].
https://doi.org/10.1002/14651858.CD011825.pub2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 07 May 2020
Cochrane Database of Systematic Reviews
Adverse events in people takingmacrolide antibiotics versus
placebo for any indication (Review)
Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann
TC, Clark J, Del Mar CB
Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, Clark J, Del Mar CB.
Adverse events in people taking macrolide antibiotics versus placebo for any indication.
Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD011825.
DOI: 10.1002/14651858.CD011825.pub2.
www.cochranelibrary.com
Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
12RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
21ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
23DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
47CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
265DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Cardiac disorders, Outcome 1 Cardiac disorders. . . . . . . . . . . . . . . 268
Analysis 2.1. Comparison 2 Ear and labyrinth disorders, Outcome 1 Hearing loss. . . . . . . . . . . . . 269
Analysis 3.1. Comparison 3 Gastrointestinal disorders, Outcome 1 Nausea. . . . . . . . . . . . . . . . 270
Analysis 3.2. Comparison 3 Gastrointestinal disorders, Outcome 2 Nausea - subgroup analysis by macrolide. . . . 271
Analysis 3.3. Comparison 3Gastrointestinal disorders, Outcome 3Nausea - subgroup analysis by route of administration. 273
Analysis 3.4. Comparison 3 Gastrointestinal disorders, Outcome 4 Vomiting. . . . . . . . . . . . . . . 275
Analysis 3.5. Comparison 3 Gastrointestinal disorders, Outcome 5 Vomiting - subgroup analysis by macrolide. . . 276
Analysis 3.6. Comparison 3 Gastrointestinal disorders, Outcome 6 Vomiting - subgroup analysis by route of
administration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 277
Analysis 3.7. Comparison 3 Gastrointestinal disorders, Outcome 7 Nausea and vomiting. . . . . . . . . . . 278
Analysis 3.8. Comparison 3 Gastrointestinal disorders, Outcome 8 Abdominal pain. . . . . . . . . . . . 279
Analysis 3.9. Comparison 3 Gastrointestinal disorders, Outcome 9 Abdominal pain - subgroup analysis by macrolide. 280
Analysis 3.10. Comparison 3 Gastrointestinal disorders, Outcome 10 Diarrhoea. . . . . . . . . . . . . . 282
Analysis 3.11. Comparison 3 Gastrointestinal disorders, Outcome 11 Diarrhoea - subgroup analysis by macrolide. . 284
Analysis 3.12. Comparison 3 Gastrointestinal disorders, Outcome 12 Gastrointestinal disorders not otherwise specified. 286
Analysis 3.13. Comparison 3 Gastrointestinal disorders, Outcome 13 Gastrointestinal disorders not otherwise specified -
subgroup analysis by macrolide. . . . . . . . . . . . . . . . . . . . . . . . . . . . 287
Analysis 4.1. Comparison 4 Nervous system disorders, Outcome 1 Dizziness. . . . . . . . . . . . . . . 289
Analysis 4.2. Comparison 4 Nervous system disorders, Outcome 2 Headache. . . . . . . . . . . . . . . 290
Analysis 4.3. Comparison 4 Nervous system disorders, Outcome 3 Taste disturbance. . . . . . . . . . . . 291
Analysis 5.1. Comparison 5 Skin and subcutaneous tissue disorders, Outcome 1 Itching. . . . . . . . . . . 292
Analysis 5.2. Comparison 5 Skin and subcutaneous tissue disorders, Outcome 2 Rash. . . . . . . . . . . . 293
Analysis 6.1. Comparison 6 General disorders and administration site conditions, Outcome 1 Fever. . . . . . . 294
Analysis 7.1. Comparison 7 Hepatobiliary disorders, Outcome 1 Hepatobiliary disorders. . . . . . . . . . . 295
Analysis 8.1. Comparison 8 Infections and infestations, Outcome 1 Blood infection. . . . . . . . . . . . 296
Analysis 8.2. Comparison 8 Infections and infestations, Outcome 2 Respiratory tract infections. . . . . . . . 297
Analysis 8.3. Comparison 8 Infections and infestations, Outcome 3 Skin and soft tissue infections. . . . . . . 298
Analysis 9.1. Comparison 9 Investigations, Outcome 1 Change in liver enzymes. . . . . . . . . . . . . . 299
Analysis 10.1. Comparison 10 Metabolism and nutrition disorders, Outcome 1 Appetite lost. . . . . . . . . 300
Analysis 11.1. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 1 Cough. . . . . . . 301
Analysis 11.2. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 2 Respiratory symptoms not
otherwise specified. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
Analysis 11.3. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 3 Wheezing. . . . . . 303
iAdverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.1. Comparison 12 Deaths, Outcome 1 Deaths - overall. . . . . . . . . . . . . . . . . . 304
Analysis 12.2. Comparison 12 Deaths, Outcome 2 Deaths - subgroup analysis by type of macrolide. . . . . . . 306
Analysis 12.3. Comparison 12 Deaths, Outcome 3 Deaths - subgroup analysis by route of administration. . . . . 309
311ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
323APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
326CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
326DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
327SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
327DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iiAdverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Adverse events in people taking macrolide antibiotics versus
placebo for any indication
Malene Plejdrup Hansen1, Anna M Scott2, Amanda McCullough2, Sarah Thorning3 , Jeffrey K Aronson4, Elaine M Beller2, Paul P
Glasziou2, Tammy C Hoffmann2, Justin Clark2, Chris B Del Mar2
1Center for General Practice at Aalborg University, Aalborg, Denmark. 2Centre for Research in Evidence-Based Practice (CREBP),
Bond University, Gold Coast, Australia. 3GCUH Library, Gold Coast Hospital and Health Service, Southport, Australia. 4Nuffield
Department of Primary Care Health Sciences, Oxford University, Oxford, UK
Contact address: Malene Plejdrup Hansen, Center for General Practice at Aalborg University, Fyrkildevej 7, Aalborg, 9220, Denmark.
mph@dcm.aau.dk, mpha@sund.ku.dk.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: New, published in Issue 1, 2019.
Citation: Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, Clark J, Del Mar
CB. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews
2019, Issue 1. Art. No.: CD011825. DOI: 10.1002/14651858.CD011825.pub2.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Macrolide antibiotics (macrolides) are among the most commonly prescribed antibiotics worldwide and are used for a wide range of
infections. However, macrolides also expose people to the risk of adverse events. The current understanding of adverse events is mostly
derived from observational studies, which are subject to bias because it is hard to distinguish events caused by antibiotics from events
caused by the diseases being treated. Because adverse events are treatment-specific, rather than disease-specific, it is possible to increase
the number of adverse events available for analysis by combining randomised controlled trials (RCTs) of the same treatment across
different diseases.
Objectives
To quantify the incidences of reported adverse events in people taking macrolide antibiotics compared to placebo for any indication.
Search methods
We searched theCochraneCentral Register ofControlledTrials (CENTRAL),which includes theCochraneAcuteRespiratory Infections
Group Specialised Register (2018, Issue 4); MEDLINE (Ovid, from 1946 to 8 May 2018); Embase (from 2010 to 8 May 2018);
CINAHL (from 1981 to 8 May 2018); LILACS (from 1982 to 8 May 2018); and Web of Science (from 1955 to 8 May 2018). We
searched clinical trial registries for current and completed trials (9 May 2018) and checked the reference lists of included studies and
of previous Cochrane Reviews on macrolides.
Selection criteria
We included RCTs that compared a macrolide antibiotic to placebo for any indication. We included trials using any of the four most
commonly usedmacrolide antibiotics: azithromycin, clarithromycin, erythromycin, or roxithromycin.Macrolides could be administered
by any route. Concomitant medications were permitted provided they were equally available to both treatment and comparison groups.
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Data collection and analysis
Two review authors independently extracted and collected data. We assessed the risk of bias of all included studies and the quality
of evidence for each outcome of interest. We analysed specific adverse events, deaths, and subsequent carriage of macrolide-resistant
bacteria separately. The study participant was the unit of analysis for each adverse event. Any specific adverse events that occurred in
5% or more of any group were reported. We undertook a meta-analysis when three or more included studies reported a specific adverse
event.
Main results
We included 183 studies with a total of 252,886 participants (range 40 to 190,238). The indications for macrolide antibiotics varied
greatly, with most studies using macrolides for the treatment or prevention of either acute respiratory tract infections, cardiovascular
diseases, chronic respiratory diseases, gastrointestinal conditions, or urogynaecological problems. Most trials were conducted in sec-
ondary care settings. Azithromycin and erythromycin were more commonly studied than clarithromycin and roxithromycin.
Most studies (89%) reported some adverse events or at least stated that no adverse events were observed.
Gastrointestinal adverse events were the most commonly reported type of adverse event. Compared to placebo, macrolides caused more
diarrhoea (odds ratio (OR) 1.70, 95% confidence interval (CI) 1.34 to 2.16; low-quality evidence); more abdominal pain (OR 1.66,
95% CI 1.22 to 2.26; low-quality evidence); and more nausea (OR 1.61, 95% CI 1.37 to 1.90; moderate-quality evidence). Vomiting
(OR 1.27, 95% CI 1.04 to 1.56; moderate-quality evidence) and gastrointestinal disorders not otherwise specified (NOS) (OR 2.16,
95% CI 1.56 to 3.00; moderate-quality evidence) were also reported more often in participants taking macrolides compared to placebo.
The number of additional people (absolute difference in risk) who experienced adverse events from macrolides was: gastrointestinal
disorders NOS 85/1000; diarrhoea 72/1000; abdominal pain 62/1000; nausea 47/1000; and vomiting 23/1000.
The number needed to treat for an additional harmful outcome (NNTH) ranged from12 (95%CI 8 to 23) for gastrointestinal disorders
NOS to 17 (9 to 47) for abdominal pain; 19 (12 to 33) for diarrhoea; 19 (13 to 30) for nausea; and 45 (22 to 295) for vomiting.
Therewas no clear consistent difference in gastrointestinal adverse events betweendifferent types ofmacrolides or route of administration.
Taste disturbances were reported more often by participants taking macrolide antibiotics, although there were wide confidence intervals
and moderate heterogeneity (OR 4.95, 95% CI 1.64 to 14.93; I² = 46%; low-quality evidence).
Compared with participants taking placebo, those taking macrolides experienced hearing loss more often, however only four studies
reported this outcome (OR 1.30, 95% CI 1.00 to 1.70; I² = 0%; low-quality evidence).
We did not find any evidence that macrolides causedmore cardiac disorders (OR 0.87, 95%CI 0.54 to 1.40; very low-quality evidence);
hepatobiliary disorders (OR 1.04, 95% CI 0.27 to 4.09; very low-quality evidence); or changes in liver enzymes (OR 1.56, 95% CI
0.73 to 3.37; very low-quality evidence) compared to placebo.
We did not find any evidence that appetite loss, dizziness, headache, respiratory symptoms, blood infections, skin and soft tissue
infections, itching, or rashes were reported more often by participants treated with macrolides compared to placebo.
Macrolides caused less cough (OR 0.57, 95% CI 0.40 to 0.80; moderate-quality evidence) and fewer respiratory tract infections (OR
0.70, 95% CI 0.62 to 0.80; moderate-quality evidence) compared to placebo, probably because these are not adverse events, but
rather characteristics of the indications for the antibiotics. Less fever (OR 0.73, 95% 0.54 to 1.00; moderate-quality evidence) was also
reported by participants taking macrolides compared to placebo, although these findings were non-significant.
There was no increase in mortality in participants taking macrolides compared with placebo (OR 0.96, 95% 0.87 to 1.06; I² = 11%;
low-quality evidence).
Only 24 studies (13%) provided useful data onmacrolide-resistant bacteria.Macrolide-resistant bacteria weremore commonly identified
among participants immediately after exposure to the antibiotic. However, differences in resistance thereafter were inconsistent.
Pharmaceutical companies supplied the trial medication or funding, or both, for 91 trials.
Authors’ conclusions
The macrolides as a group clearly increased rates of gastrointestinal adverse events. Most trials made at least some statement about
adverse events, such as “none were observed”. However, few trials clearly listed adverse events as outcomes, reported on the methods
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used for eliciting adverse events, or even detailed the numbers of people who experienced adverse events in both the intervention and
placebo group. This was especially true for the adverse event of bacterial resistance.
P L A I N L A N G U A G E S U M M A R Y
Adverse events in people taking macrolide antibiotics
Review question
We wanted to find out if people treated with a macrolide antibiotic experienced more adverse events than those treated with placebo.
Background
Macrolide antibiotics are a group of antibiotics that are commonly used to treat both acute and chronic infections. The four most
frequently used macrolides are: azithromycin, clarithromycin, erythromycin, and roxithromycin. People taking macrolide antibiotics
are at risk of experiencing adverse events such as nausea, diarrhoea, or rash.
Search date
We searched the literature up to May 2018.
Study characteristics
We included 183 studies with a total of 252,886 participants. Most studies were conducted in the hospital setting. Azithromycin and
erythromycin were more commonly studied than clarithromycin and roxithromycin. Most studies (89%) reported some adverse events,
or at least stated that no adverse events were observed.
Study funding sources
Drug companies supplied trial medications or funding, or both, in 91 studies. Funding sources were unclear in 59 studies.
Key results
People treated with a macrolide antibiotic experienced gastrointestinal adverse events such as nausea, vomiting, abdominal pain, and
diarrhoea more often than those treated with placebo.
Taste disturbances were reported more often by people taking macrolides than those taking a placebo. However, as very few studies
reported on these adverse events, these results should be interpreted with caution.
Hearing loss was reported more often by people taking macrolide antibiotics, however only four studies reported this outcome.
Macrolides caused less cough and fewer respiratory tract infections than placebo.
We did not find any evidence that macrolides caused more cardiac disorders, liver disorders, blood infections, skin and soft tissue
infections, changes in liver enzymes, appetite loss, dizziness, headache, respiratory symptoms, itching, or rashes than placebo.
We did not find more deaths in people treated with macrolides than in those treated with placebo.
Very limited information was available to assess if people treated with a macrolide antibiotic were at greater risk of developing resistant
bacteria than those treatedwith placebo.However, bacteria that did not respond tomacrolide antibiotics weremore commonly identified
immediately after treatment in people taking a macrolide than in those taking a placebo, but differences in resistance thereafter were
inconsistent.
Quality of the evidence
The quality of the evidence ranged from very low (cardiac disorders, change in liver enzymes, liver disorders) to low (abdominal pain,
death, diarrhoea, dizziness, hearing loss, skin and soft tissue infections, taste disturbance, wheeze) to moderate (appetite loss, blood
infection, cough, fever, headache, itching, nausea, rash, respiratory symptoms, respiratory tract infections, vomiting).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gastrointestinal adverse events in people taking macrolide antibiotics versus placebo for any indication
Patient or population: any indicat ion
Setting: any sett ing
Intervention: macrolide ant ibiot ics (azithromycin, clarithromycin, erythromycin, or roxithromycin, administered by any route)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with macrolide an-
tibiotics
Gastrointest inal disor-
ders not otherwise
specif ied
90 per 1000 176 per 1000
(133 to 228)
OR 2.16
(1.56 to 3.00)
3295
(23 RCTs)
⊕⊕⊕©
MODERATE1
NNTH = 12
Abdominal pain 114 per 1000 176 per 1000
(135 to 225)
OR 1.66
(1.22 to 2.26)
7776
(23 RCTs)
⊕⊕©©
LOW12
NNTH = 17
Diarrhoea 89 per 1000 143 per 1000
(116 to 175)
OR 1.70
(1.34 to 2.16)
23,754
(37 RCTs)
⊕⊕©©
LOW12
NNTH = 19
Nausea 107 per 1000 162 per 1000
(142 to 186)
OR 1.61
(1.37 to 1.90)
14,983
(28 RCTs)
⊕⊕⊕©
MODERATE1
NNTH = 19
Vomit ing 94 per 1000 117 per 1000
(98 to 140 )
OR 1.27
(1.04 to 1.56)
5328
(15 RCTs)
⊕⊕⊕©
MODERATE1
NNTH = 45
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NNTH: number needed to treat for an addit ional harmful outcome; OR: odds rat io; RCT : randomised controlled trial
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level due to imprecision. The outcome was reported in only a small proport ion of the included studies.
2Downgraded one level due to inconsistency. I² = 59% for abdominal pain, I² = 74% for diarrhoea.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Macrolide antibiotics, often referred to as macrolides, are among
the most commonly prescribed antibiotics worldwide. Macrolides
are often prescribed for the treatment of acute upper and lower
respiratory infections (Laopaiboon 2015; van Driel 2016), pelvic
inflammatory disease (Savaris 2017), skin and soft tissue infections
(Dalal 2017), and to eradicate Helicobacter pylori (Ford 2016).
Macrolides are frequently the drug of choice for people allergic to
penicillin.
As well as antibiotic activity, macrolides have anti-inflammatory
and immunomodulatory activity (Spagnolo 2013), and are used
to treat several chronic respiratory tract conditions such as dif-
fuse panbronchiolitis (Lin 2015), cystic fibrosis (Southern 2012),
bronchiectasis (Hnin 2015), asthma (Kew 2015), and chronic rhi-
nosinusitis (Head 2016). Long-term therapy has also been used
for decades for the treatment of acne vulgaris, using both the an-
tibacterial and anti-inflammatory effects of macrolides (Dawson
2013). There are various other indications for treatment with
macrolide antibiotics, such as gastroparesis (Enweluzo 2013), tra-
choma (Evans 2011), typhoid fever (Chandey 2012), and prevent-
ing Mycobacterium avium complex infection in people with HIV
infection (Uthman 2013). Several other indications exist or are
being tested.
Description of the intervention
Erythromycin, the first discovered macrolide antibiotic, has been
in use since the early 1950s. A series of semisynthetic compounds
were subsequently developed,with clarithromycin, roxithromycin,
and azithromycin being the most commonly used clinically
(Zuckerman 2009). The availability of these new macrolides has
substantially reduced the use of erythromycin over recent years,
as they have greater acid stability in the digestive tract, improved
oral bioavailability, longer half-lives, and diminished gastrointesti-
nal adverse reactions (Dougherty 2012). In general, macrolides
have amoderately broad spectrum of activity, which includes most
gram-positive but only selected gram-negative organisms, as well
as several bacteria responsible for intracellular infections, such as
Mycoplasma spp,Chlamydia spp, and Legionella spp. Azithromycin
has more potent antibacterial activity against gram-negative or-
ganisms than erythromycin and has an exceptional ability to ac-
cumulate inside eukaryotic cells, resulting in a favourable profile
against intracellular bacteria (Zuckerman 2009).
In the USA, macrolides are the most commonly prescribed antibi-
otics togetherwith penicillins (Hicks 2013). InEurope,macrolides
are also among the most commonly prescribed antibiotics in the
community (ECDC 2017a). However, resistance to macrolides
has become a major problem, and macrolides are no longer always
effective in treating common infections, such as community-ac-
quired pneumonia (ECDC 2017b).
How the intervention might work
Themost commonly used therapeuticmacrolides are characterised
by a 14-, 15- or 16-membered lactone ring, to which one or
more sugars are attached (Dinos 2017). Macrolides are consid-
ered as bacteriostatic antibiotics. Macrolides are protein synthesis
inhibitors, exerting their antimicrobial effect by preventing the
bacterial ribosome from translating its messenger ribonucleic acid
(RNA) into new proteins (Dougherty 2012). The immunomod-
ulatory properties of macrolides are related to the lactone ring and
are seen with the 14-membered ring macrolides (erythromycin,
clarithromycin, and roxithromycin) and the 15-membered ring
macrolides (azithromycin) (Spagnolo 2013). Although the precise
mechanism of the immunomodulatory properties is unknown, it
has been proposed that macrolides attenuate mucous hypersecre-
tion, reduce production of pro-inflammatory cytokines, and have
a suppressive effect on lymphocytic activity (Sadarangani 2015).
Taking macrolides also exposes people to the risk of various ad-
verse events. For example, gastrointestinal adverse reactions such
as abdominal pain, nausea, vomiting, and diarrhoea are common.
The mechanism underlying these reactions is believed to be partly
motilin-receptor agonism and consequently stimulation of stom-
ach and gut motility (Abu-Gharbieh 2004). Ototoxicity (hearing
loss and tinnitus) and hepatotoxicity (e.g. raised liver enzymes,
hepatitis, and intrahepatic cholestasis) have also been reported in
people taking macrolides. Headache, taste disturbances, and hae-
matologic toxicity such as leukopenia, thrombocytopenia, agranu-
locytosis, neutropenia, andneutrophilia are also seen. Allergic reac-
tions such as eosinophilia, fever, and rashes are rarely reported, as is
Candida overgrowth and pseudomembranous enterocolitis caused
by Clostridium difficile (Dougherty 2012; Zuckerman 2009).
Cardiac toxicity may complicate the use of macrolides, as
macrolide antibiotics inhibit the delayed rectifier potassium cur-
rent (IKr ), resulting in prolongation of cardiac repolarisation (pro-
longation of the QT interval), which can cause cardiac arrhyth-
mias (Owens 2006). Observational studies have shown that both
azithromycin and clarithromycin are associatedwith a significantly
increased risk of cardiovascular death (Ray 2012; Svanström 2013;
Svanström 2014). However, a Danish cohort study comparing
azithromycin with penicillin V found that the former was not
associated with a significantly increased risk, suggesting that the
increased risk of cardiovascular death observed in people taking
azithromycin compared with no antibiotic use was attributable to
underlying patient factors that led to the prescription of antibi-
otics (Svanström 2013).
Finally, there is a well-documented association between antibiotic
consumption and the development of bacterial resistance at both
the individual and community level, and people taking macrolides
are at risk of becoming carriers of resistant bacteria (Bell 2014).
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Definitions
An adverse event is an adverse outcome that occurs while a per-
son is taking a drug, but the event is not (or not necessarily) at-
tributable to the drug taken (Edwards 2000). It is recommended
that the recording of adverse events in clinical trials should distin-
guish suspected adverse effects from suspected adverse reactions
(Aronson 2013).
Adverse effects and adverse reactions have different manifestations
by which they can be recognised (Aronson 2013):
• adverse reactions are unwanted outcomes that the person
experiences and that are detected by their clinical manifestations
(symptoms or signs, or both);
• adverse effects are unwanted outcomes of which the person
is not aware; they are usually detected by laboratory tests (e.g.
biochemical, haematological, immunological, radiological,
pathological tests) or by clinical investigations (e.g.
gastrointestinal endoscopy, cardiac catheterisation).
Serious adverse events are often reported separately. These are ad-
verse events that occur at any dose and result in death or life-
threatening events; requirement for hospitalisation or prolonga-
tion of existing hospitalisation; persistent or significant disability;
or congenital anomalies, or are events that are considered medi-
cally important (ICH 2003).
Why it is important to do this review
The current understanding of adverse events in people taking an-
tibiotics is largely derived from observational studies, in which es-
timatesmay be biased because it is hard to distinguish adverse drug
reactions from disease-related symptoms. One way of addressing
this problem is to investigate common adverse events encountered
in randomised, placebo-controlled trials of antibiotics. This study
design controls for disease-related symptoms, allowing for better
quantification of antibiotic-related adverse events.
However, most randomised controlled trials are set up to demon-
strate the benefits of antibiotic treatment for specific infections,
and these studies are often not powered to quantify adverse events
(Vandenbroucke 2004). The Cochrane Handbook for Systematic
Reviews of Interventions states that “many adverse events are too
uncommon or too long-term to be observed within randomised
trials” (Higgins 2011). As a consequence, a typical systematic re-
view of controlled trials focusing on a specific indication may not
provide sufficient evidence on the adverse events profile of an in-
tervention, for example antibiotics (Zorzela 2014). Because ad-
verse events are not disease-specific (with a very few exceptions,
e.g. ampicillin rash in people with Epstein-Barr virus acute in-
fectious mononucleosis), it is possible to ’borrow strength’ from
studies using the same intervention for different diseases to better
estimate adverse events (Chen 2014).
We undertook this review to quantify adverse events in people
using macrolide antibiotics, independently of the indication or
effects of the treatments. The intent is to support clinicians and
patients in evaluating harms as well as benefits in the choice of
management when antibiotics are contemplated.
O B J E C T I V E S
To quantify the incidences of reported adverse events in people
taking macrolide antibiotics compared to placebo for any indica-
tion.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised, placebo-controlled trials of any of the
four most commonly used macrolide antibiotics: azithromycin,
clarithromycin, erythromycin, or roxithromycin. We included tri-
als with more than two intervention arms if we could identify a
macrolide arm and a placebo arm.
We excluded purely pharmacodynamic studies and purely phar-
macokinetic studies, unless they also reported clinical measure-
ments. We also excluded studies in which fewer than 20 partici-
pants were randomised to each arm.
Types of participants
We included individuals of all ages taking a macrolide antibiotic
for any indication.
Types of interventions
We included trials of macrolides delivered by any route, including
oral, topical, intravenous, and intramuscular. Use of concomitant
medications was permitted.
Types of outcome measures
Primary outcomes
1. Any reported adverse event that occurred in 5% or more of
any group (Zarin 2016).
2. Death.
3. Subsequent carriage of macrolide-resistant bacteria.
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Secondary outcomes
None.
Search methods for identification of studies
Electronic searches
We searched the following databases up to 8 May 2018:
• the Cochrane Central Register of Controlled Trials, which
contains the Cochrane Acute Respiratory Infections Group
Specialised Register (CENTRAL; 2018, Issue 4) in the Cochrane
Library using the strategy in Appendix 1;
• MEDLINE (Ovid) (from 1946 to 8 May 2018) using the
search strategy in Appendix 1;
• Embase (Elsevier) (from 2010 to 8 May 2018) using the
search strategy in Appendix 2;
• CINAHL (EBSCO) (Cumulative Index to Nursing and
Allied Health Literature) (from 1981 to 8 May 2018) using the
search strategy in Appendix 3;
• LILACS (BIREME) (Latin American and Caribbean
Health Science Information database) (from 1982 to 8 May
2018) using the search strategy in Appendix 4; and
• Web of Science (Clarivate Analytics) (from 1955 to 8 May
2018) using the search strategy in Appendix 5.
We used the search strategy described in Appendix 1 to search
MEDLINE and CENTRAL. We combined the search strategy
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision); Ovid format (Higgins 2011).
We adapted the search strategy to search Embase (Appendix 2),
CINAHL (Appendix 3), LILACS (Appendix 4), and Web of Sci-
ence (Appendix 5).
We searched the following trial registries on 9 May 2018:
• World Health Organization (WHO) International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( clinicaltrials.gov).
We did not restrict the results by language or publication status
(published, unpublished, in press, or in progress).
Searching other resources
We checked the reference lists of all primary studies for additional
trials by performing a backward citation (cited references) search in
Web of Science.We adapted theCochraneHighly Sensitive Search
Strategy for identifying randomised trials in MEDLINE: sensitiv-
ity- and precision-maximising version (2008 revision); Ovid for-
mat, Higgins 2011, for use in EndNote 2016 on these results,
before they were screened.
We searched the Cochrane Library (title, abstract, and keyword
fields) using the following terms: macrolide, azithromycin, clar-
ithromycin, erythromycin, or roxithromycin, to exploit the refer-
ence lists of previous Cochrane Reviews on macrolide antibiotics.
Data collection and analysis
Selection of studies
Two review authors (MPH and ST, AMcC, or AMS) indepen-
dently screened the titles and abstracts of all studies identified by
the searches for potential relevance. We retrieved full-text copies
of all potentially relevant articles for full-text evaluation. Any dis-
putes were resolved by consensus or by consulting a third review
author (CDM).
We collated multiple reports of the same study to ensure that
each study, rather than each report, was analysed. The process for
selecting studies is detailed in a PRISMA flow chart (Figure 1)
(Moher 2009).
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Figure 1. PRISMA study flow diagram.
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Data extraction and management
Two review authors (MPH and AMcC or AMS) independently
extracted data from the included studies using a standardised ex-
traction form.
We extracted the following information.
• Trial characteristics and methodological quality: year of
publication, study design, number of participants, study setting,
information for assessing risk of bias.
• Participant characteristics: age, sex, concomitant
medications if relevant.
• Information about the intervention: indication for
treatment, type of macrolide, route of administration, dose of
treatment, duration of treatment, total treatment dose.
• Outcome measures: whether adverse events were stated as
an outcome, any reported adverse events (including death and
data on antimicrobial resistance), method of eliciting adverse
events.
Assessment of risk of bias in included studies
Two review authors (MPH and AMcC or AMS) independently
assessed the risks of common biases for each of the included stud-
ies using the ’Risk of bias’ tool described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). Any
disagreements were resolved by discussion or by consulting a third
review author (CDM). We assessed risk of bias according to the
following seven domains:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias); and
• other sources of bias.
We assessed each domain as having a high, low, or unclear risk of
bias and provided a justification for our judgement. Furthermore,
we summarised the ’Risk of bias’ judgements across different stud-
ies for each of the seven domains.
Measures of treatment effect
We expressed outcome measures as odds ratios (OR) with ac-
companying 95% confidence intervals (CI). When appropriate,
odds ratios were also expressed as absolute risk differences (ARDs),
based on average rates of adverse events in the control groups, and
converted to number needed to treat for an additional harmful
outcome (NNTH) to interpret the results from the meta-analysis.
We calculated NNTH in the following manner:
NNTH = (PEER*(OR - 1)) + 1/(PEER*(OR - 1)*(1 - PEER))
(where PEER = patient expected event rate (i.e. the rate of events
in the control population), OR = odds ratio).
Unit of analysis issues
For each of the specific adverse events, including death, the par-
ticipant was the unit of analysis. We used participants and iso-
lates (colonies of bacteria grown microbiologically that arise from
one or few individual bacteria) as units of analysis when report-
ing subsequent carriage of macrolide-resistant bacteria. Reported
data from the included large cluster-randomised controlled trial
were adjusted for clustering by the trial authors and no additional
adjustments were performed (Keenan 2018).
Dealing with missing data
We contacted trial authors when adverse events were incompletely
reported and contact details (an e-mail address) were provided in
the publication. In case of no reply or message undeliverable, we
did not make a second attempt to contact authors. We did not
contact authors if a study provided no information on adverse
events.
Assessment of heterogeneity
We used the I² statistic to measure statistical heterogeneity, as
recommended in theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Assessment of reporting biases
Outcome reporting bias is particularly important for adverse
events, as they are often not the primary outcome. For each study,
we searched for information about whether adverse events was pre-
defined as an outcome, the method of eliciting adverse events, and
whether adverse events were reported or not. This information is
provided in Characteristics of included studies.
Data synthesis
Classification of adverse events
Some adverse events are reported under different names but are
subsets of the same phenomenon. To address this, we classified
the adverse events using the Medical Dictionary for Regulatory
Activities (MedDRA), developed by the International Council for
HarmonisationofTechnical Requirements for Pharmaceuticals for
Human Use (MedDRA 2018). MedDRA is a clinically validated
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and standardised hierarchy consisting of five levels, arranged from
very specific to very general:
1. System Organ Class, e.g. gastrointestinal disorders;
2. High Level Group Term, e.g. gastrointestinal signs and
symptoms;
3. High Level Term, e.g. nausea and vomiting symptoms;
4. Preferred Term, e.g. nausea;
5. Lowest Level Term, e.g. feeling queasy.
One review author (MPH) classified reported individual adverse
events at the most specific level by means of the MedDRA Web-
Based Browser tool (MedDRA 2018), and then grouped them
under the primary SystemOrganClass, according to theMedDRA
coding system. There are 27 System Organ Classes, as follows.
1. Blood and lymphatic system disorders.
2. Cardiac disorders.
3. Congenital, familial, and genetic disorders.
4. Ear and labyrinth disorders.
5. Endocrine disorders.
6. Eye disorders.
7. Gastrointestinal disorders.
8. General disorders and administration site conditions.
9. Hepatobiliary disorders.
10. Immune system disorders.
11. Infections and infestations.
12. Injury, poisoning, and procedural complications.
13. Investigations.
14. Metabolism and nutrition disorders.
15. Musculoskeletal and connective tissue disorders.
16. Neoplasms benign, malignant, and unspecified.
17. Nervous system disorders.
18. Pregnancy, puerperium, and perinatal conditions.
19. Product issues.
20. Psychiatric disorders.
21. Renal and urinary disorders.
22. Reproductive system and breast disorders.
23. Respiratory, thoracic, and mediastinal disorders.
24. Skin and subcutaneous tissue disorders.
25. Social circumstances.
26. Surgical and medical procedures.
27. Vascular disorders.
Two review authors (MPH and AMcC or AMS) then attempted to
reclassify the adverse events to a lower common hierarchical level
within each System Organ Class to enable comparisons between
studies. Adverse events were most often identified at the Preferred
Term level (e.g. nausea or vomiting). However, some studies only
reported at the High Level Term level (e.g. nausea and vomiting
symptoms) or Lowest Level Term level (e.g. gastrointestinal disor-
der NOS).
We needed to manage a long list of infrequently reported adverse
events that were unlikely to be clinically significant, and accord-
ingly set a threshold of ≥ 5% to analyse (Zarin 2016). However,
because it is possible that less frequent adverse events might be
important, we extracted these to facilitate future analysis by inter-
ested investigators (Hansen 2018a; Hansen 2018b).
Analysis
When only one or two studies reported a specific adverse event, at
anyMedDRA level, we reported it simply as a percentage of events
in each group, and calculated P values (reported as rarely reported
adverse events). We undertook a meta-analysis when ≥ 3 studies
reported a specific adverse event. If studies reported more than
one type of adverse event (e.g. sore throat and nasal congestion)
within the same analysis (e.g. respiratory symptoms not otherwise
specified), we included only the adverse event with the largest
number of events in the meta-analysis to avoid the risk of double-
counting. Haemoptysis is included in the meta-analysis of cough,
as both types of adverse events were coded in the same adverse
event group (coughing and associated symptoms).
When studies reported on deaths for several follow-up periods,
we used data from the follow-up period that was mainly in line
with the maximum follow-up period used in most of the included
studies for themeta-analysis.WeusedReviewManager 5 to analyse
data (ReviewManager 2014). Aswe expected heterogeneity among
the included studies, we used random-effectsmeta-analysismodels
(Higgins 2011).
Some studies reported the adverse event data of macrolide resis-
tance by isolates rather than by participants, and we modified the
protocol to include those data. Whether the data were related to
participants or isolates (which include studies limiting isolates to
resistant streptococci), we have reported on the absolute differ-
ence, in percentage:
([absolute value of difference in macrolide-resistant bacteria after
treatment] - [absolute value of difference in macrolide-resistant
bacteria before treatment]
and the relative difference:
[difference in macrolide-resistant bacteria after treatment] / [dif-
ference in macrolide-resistant bacteria before treatment]).
’Summary of findings’ table and GRADE
We created two ‘Summary of findings’ tables. Summary of findings
for the main comparison presents the following gastrointesti-
nal outcomes: not otherwise specified gastrointestinal disorders,
abdominal pain, diarrhoea, nausea, and vomiting. Summary of
findings 2 presents other outcomes: cardiac disorders, hearing loss,
taste disturbance, hepatobiliary disorders, and deaths. We used
GRADE to rate the overall quality of evidence of each of the out-
comes as either high,moderate, low, or very low, employing the five
GRADE considerations (study limitations, consistency of effect,
indirectness, imprecision, and publication bias) (Atkins 2004).We
used methods and recommendations described in Section 8.5 and
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Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), employing GRADEpro GDT soft-
ware (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
We decided a priori that if sufficient data were available we would
undertake subgroup analyses according to:
1. age groups (children, adults, and elderly people);
2. type of macrolide (erythromycin, clarithromycin,
roxithromycin, or azithromycin);
3. route of administration (topical, oral, intramuscular,
intravenous);
4. antibiotic dosage (dose and frequency of administration);
and
5. duration of therapy.
At least three studies were required for a subgroup analysis.
Sensitivity analysis
We decided a priori to perform sensitivity analyses by excluding
studies with missing data on the outcome (adverse events). How-
ever, as no studies had more than 20% of randomised participants
lost to follow-up, none of the studies that provided data for the
meta-analyses were assessed as being at high risk of attrition bias.
R E S U L T S
Description of studies
We presented information about the studies in Characteristics
of included studies, Characteristics of excluded studies, and
Characteristics of ongoing studies.
Results of the search
We retrieved a total of 8882 records from our database searches
(electronic searches, n = 8663; trial registry searches, n = 219). We
removed 1338 duplicates and an additional 2360 records when
the randomised controlled trial (RCT) filter was applied to the
backward citation searches.
We excluded4508 records based on title and abstract screening and
discarded 195 trial registrations as they were clearly not relevant
or there was little likelihood of a subsequent publication.
We excluded another four records based on incorrect citations, and
one PhD thesis due to no author reply. We assessed the remaining
452 full-text articles for eligibility and excluded 129 full-text ar-
ticles, of which we have reported the reasons for exclusion for 17
key studies; see the Characteristics of excluded studies table. We
included 312 full-text records, comprising 183 studies (Figure 1).
A few of the included trials were published in languages other than
English: Chinese (Wang 2012; Yang 2013), Farsi (Akhyani 2003;
Paknejad 2010), German (Rozman 1984), Korean (Kim 2004),
and Spanish (Garcia-Burguillo 1996).
We identified 64 Cochrane Reviews on macrolide antibiotics.
However, we did not include any additional studies based on our
exploration of the reference lists of these Cochrane Reviews.
Included studies
We included 183 randomised placebo-controlled trials involving
a total of 252,886 participants.
Participants and settings
A total of 30 trials included only children aged up to 18 years; 61
trials included adults aged 18 to 64 years, and two trials included
elderly people aged over 65 years; 16 trials included both children
and adults; 64 trials included both adults and elderly people; three
trials included children, adults, and elderly people; and seven trials
did not specify the ages of participants.
Macrolide antibiotics were used for treatment or prevention of the
following indications.
• Acute respiratory infections (21 studies) (Bacharier 2015;
Beigelman 2015; Brickfield 1986; Dunlay 1987; Grob 1981;
Halperin 1999; Haye 1998; Hyde 2001; Kaiser 2001; King
1996; Kneyber 2008; Lildholdt 2003; Mandhane 2017;
McCallum 2013; McCallum 2015; McDonald 1985; Moller
1990; Petersen 1997; Pinto 2012; Schalen 1993; Van Delden
2012).
• Arthritis (4 studies) (Kvien 2004; Ogrendik 2007;
Ogrendik 2011; Sadreddini 2009).
• Bacterial carriage (3 studies) (Malhotra-Kumar 2007a;
Malhotra-Kumar 2007b; Wilson 1977; Wilson 1979).
• Cancer (2 studies) (Barkhordar 2018; Bergeron 2017).
• Cardiovascular diseases (24 studies) (Anderson 1999; Berg
2005; Cercek 2003; Grayston 2005; Gupta 1997; Gurfinkel
1999; Hillis 2004; Ikeoka 2007; Jackson 1999; Jespersen 2006;
Joensen 2008; Kaehler 2005; Karlsson 2009; Kim 2004;
Leowattana 2001; Neumann 2001; O’Connor 2003; Parchure
2002; Sander 2002; Sinisalo 2002; Vainas 2005; Vammen 2001;
Wiesli 2002; Zahn 2003).
• Chronic respiratory diseases (39 studies) (Albert 2011;
Altenburg 2013; Amali 2015; Anthony 2014; Ballard 2011;
Banerjee 2004; Berkhof 2013; Black 2001; Branden 2004; Brill
2015; Brusselle 2013; Cameron 2013; Clement 2006; Corris
2015; Fonseca-Aten 2006; Gibson 2017; Hahn 2006; Hahn
2012; Haxel 2015; Hodgson 2016; Johnston 2016; Kostadima
2004; Kraft 2002; Ozdemir 2011; Saiman 2003; Saiman 2010;
Seemungal 2008; Serisier 2013; Shafuddin 2015; Simpson 2008;
Uzun 2014; Valery 2013; Veskitkul 2017; Videler 2011; Vos
2011; Wallwork 2006; Wang 2012; Wolter 2002; Wong 2012).
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• Dental problems (15 studies) (Agarwal 2012; Agarwal
2017; Andere 2017; Bajaj 2012; Botero 2013; Bystedt 1980;
Kathariya 2014; Martande 2015; Martande 2016; Paknejad
2010; Pradeep 2011; Pradeep 2013; Sampaio 2011; Shanson
1985; Smith 2002).
• Eye infections (Yang 2013).
• Gastrointestinal conditions (31 studies) (Altraif 2011; Aly
2007; Andremont 1981; Bala 2008; Berne 2002; Bonacini 1993;
Carbonell 2006; Curry 2004; Czarnetzki 2015; Ehsani 2013;
Frossard 2002; Gharpure 2001; Gokmen 2012; Jun 2014;
Kalliafas 1996; Lanza 1998; Mandal 1984; Mathai 2007; Memis
2002; Narchi 1993; Ng 2007; Nuntnarumit 2006; Oei 2001;
Patole 2000; Peterson 1996; Reignier 2002; Robins-Browne
1983; Roy 1998; Sirinavin 2003; Smith 2000; Yeo 1993).
• Infections associated with HIV infection (5 studies)
(Currier 2000; El-Sadr 2000; Jablonowski 1997; Oldfield 1998;
Pierce 1996).
• Improvement of immune responses (Grassly 2016).
• Malaria (3 studies) (Andersen 1998; Heppner 2005; Taylor
1999).
• Prevention of childhood mortality (Keenan 2018).
• Sepsis (2 studies) (Giamarellos-Bourboulis 2008;
Giamarellos-Bourboulis 2014).
• Skin or soft tissue complaints (9 studies) (Ahmed 2014;
Akhyani 2003; Amer 2006; Amland 1995; Avci 2013; Glass
1999; Pandhi 2014; Rozman 1984; Schwameis 2017)
• Urogynaecological problems (22 studies) (Alger 1991;
Eschenbach 1991; Garcia-Burguillo 1996; Hooton 1990; Kaul
2004; Kenyon 2001a; Kenyon 2001b; Klebanoff 1995; Martin
1997; McCormack 1987; McGregor 1986; McGregor 1990;
McGregor 1991; Mercer 1992; Paul 1998; Rajaei 2006; Roca
2016a; Sorensen 1992; Tita 2016; Van den Broek 2009; Walsh
1998; Winkler 1988).
Of the 183 included studies, 129 were conducted in secondary
care, nine in primary care (Brickfield 1986; Dunlay 1987;
Grob 1981; Hahn 2006; Hahn 2012; Haye 1998; King 1996;
McDonald 1985; Petersen 1997), two in both primary and sec-
ondary care (Brill 2015; Johnston 2016), and 14 in dental care
(Agarwal 2012; Agarwal 2017; Andere 2017; Bajaj 2012; Botero
2013; Kathariya 2014;Martande 2015;Martande 2016; Paknejad
2010; Pradeep 2011; Pradeep 2013; Sampaio 2011; Shanson
1985; Smith 2002). Another 22 trials were conducted in various
settings, including: villages in sub-Saharan Africa (Andersen 1998;
Keenan 2018), among residents travelling to Mexico (Andremont
1981), centres or clinics not specified (Bacharier 2015; Hodgson
2016; Jablonowski 1997; Lanza 1998; O’Connor 2003; Pierce
1996; Walsh 1998), antenatal clinics in Southern Malawi (Van
den Broek 2009), university-based outpatient clinics (Currier
2000), households (Halperin 1999), remote forest and scrub-cov-
ered foothills in Thailand (Heppner 2005), an urban slum area
of Nairobi in Kenya (Kaul 2004), universities (Malhotra-Kumar
2007a; Malhotra-Kumar 2007b; Wilson 1977; Wilson 1979),
food factories in Thailand (Sirinavin 2003), soldiers and civilians
in Indonesia (Taylor 1999), community clinics in Australia and
a tertiary paediatric hospital in New Zealand (Valery 2013), and
infants living in the Vellore district in India (Grassly 2016). The
setting was not specified clearly in seven trials (Cameron 2013;
El-Sadr 2000; Jackson 1999; Kraft 2002; Oldfield 1998; Rozman
1984; Schwameis 2017).
Interventions
Azithromycin was used as one of the treatment arms in 80 studies,
erythromycin in 66 studies, clarithromycin in 23 studies, and rox-
ithromycin in 14 studies. Five studies had two intervention arms,
both using one of the four includedmacrolides. In Andersen 1998,
one arm received azithromycin 250 mg per day for 10 weeks and
one arm received azithromycin 1000 mg per week for 10 weeks. In
Gupta 1997, both armswere treatedwith azithromycin for three or
six days. Kostadima 2004 had two intervention arms, both treated
with clarithromycin 250 mg, one twice, and one three times a
day. In the study by Malhotra-Kumar and colleagues, one arm
received azithromycin 500 mg for three days (Malhotra-Kumar
2007a), and the other arm received clarithromycin 1000 mg for
seven days (Malhotra-Kumar 2007b). In McCormack 1987, the
form of erythromycinwas changed from the estolate to the stearate
about halfway through the study after reports of liver damage due
to the former appeared; these two treatment arms were reported
separately.
Some studies specified the form of erythromycin used: 12 studies
used erythromycin base, 3 erythromycin estolate, 10 studies ery-
thromycin ethylsuccinate, 11 studies erythromycin lactobionate,
and 5 studies erythromycin stearate.
Macrolides were delivered orally in 154 studies, intravenously
in 20 studies (Altraif 2011; Ballard 2011; Berne 2002;
Bonacini 1993; Carbonell 2006; Czarnetzki 2015; Ehsani 2013;
Frossard 2002; Gharpure 2001; Giamarellos-Bourboulis 2008;
Giamarellos-Bourboulis 2014; Jun 2014; Kalliafas 1996; Narchi
1993; Ozdemir 2011; Reignier 2002; Smith 2000; Tita 2016; Van
Delden 2012; Yeo 1993), and topically in nine studies (Agarwal
2012; Agarwal 2017; Bajaj 2012; Glass 1999; Kathariya 2014;
Pradeep 2013;Rozman 1984; Schwameis 2017; Yang2013).None
of the included studies administered the macrolides intramuscu-
larly.
In 131 of the 183 studies, the study participants used concomitant
medications. One study advised participants not to use concomi-
tant medications (Avci 2013). In 51 studies, the authors did not
clearly specify if concomitant medications were permitted.
Outcomes
Adverse events were reported in 146 studies. Three of these stud-
ies reported only the number of adverse events, rather than the
numbers of participants with adverse events (Andersen 1998;
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Bergeron 2017; Brusselle 2013), and were therefore excluded from
the analyses to avoid the potential problem of double-counting
of events. In 17 studies, the authors stated that no adverse events
were observed or reported (Agarwal 2012; Agarwal 2017; Altraif
2011; Andremont 1981; Bajaj 2012; Bala 2008; Carbonell 2006;
Kathariya 2014; Mandal 1984; Martande 2016; Mathai 2007;
McCallum 2013; Memis 2002; Moller 1990; Oei 2001; Vammen
2001; Veskitkul 2017). Twenty studies did not report adverse
events (excluding data on death or resistant bacteria, or both) (Berg
2005; Ehsani 2013; Fonseca-Aten 2006; Garcia-Burguillo 1996;
Grob 1981; Jablonowski 1997; Kalliafas 1996; Kneyber 2008;
Leowattana 2001; Neumann 2001; Paknejad 2010; Parchure
2002; Paul 1998; Pinto 2012; Robins-Browne 1983; Roy 1998;
Sander 2002; Schalen 1993; Wang 2012; Winkler 1988).
A few studies provided additional information on adverse events
(Ahmed 2014; Cameron 2013; Gibson 2017; Grassly 2016;
Pradeep 2011; Roca 2016a), and when authors were contacted by
e-mail (Ahmed 2016 [pers comm]; Grassly 2017 [pers comm];
Kathariya 2016 [pers comm]; Powell 2018 [pers comm]; Roca
2016b [pers comm]; Thomsen 2016 [pers comm]).
Thirteen studies reported on participants with subsequent carriage
of macrolide-resistant bacteria; eight studies reported isolates with
macrolide-resistant bacteria; and three studies specifically reported
the proportion of macrolide-resistant streptococci. Fifty-two stud-
ies reported on deaths.
Study funding sources
Funding sources of the 183 included studies are reported in the
Characteristics of included studies table. Pharmaceutical compa-
nies supplied the trial medication, funding, or both for 91 of the
included studies; 33 studies were non-industry funded; and the
funding sources were unclear in 59 studies.
Excluded studies
Weexcluded129 studies.However, for brevity, we elected to report
only 17 key studies. See the Characteristics of excluded studies
table. We excluded these 17 studies for the following reasons.
• Cross-over trial, reporting adverse events only after cross-
over (Ferahbas 2004).
• Only reported on pharmacodynamic outcomes
(microbiome) (Doan 2017; Parker 2017).
• Not placebo-controlled (Pazoki-Toroudi 2010; Rasi 2008;
Weber 1993).
• Not possible to identify if participants were treated with
clarithromycin or azithromycin (Figueiredo-Mello 2018).
• Participants randomised to receive both a macrolide
antibiotic and metronidazole (Aboud 2009).
• Participants received erythromycin on top of placebo if feed
failure (Makkar 2016).
• Sample size too small (Ballard 2007; Gong 2014; Nielsen
2016).
• The unit of randomisation was asthma episodes rather than
participants (Stokholm 2016).
• Quasi-randomised or non-randomised design (Batieha
2002; Sharma 2000; Yamamoto 1992; Zhang 2006).
Ongoing studies
We identified six ongoing studies (Chang 2012; Gonzalez-
Martinez 2017; Kobbernagel 2016; Mosquera 2016; Pavlinac
2017; Vermeersch 2016). The macrolide used in all six studies was
azithromycin.
Studies awaiting classification
Twenty-four trials identified by the clinical trial registry searches
are awaiting classification and are listed in the Characteristics
of studies awaiting classification table. We identified five ab-
stracts based on four trials in the database searches (Dicko 2016;
Gregersen 2017; Milito 2017; Ramsey 2017), however we were
not able to locate peer-reviewed publications of these trials.
Risk of bias in included studies
We assessed all 183 included studies using the six domains in the
Cochrane ‘Risk of bias’ tool as described in theCochraneHandbook
for Systematic Review of Interventions (Higgins 2011). Details of
the ’Risk of bias’ assessments are provided in Characteristics of
included studies and summarised in Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We assessed 119 studies, most of which used either computer-
generated randomisation or random number tables, as at low risk
of bias. We assessed one study as at high risk of bias because ran-
domisation was by lottery (Ahmed 2014). We assessed 63 studies
that did not provide detailed information about the randomisa-
tion method used as at unclear risk of bias.
Allocation concealment
We assessed 112 studies as at low risk of bias for allocation conceal-
ment. Most studies used central allocation, but some also used se-
quentially numbered, identical drug containers, or sealed, opaque
envelopes. We assessed studies with either insufficient or no infor-
mation about allocation concealment as at unclear risk of bias.
Blinding
Blinding of participants and personnel
We assessed three studies as at high risk of bias for this domain
(Brill 2015;Wilson 1977;Wilson 1979).Wilson 1977 andWilson
1979 did not use an identical placebo. In the four-armed study
by Brill 2015, the placebo was given as one tablet daily, while the
macrolide treatment was taken three times per week.
We assessed 34 studies as at unclear risk of bias because the placebo
was not described in sufficient detail to judge whether blinding of
participants and personnel was sufficient. The remaining studies
used an identical placebo and were assessed as at low risk of bias.
Blinding of outcome assessment
We assessed 158 studies as at low risk of bias for blinding of out-
come assessment. We assessed studies as at low risk of bias if blind-
ing of all possible outcome assessors was judged sufficient; if stud-
ies only reported objective outcomes (death, data on antimicrobial
resistance); or if no relevant outcomes were reported. We assessed
17 studies at unclear risk of bias because it was unclear if study
participants, clinicians, and other possible outcome assessors were
blinded.
Incomplete outcome data
We assessed one study as at high risk of bias for incomplete data
reporting because over 20% of study participants were excluded
from the final analysis without providing reasons (Paul 1998). We
assessed 15 studies as at unclear risk of bias. We assessed most
studies as at low risk of bias, with noor limited participant dropout,
or with reasons for dropouts provided.
Selective reporting
We assessed 56 studies that either did not report adverse events
or where reporting was incomplete as at high risk of selective re-
porting. We assessed 42 studies as at unclear risk of bias for this
domain. We judged 85 studies, all of which reported on adverse
events and most of which reported on the method for eliciting
adverse events, as at low risk of bias.
Other potential sources of bias
Weassessed 174 studies as at low risk of other bias.We assessednine
studies as at unclear risk of bias: four had an uneven distribution of
participants allocated to the trial arms (Amali 2015; Lanza 1998;
Peterson 1996; Taylor 1999), and five had baseline imbalances
(Frossard 2002; Gokmen 2012; Gurfinkel 1999; Mathai 2007;
Wolter 2002).
Effects of interventions
See: Summary of findings for the main comparison
Gastrointestinal adverse events in people taking macrolide
antibiotics versus placebo for any indication; Summary of
findings 2 Other adverse events in people taking macrolide
antibiotics versus placebo for any indication
See Summary of findings for the main comparison for adverse
events in people taking macrolide antibiotics versus placebo for
any indication.
Primary outcomes
1. Any reported adverse event that occurred in 5% or more
of any group
Sufficient numbers of adverse events were reported to perform
meta-analyses for 11 of the 27 System Organ Classes.
i. Cardiac disorders
Seven studies reported cardiac disorders as adverse events, in-
volving 1715 participants with 115 events (Albert 2011; Berkhof
2013; Gupta 1997; Kim 2004; Smith 2000; Vammen 2001; Vos
2011). The cardiovascular adverse events reported were arrhyth-
mias, acute coronary syndrome, and not specified cardiac events.
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We found no difference in cardiac disorders in participants tak-
ing macrolide antibiotics compared to participants taking placebo
(odds ratio (OR) 0.87, 95% confidence interval (CI) 0.54 to 1.40;
I² = 9%; Analysis 1.1). We judged the evidence for cardiac disor-
ders to be of very low-quality due to high risk of reporting bias
and imprecision.
ii. Ear and labyrinth disorders
Hearing loss was reported in four studies, involving 1369 par-
ticipants with 284 events (Albert 2011; Altenburg 2013; Hahn
2012; Saiman 2003). None of the studies explicitly stated if they
reported on short- or long-term hearing loss. Participants taking
macrolides experienced hearing loss more often than those taking
placebo (OR 1.30, 95% CI 1.00 to 1.70; I² = 0%; Analysis 2.1),
although the findings are non-significant. The absolute risk dif-
ference (ARD) of experiencing hearing loss was 42/1000 people,
and the number of people treated with macrolides for one to ex-
perience the adverse event of hearing loss (number needed to treat
for an additional harmful outcome (NNTH)) was 24 (95% CI
11 to infinity). We judged the evidence for hearing loss as of low-
quality due to high risk of reporting bias and imprecision.
iii. Gastrointestinal disorders
Nausea was an outcome in 28 studies (14,983 participants), and
vomiting an outcome of 15 studies (5328 participants). Partici-
pants taking macrolides had more nausea (OR 1.61, 95% CI 1.37
to 1.90; I² = 35%; Analysis 3.1) and vomiting (OR 1.27, 95%
CI 1.04 to 1.56; I² = 6%; Analysis 3.4) than participants taking
placebo. When reported together, macrolides were not associated
with nausea and vomiting (High Level Term) (OR 0.92, 95% CI
0.60 to 1.42; I² = 0%; Analysis 3.7).
Compared to those taking placebo, participants taking amacrolide
antibiotic more often experienced abdominal pain (OR1.66, 95%
CI 1.22 to 2.26; I² = 58%; Analysis 3.8); diarrhoea (OR1.70, 95%
CI 1.34 to 2.16; I² = 74%; Analysis 3.10); and gastrointestinal
disorders not otherwise specified (NOS) (when gastrointestinal
disorders were reported together) (OR 2.16, 95%CI 1.56 to 3.00;
I² = 42%; Analysis 3.12).
The number of additional people who experienced adverse events
frommacrolides compared to placebo (ARD) was: gastrointestinal
disorders NOS: 85/1000; diarrhoea: 72/1000; abdominal pain:
62/1000; nausea: 47/1000; and vomiting: 23/1000. The NNTH
ranged from 12 (95% CI 8 to 23) for gastrointestinal disorders
NOS to 17 (9 to 47) for abdominal pain; 19 (12 to 33) for diar-
rhoea; 19 (13 to 30) for nausea; and 45 (22 to 295) for vomiting.
We judged the evidence for abdominal pain and diarrhoea to be
of low-quality due to inconsistency and imprecision, and the ev-
idence of nausea, vomiting, nausea and vomiting, and gastroin-
testinal disorders NOS to be of moderate quality due to impreci-
sion.
iv. Nervous system disorders
There was insufficient evidence to determine whether macrolides
caused dizziness based on the three studies reporting this outcome
(376 participants, 31 events) (OR 1.83, 95%CI 0.85 to 3.95; I² =
0%; Analysis 4.1). Macrolides were not associated with headache
in 12 trials with 1386 participants, 195 events (OR 0.81, 95%
CI 0.58 to 1.11; I² = 0%; Analysis 4.2). However, macrolides did
cause taste disturbance in five trials, involving 932 participants,
reporting 81 instances (OR 4.95, 95% CI 1.64 to 14.93; I² =
46%; Analysis 4.3). The ARD of experiencing taste disturbances
was 117/1000 people, and the number of people treated with
macrolides for one to experience the adverse event of taste distur-
bance (NNTH) was 11 (4 to 62).
We judged the evidence for taste disturbance and dizziness as of
low-quality due to very serious imprecision, and the evidence for
headache as moderate quality due to imprecision.
v. Skin and subcutaneous tissue disorders
Macrolides did not cause increased itching in four trials with 1388
participants reporting 99 events (OR 1.11, 95% CI 0.73 to 1.67;
I² = 0%; Analysis 5.1) or rash in eight trials of 5314 participants
reporting rash in 360 instances (OR 1.13, 95% CI 0.91 to 1.41;
I² = 0%; Analysis 5.2).We judged the evidence of itching and rash
as of moderate quality due to imprecision.
vi. General disorders and administration site conditions
Seven studies (2451 participants) reported fever (Bonacini 1993;
Clement 2006;Grassly 2016;Heppner 2005;Roca 2016a; Saiman
2003; Saiman 2010). We found that fever was reduced in partici-
pants taking macrolides compared to placebo (OR 0.73, 95% CI
0.54 to 1.00; I² = 35%; Analysis 6.1), although the findings were
non-significant. We judged the evidence for fever as of moderate
quality due to imprecision.
vii. Hepatobiliary disorders
Four trials reported 23 hepatobiliary disorders as adverse events
(cholestatic jaundice, cholangitis, or abnormal hepatic function)
(Aly 2007; Black 2001; Nuntnarumit 2006; Yeo 1993). We did
not find a difference in the occurrence of hepatobiliary disorders
between the participants in the macrolides and placebo groups
(OR 1.04, 95% CI 0.27 to 4.09; I² = 47%; Analysis 7.1). We
judged the evidence for hepatobiliary disorders as of very low-
quality due to indirectness and very serious imprecision.
viii. Infections and infestations
Four studies reported blood infections (356 participants with 99
events) (Aly 2007; Berne 2002; Ng 2007; Nuntnarumit 2006).
We found no difference in the number of blood infections in
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participants takingmacrolide antibiotics compared to those taking
placebo (OR 0.83, 95% CI 0.52 to 1.34; I² = 0%; Analysis 8.1).
Macrolides reduced respiratory tract infections (11 trials, 11,062
participants, 1078 events) (OR 0.70, 95% CI 0.62 to 0.80; I²
= 0%; Analysis 8.2), while for skin and soft tissue infections (3
trials, 263 participants, and only 9 events) there was no difference
between groups (OR 1.57, 95%CI 0.53 to 4.64; I² = 0%; Analysis
8.3). We judged the evidence for blood infections and respiratory
tract infections as of moderate quality due to imprecision, and the
evidence for skin and soft tissue infections as of low-quality due
to very serious imprecision.
ix. Investigations
There was insufficient evidence to determine whether macrolides
caused changes in liver enzymes (reported as either “elevated” or
“abnormal”) in the six trials reporting these adverse events (144
events among 1187 participants) (OR 1.56, 95%CI 0.73 to 3.37)
because of wide confidence intervals and high heterogeneity (I² =
71%; Analysis 9.1). We judged the evidence for changes in liver
enzymes as of very low-quality due to inconsistency and very seri-
ous imprecision.
x. Metabolism and nutrition disorders
Five studies reported appetite loss (2183 participants with 248
events) (Eschenbach 1991; Heppner 2005;Martin 1997; Petersen
1997; Saiman 2003). We found no difference in appetite loss
between participants takingmacrolide antibiotics and those taking
placebo (OR 1.10, 95%CI 0.84 to 1.43; I² = 16%; Analysis 10.1).
We judged the evidence for appetite loss as of moderate quality
due to imprecision.
xi. Respiratory, thoracic and mediastinal disorders
Six trials reported that macrolides reduced cough (1587 partic-
ipants with 390 events) (OR 0.57, 95% CI 0.40 to 0.80; I² =
14%; Analysis 11.1). We did not find evidence that macrolides
caused more respiratory symptoms NOS in eight trials of 2176
participants reporting 461 events (OR 1.02, 95%CI 0.82 to 1.25;
I² = 0%; Analysis 11.2) or wheeze in three trials of 484 partici-
pants reporting 41 events (OR 2.20, 95% 0.74 to 6.52; I² = 49%;
Analysis 11.3). We judged the evidence for cough and respiratory
symptoms NOS as of moderate quality due to imprecision, and
the evidence for wheeze as of low-quality due to very serious im-
precision.
xii. Rarely reported adverse events
Rarely reported adverse events are presented in a separate ta-
ble according to System Organ Classes (Table 1). No differences
were observed for most rarely reported adverse events between the
macrolides and placebo groups. The exceptions are listed below.
Adverse events significantly more common in people treated
with a macrolide
• Rectal disorder (P = 0.004) (Pierce 1996).
• Flatulence (P < 0.001) (Jespersen 2006).
• Upset stomach (P < 0.001) (Jespersen 2006).
• Infusion site pain (P < 0.001) (Giamarellos-Bourboulis
2014).
• Allergic reactions (P = 0.041) (Hyde 2001).
• Gastroenteritis (P = 0.006) (Cameron 2013).
Adverse events significantly more common in people taking a
placebo
• Dyspepsia (P = 0.040) (Lanza 1998).
• Puerperal pyrexia (P = 0.001) (Tita 2016).
• Infections NOS (P = 0.001) (Roca 2016a).
• Otitis (P = 0.005) (Cameron 2013).
2. Death
Macrolides did not cause increased mortality in 52 studies with
216,246 participants reporting 6923 events (OR 0.96, 95% 0.87
to 1.06; I² = 11%; Analysis 12.1). Five studies reported on num-
ber of deaths at various time points; see Table 2 for details
(Giamarellos-Bourboulis 2008; Gurfinkel 1999; Jespersen 2006;
Keenan 2018; Van den Broek 2009). We obtained number of
deaths (all-cause mortality) at 10-year follow-up of the CLARI-
COR trial, Jespersen 2006, by e-mail correspondence withWinkel
2017 [pers comm]. We judged the evidence for death as of low-
quality due to indirectness and imprecision.
3. Subsequent carriage of macrolide-resistant bacteria
Thirteen studies reported on participants with macrolide-resistant
bacteria following treatment with macrolide antibiotics (Table 3).
The range of absolute increases across the studies in the numbers
of participants carrying macrolide-resistant organisms was 0% to
43%. No clear trend was observed in studies reporting on resistant
bacteria at multiple time points: two trials showed an absolute
decrease in resistance over time (Berg 2005; Valery 2013); one
showed an absolute increase over time (Roca 2016a); and one
initially reported an absolute increase followed by a decrease (
Sirinavin 2003). Four studies reported a small (< 10%) relative
increase in resistance (Bacharier 2015; Brusselle 2013; McCallum
2015; Wilson 1977), and three studies reported a small relative
decrease in resistance (Berkhof 2013; Gibson 2017; Uzun 2014).
Valery 2013 and Sirinavin 2003 showed an initial relative increase
in resistance followed by a decrease over time.
Eight studies reported on the proportion of macrolide-resistant
isolates following macrolide treatment. The absolute increase in
resistance ranged from 0% to 55% for studies reporting on
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macrolide-resistant isolates at a single follow-up point (Albert
2011; Altenburg 2013; Berg 2005; Seemungal 2008; Tita 2016;
Videler 2011; Wilson 1979). A single trial reported on macrolide-
resistant isolates at multiple time points, showing an initial abso-
lute increase (at week 26) followed by a gradual decrease to 0% at
week 78 (Lildholdt 2003). There was a mixed picture for relative
increase in resistance, with three trials showing a small (< 10%)
relative decrease in resistance (Albert 2011; Berg 2005; Videler
2011); one showing a small relative increase (Altenburg 2013);
and one trial showing an initial relative increase followed by a de-
crease over time (Lildholdt 2003) (Table 4).
Three trials reported the proportion of macrolide-resistant strep-
tococci isolates (Brusselle 2013; Serisier 2013), of which one
trial had two active treatment arms (Malhotra-Kumar 2007a;
Malhotra-Kumar 2007b). Absolute increase in resistance de-
creased over time in Brusselle 2013, Malhotra-Kumar 2007a, and
Malhotra-Kumar 2007b. Two trials also reported an initial rel-
ative increase in macrolide-resistant bacteria followed by a de-
crease over time (Brusselle 2013; Malhotra-Kumar 2007b); and
Malhotra-Kumar 2007a reported an initial decrease in relative re-
sistance, but its magnitude decreased over time (Table 5).
Subgroup analysis
The protocol prespecified the following subgroup analyses: age
groups, type of macrolide, route of administration, antibiotic
dosage, and duration of therapy. However, we were unable to un-
dertake all planned subgroup analyses because either there were
too few studies in the subgroup (< 3); data were confounded (e.g.
subgroups not reported separately); or we decided against ‘dura-
tion of therapy’ from which, together with daily dose, we had
hoped to estimate peak or steady-state blood concentrations, but
could not. We conducted the following subgroup analyses.
i. Nausea
Type of macrolide: the increased nausea caused by roxithromycin
(OR 3.29, 95% CI 1.15 to 9.43) compared with either azithro-
mycin (OR 1.66, 95% CI 1.27 to 2.16) or erythromycin (OR
1.58, 95% CI 1.23 to 2.04) was not significant (test for subgroup
differences P = 0.41) (Analysis 3.2).
Route of administration: intravenous administration of macrolides
(OR 3.04, 95% CI 0.69 to 13.51) was not significantly different
from oral administration (OR 1.57, 95% CI 1.35 to 1.81; P =
0.38; Analysis 3.3).
ii. Vomiting
Type of macrolide: erythromycinwas not significantlymore likely to
cause vomiting (OR1.46, 95%CI1.07 to 1.98) than azithromycin
(OR 1.06, 95% CI 0.76 to 1.49; P = 0.17; Analysis 3.5).
Route of administration: intravenous administration of macrolides
(OR 1.21, 95% CI 0.88 to 1.66) was not significantly different
from oral administration (OR 1.32, 95% CI 0.97 to 1.78; P =
0.70; Analysis 3.6).
iii. Abdominal pain
Type of macrolide: erythromycin and azithromycin caused similar
increases of abdominal pain (OR 3.16, 95% CI 1.14 to 8.75) and
(OR 1.47, 95% CI 1.01 to 2.13), respectively; P = 0.16 (Analysis
3.9).
iv. Diarrhoea
Type of macrolide: clarithromycin did not cause diarrhoea signifi-
cantly more often (OR 2.09, 95% CI 1.70 to 2.56) than azithro-
mycin (OR 1.96, 95% CI 1.37 to 2.81), erythromycin (OR 1.36,
95% CI 0.94 to 1.98), or roxithromycin (OR 0.88, 95% CI 0.38
to 2.07); P = 0.07 (Analysis 3.11).
v. Gastrointestinal NOS
Type of macrolide: erythromycin was not significantly more likely
to cause gastrointestinal adverse events NOS (OR 4.00, 95% 1.83
to 8.74) than azithromycin (OR 1.77, 95% CI 1.30 to 2.42); P =
0.06 (Analysis 3.13).
vi. Deaths
Type of macrolide: roxithromycin did not cause death significantly
more often (OR 1.03, 95% CI 0.76 to 1.41) than azithromycin
(OR 0.97, 95% 0.85 to 1.10), clarithromycin (OR 0.86, 95%
0.59 to 1.24), or erythromycin (OR 0.73, 95% 0.38 to 1.40); P
= 0.74 (Analysis 12.2).
Route of administration: intravenous administration of macrolides
(OR 0.83, 95% CI 0.63 to 1.10) was not significantly different
from oral administration (OR 0.98, 95% CI 0.88 to 1.10); P =
0.28 (Analysis 12.3).
Sensitivity analyses
We decided a priori to perform sensitivity analyses by excluding
those studies with missing data on the outcome (adverse events).
However, none of the studies that provided data for the meta-
analyses had more than 20% of randomised participants lost to
follow-up, that is were assessed as being at high risk of attrition
bias.
Supplementary data
In this Cochrane Review we have reported on any reported adverse
event that occurred in 5% or more of any group. However, we
extracted all adverse events and grouped them by primary System
OrganClass, according to theMedDRA coding system (MedDRA
2018). See adverse events by System Organ Classes: threshold ≥
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5%, Hansen 2018a, and adverse events by System Organ Classes
< 5%, Hansen 2018b.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Other adverse events in people taking macrolide antibiotics versus placebo for any indication
Patient or population: any indicat ion
Setting: any sett ing
Intervention: macrolide ant ibiot ics (azithromycin, clarithromycin, erythromycin, or roxithromycin, administered by any route)
Comparison: placebo
Outcomes Anticipated absolute effects*
(95% CI)
Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with macrolide an-
tibiotics
Cardiac disorders 73 per 1000 64 per 1000
(41 to 99)
OR 0.87
(0.54 to 1.40)
1715
(7 RCTs)
⊕©©©
VERY LOW 12
Hearing loss 187 per 1000 230 per 1000
(187 to 281)
OR 1.30
(1.00 to 1.70)
1369
(4 RCTs)
⊕⊕©©
LOW 13
NNTH = 24
Taste disturbance 27 per 1000 119 per 1000
(43 to 290)
OR 4.95
(1.64 to 14.93)
932
(5 RCTs)
⊕⊕©©
LOW 4
NNTH = 11
Hepatobiliary disorders 48 per 1000 50 per 1000
(14 to 172)
OR 1.04
(0.27 to 4.09)
443
(4 RCTs)
⊕©©©
VERY LOW 45
Deaths 34 per 1000 32 per 1000
(29 to 35)
OR 0.96
(0.87 to 1.06)
216,246
(52 RCTs)
⊕⊕©©
LOW 16
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; NNTH: number needed to treat for an addit ional harmful outcome; OR: odds rat io; RCT : randomised controlled trial
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level due to imprecision. The outcome was reported in only a small proport ion of the included studies.
2Downgraded two levels due to risk of bias. High risk of report ing bias for Kim 2004, as they only report on major cardiac
events and no other possible adverse events. Important ly, the study populat ion consists of part icipants with acute coronary
syndrome who underwent percutaneous coronary intervent ion. High risk of bias for Gupta 1997, as they report on adverse
events as a total for both treatment regimens (azithromycin dose 1500 mg or 3000 mg). Important ly, the study populat ion
consists of male survivors of myocardial infarct ion, and the events are reported as adverse cardiovascular events.
3Downgraded one level due to risk of bias. High risk of report ing bias for Saiman 2003, as hearing loss (judged by audiology
test ing) was only reported for about 50% of part icipants assigned.
4Downgraded two levels due to very serious imprecision. The outcome was reported in only a very small proport ion of the
included studies, and there were large conf idence intervals.
5Downgraded one level due to indirectness. Two out of four studies did not clearly state adverse events as an outcome or did
not report on standardised adverse event ascertainment (Aly 2007; Black 2001).
6Downgraded one level due to indirectness. Death is reported in this review regardless if reported as a primary outcome or
adverse event in the primary studies.
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D I S C U S S I O N
Summary of main results
This multi-indication review included 183 randomised, placebo-
controlled trials (RCTs) involving a total of 252,886 participants.
The indications for macrolide antibiotics varied greatly, with most
studies using macrolides for the treatment or prevention of acute
respiratory tract infections, cardiovascular diseases, chronic respi-
ratory diseases, gastrointestinal conditions, or urogynaecological
problems. Azithromycin and erythromycin were more commonly
studied than clarithromycin and roxithromycin.
Themost commonly reported adverse events were gastrointestinal.
Participants taking macrolide antibiotics experienced vomiting,
nausea, diarrhoea, abdominal pain, and gastrointestinal disorders
NOS significantly more often than those taking a placebo.
We found low-quality evidence thatmacrolides caused taste distur-
bances, although there were wide confidence intervals and mod-
erate heterogeneity.
Participants taking macrolides experienced hearing loss more of-
ten than those taking a placebo, although the findings were non-
significant.
We did not find any evidence that macrolides caused more car-
diac disorders, hepatobiliary disorders, or changes in liver enzymes
compared to placebo.
In the overall meta-analysis there was no evidence of an increase in
deaths in participants treated with macrolides compared to those
treated with placebo.
Very few of the included studies reported on macrolide-resistant
bacteria. Macrolide-resistant bacteria were more commonly iden-
tified among participants immediately after exposure to the an-
tibiotic, as expected, but there was little pattern of the decay of
resistance thereafter.
Pharmaceutical companies supplied the trial medication or pro-
vided funding, or both, for about 50% of the included studies.
Overall completeness and applicability of
evidence
Some of the outcomes were based on very few studies, despite the
large total (183 trials) of included studies. However, most studies
did report on some adverse events, and only 20 studies did not
report on any adverse events.
The strengths of this review include the large set of RCTs to anal-
yse. Randomised controlled trials avoid the complexity of attempt-
ing to distinguish symptoms caused by the treatment (antibiotics)
or the disease (for which antibiotics were used), which makes ob-
servational studies weak for answering this question. Additionally,
we included trials that allowed concomitant medications (when
they were equally available in the placebo group), which might
have caused drug interactions, and possibly have amplified any
adverse event rates, which is an advantage when generalising to
normal use.
One limitation is the assumptions made to decide what outcomes
are adverse events and which are disease outcomes (for trials test-
ing antibiotic efficacy); deaths, cardiac disorders, and symptoms of
acute respiratory infections are examples. Furthermore, it was not
possible to test dose effects because of the confusion surrounding
the different forms of macrolide, especially erythromycin (which
was used in estolate, stearate, base, and ethylsuccinate forms). A
failure of most studies to report participant age groups’ data dis-
cretelymeant that we could not analyse the effect of age on adverse
events.
When trial authors reported adverse events, it was not always ob-
vious if they reported the numbers of adverse events or the num-
bers of participants with adverse events. Consequently, there is a
risk of double-counting when performing a systematic review re-
porting adverse events data. In this systematic review, we aimed to
report only adverse events from trials that reported the numbers of
participants with adverse events. However, some of the included
studies did not clearly specify if they reported on participants with
adverse events, and in those cases our assessments have been based
on inferences made by comparing the total numbers of partici-
pants and events they reported.
We tried to collect information on the follow-up period for report-
ing on adverse events from all of the included studies. However, in
most cases it was not possible to calculate the follow-up period for
the reporting of adverse events, as most trial authors only clearly
reported the follow-up period for the main outcome(s) and not
for adverse events.
We did not plan to perform a subgroup analysis based on indica-
tions formacrolide treatment, as we anticipated that adverse events
are not disease-specific. However, different populations might ex-
perience different adverse events. For example, people with cer-
tain susceptibility factors have an increased risk of arrhythmias in
response to macrolides (Albert 2014). Nevertheless, such differ-
ences need not necessarily be related to different indications for
treatment rather than differences in individual susceptibility.
Quality of the evidence
The quality of evidence according to GRADE assessment ranged
from very low (cardiac disorders, change in liver enzymes, hepato-
biliary disorders) to low (abdominal pain, death, diarrhoea, dizzi-
ness, hearing loss, skin and soft tissue infections, taste disturbance,
wheeze) to moderate (appetite loss, blood infection, cough, fever,
gastrointestinal disorders NOS, headache, itching, nausea, nausea
and vomiting, rash, respiratory symptoms NOS, respiratory tract
infections, vomiting). We downgraded the quality of the evidence
due to high risk of reporting bias, inconsistency, indirectness, and
imprecision.
23Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Potential biases in the review process
The interpretation of an adverse event differed significantly be-
tween trial authors. For example, some authors reported on pneu-
monia as a complication and wheezing as a disease-specific symp-
tom, while others reported on these as an adverse event. When
extracting data from the included trials, two review authors inde-
pendently searched for any information that could be interpreted
as an adverse event, regardless of how this was reported in the
original trial. Consequently, this review may report on outcomes
that some trial authors did not consider to be an adverse event. An
exception was the study by Andremont 1981, which we excluded
from the meta-analysis on diarrhoea as the trial tested a macrolide
antibiotic versus placebo for the prevention of traveller’s diarrhoea
and reported on diarrhoea as a primary outcome. We assessed the
reported cases of diarrhoea (four participants in the placebo group)
as caused by virus/bacteria, rather than by treatments.
Less than one-third of the included RCTs reported on death (52
studies), and even fewer reported on data on macrolide-resistant
bacteria (24 studies). There is strong evidence that much of the
information on adverse events remains unpublished, and that the
number - and range - of adverse events is higher in unpublished ver-
sions of the same study (Golder 2016). We searched six databases,
the reference lists of included trials, the World Health Organiza-
tion (WHO) International Clinical Trials Registry Platform and
ClinicalTrials.gov for ongoing trials, and exploited the reference
lists of previous Cochrane Reviews on macrolide antibiotics. We
also contacted authors if they reported incompletely on adverse
events and contact details (an e-mail address) were available. How-
ever, we did not contact each of the 183 trial authors asking for
unpublished data on adverse events, and consequently it is possi-
ble that we missed information on adverse events, including death
and data on macrolide-resistant bacteria.
The methods used for eliciting adverse events varied greatly be-
tween the included trials and included spontaneous reporting, ask-
ing participants, use of a questionnaire, identification during a
clinical examination, and/or laboratory testing. Also, many stud-
ies did not provide any information on how the information on
adverse events was obtained. A newly published Cochrane Review
raises concerns that methods used for eliciting adverse events may
influence the detection of these data (Allen 2018). The review
authors found that there was a risk for underdetection of adverse
events in studies using amore general elicitationmethod compared
to those using a comprehensive method (Allen 2018). This possi-
ble underdetection of adverse eventsmight have compromised our
ability to pool data, as we required at least three studies reporting
on a specific adverse event in order to perform a meta-analysis.
Agreements and disagreements with other
studies or reviews
This Cochrane Review is the first multi-indication review on ad-
verse events in people takingmacrolides that includes studies using
the same intervention for different diseases (Chen 2014). How-
ever, several other reviews have presented data on adverse events
in people taking macrolides for various indications. Some reviews,
such as Ni 2015, have only presented the total number of adverse
events, whilst other authors have presented data for specific adverse
events (Shi 2014). Shi 2014 studied macrolides for bronchiectasis,
presenting both efficacy and adverse outcomes, and finding ab-
dominal pain (risk ratio (RR) 6.2, 95% CI 1.43 to 26.83) and di-
arrhoea (RR 2.89, 95% CI 1.13 to 7.35) significantly more often
in participants treated with a macrolide than in those treated with
a placebo. Also, in line with our findings, that review found no
increased risk of headache in participants treated with a macrolide
(RR0.62, 95%CI 0.17 to 2.29). Reporting of other adverse events
in the Cochrane Review by Shi and colleagues was limited by lack
of statistical power (Shi 2014).
The absence of a signal of liver damage in this review contrasts
with older reports that macrolide antibiotics, erythromycin in par-
ticular, can cause two different types of liver damage - changes
in liver enzymes and cholestatic jaundice (Braun 1976; Ginsburg
1976). There are several possible explanations for the dissonance
between our review and the previous reports. Because many of
the older reports were anecdotal, the associations may have oc-
curred purely by chance; alternatively, newer formulations of ery-
thromycin may be less hepatotoxic; previous observational studies
may have been confounded by indication, hepatobiliary adverse
effects having been caused by the infections being treated; or the
risk of hepatotoxicity may be real but too small to have met our
eligibility entry requirement that adverse events should have af-
fected ≥ 5% of participants. Settling this question may need in-
terrogation of large data sets beyond the remit of this review.
Findings when cardiovascular adverse events are reported in peo-
ple taking macrolide antibiotics are contradictory. Observational
studies have shown that treatment with macrolide antibiotics is
associated with an increased risk of cardiovascular outcomes, in-
cluding cardiovascular deaths, myocardial infarction, and arrhyth-
mias (Wong 2017). In contrast, meta-analyses of RCTs did not
show an increased cardiovascular risk (Wong 2017). Our findings
concur with the RCT-derived data, as we did not find evidence
of an increased risk of cardiac disorders in participants taking a
macrolide antibiotic compared with placebo.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antimicrobial resistance is one of the key global health problems
facing our generation, with antibiotic use being the main driver
(O’Neill 2014; WHO 2018). Most antibiotics used in humans
are used in primary care (DANMAP 2016), and particularly in
general practice (Aabenhus 2016). For some infections, such as
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acute respiratory infections, the benefits of antibiotic treatment
are minimal, if any. We undertook this systematic review to quan-
tify adverse events in people using macrolide antibiotics, indepen-
dently of the indication or effects of treatment, and found that
macrolides as a group increased rates of gastrointestinal adverse
events. The intention of this review is to support clinicians and
patients in evaluating harms as well as benefits in the choice of
management when antibiotics are contemplated.
Implications for research
Poor and inconsistent reporting of adverse events in clinical trials
is well known (Hodkinson 2013). Most trials reported on some
adverse events, or at least stated that no adverse events were ob-
served. Nonetheless, trial authors are encouraged to clearly state
adverse events (including data on resistant bacteria) as outcomes;
to report on the methods used for eliciting adverse events; and
preferably to report both the number of each specific adverse event
and the number of people with each event in both the intervention
and control groups.
Most systematic reviews of antimicrobial treatments ignore the
problem of antimicrobial resistance (Leibovici 2003), and a frame-
work for addressing antibiotic resistance in systematic reviews has
recently been proposed for use in Cochrane Review protocols
and Cochrane Reviews (Leibovici 2016). A revised version of the
Strengthening the Reporting ofObservational Studies in Epidemi-
ology (STROBE) framework was published in 2016 to increase
the appropriateness of reporting for epidemiological studies, fo-
cusing on the link between resistant bacteria and antibiotic use
(Tacconelli 2016). Only 24 (13%) of the trials included in our
review provided useful data on macrolide-resistant bacteria. Con-
sequently, not only review authors, but also authors conducting
primary research on antimicrobial treatments are encouraged to
measure and report on resistance data in future research projects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 61 adults (macrolide n = 31, placebo n = 30)
Age in years (range): 30 to 50
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: clarithromycin
Route: topical
Dose per day: 0.5% gel x 1
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Ascertainment of adverse events: unclear
Adverse events: states that no adverse events were observed or reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
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Agarwal 2012 (Continued)
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment. However, report on
adverse events
Other bias Low risk None were identified.
Agarwal 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 63 adults (macrolide n = 31, placebo n = 32)
Age in years (range): 30 to 50
Setting: dental care
Interventions Indication: chronic periodontitis in people with type 2 diabetes mellitus
Type of macrolide: azithromycin
Route: topical
Dose per day: 0.2 mL of 0.5% gel
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Ascertainment of adverse events: participants asked
Adverse event: authors state that no adverse events were observed or reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported. Authors thank supplying companies.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if matching placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner
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Agarwal 2017 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome.
However, clear ascertainment and report
on (no) adverse events
Other bias Low risk None were identified.
Ahmed 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 children and adults (macrolide n = 30, placebo n = 30)
Age in years (mean ± SD): macrolide: 23.13 ± 10.34, placebo: 21.67 ± 7.42
Setting: secondary care
Interventions Indication: pityriasis rosea
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 250 mg (child)/500 mg (adult) x 2
Duration of treatment: 7 days
Total treatment dose: 7000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Ascertainment of adverse events: unclear
Adverse event: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation was done by lottery
method.
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Ahmed 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Akhyani 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 46 children and adults (macrolide n = 23, placebo n = 23)
Age in years (mean (range)): 21.5 (11 to 36)
Setting: secondary care
Interventions Indication: pityriasis rosea
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7 days
Total treatment dose: 7000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Ascertainment of adverse events: unclear
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
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Akhyani 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if matching placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Albert 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1142 adults and elderly (macrolide n = 570, placebo n = 572)
Age in years (mean ± SD): macrolide: 65 ± 9, placebo: 66 ± 8
Setting: secondary care
Interventions Indication: prevention of an exacerbation in people with chronic obstructive pulmonary
disease
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 1 year
Total treatment dose: 91,250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked and clinical examination/laboratory
tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: data reported
Funding sources Funded by the National Institutes of Health. Several authors are on pharmaceutical
boards
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Albert 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome in the
protocol, andparticipantswere asked about
adverse events/were examined
Other bias Low risk None were identified.
Alger 1991
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 84 children and adults (macrolide n = 40, placebo n = 44)
Age in years (mean ± SD): macrolide: 21.7 ± 4.2, placebo: 21.3 ± 4.0
Setting: secondary care
Interventions Indication: antenatal Chlamydia trachomatis infection
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 1332 mg
Duration of treatment: 14 days
Total treatment dose: 18,648 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by a grant from the Upjohn Company. Role of funding source unclear
Notes Concomitant medication: unclear
Risk of bias
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Alger 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Unclear if the placebo group was generated
from another trial
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome
and unclear ascertainment. However, ad-
verse events reported
Other bias Low risk None were identified.
Altenburg 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 89 adults and elderly (macrolide n = 45, placebo n = 44)
Age in years (mean ± SD): macrolide: 59.9 ± 12.3, placebo: 64.6 ± 9.1
Setting: secondary care
Interventions Indication: prevention of pulmonary exacerbations in people with non-cystic fibrosis
bronchiectasis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 12 months
Total treatment dose: 91,250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant diary and clinical examination/laboratory
tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
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Altenburg 2013 (Continued)
Funding sources A research grant from the Foreest Medical School was used for paying salaries. The study
was supported by an unrestricted grant from GlaxoSmithKline. Azithromycin tablets
were supplied by Teva Netherlands
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised computer-generated randomi-
sation
Allocation concealment (selection bias) Low risk Numbers on the boxesmatched a treatment
allocation, in accordance with a computer-
generated allocation sequence that was kept
in a safe place in the pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, adverse events re-
ported
Other bias Low risk None were identified.
Altraif 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 102 adults and elderly (macrolide n = 53, placebo n = 49)
Age in years (mean ± SD): macrolide: 62.3 ± 9.8, placebo: 62.7 ± 14.7
Setting: secondary care
Interventions Indication: variceal bleeding in people with liver cirrhosis
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 125 mg
Duration of treatment: 1 day
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Altraif 2011 (Continued)
Total treatment dose: 125 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: states that no adverse events were observed or reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and endo-
scopist/clinician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome. How-
ever, unclear ascertainment and states that
no adverse events were observed
Other bias Low risk None were identified.
Aly 2007
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 children (macrolide n = 30, placebo n = 30)
Age in days (median (range)): macrolide: 2.0 (2.0 to 24.0), placebo: 2.0 (2.0 to 10.0)
Setting: secondary care
Interventions Indication: feeding intolerance in preterm infants
Type of macrolide: erythromycin ethylsuccinate
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Aly 2007 (Continued)
Route: per oral
Dose per day: 3 mg/kg
Duration of treatment: the study medicine was to stop once the primary endpoint was
achieved
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Allocation concealed by cards provided in
consecutively numbered, opaque, sealed
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both active drug and placebo were mixed
thoroughly into the milk feeds by desig-
nated staff not involved in the clinical man-
agement of the infants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. Adverse events/
complications reported
Other bias Low risk None were identified.
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Amali 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 66 children and adults (macrolide n = 22, placebo n = 44)
Age in years (mean ± SD (range)): macrolide: 34.9 ± 9.2 (18 to 57), placebo: 39.1 ± 10.
7 (15 to 62)
Setting: secondary care
Interventions Indication: chronic rhinosinusitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 84 days
Total treatment dose: 21,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, and individuals
analysing data were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups. Rea-
sons for dropout given
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, incomplete report-
ing of adverse events
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Amali 2015 (Continued)
Other bias Unclear risk 2:1 randomisation design
Amer 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 49 children (macrolide n = 25, placebo n = 24)
Age in years (mean): macrolide: 8.0, placebo: 8.4
Setting: secondary care
Interventions Indication: pityriasis rosea
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg (maximum)
Duration of treatment: 5 days
Total treatment dose: 2500 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by a grant from Pfizer Inc.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
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Amer 2006 (Continued)
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment of adverse events at each follow-up
visit and adverse events reported
Other bias Low risk None were identified.
Amland 1995
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 339 children, adults, and elderly (macrolide n = 171, placebo n =
168)
Age in years mean (range): male: macrolide: 30 (7 to 85), placebo: 28 (6 to 84); female:
macrolide 33 (6 to 84), placebo: 33 (7 to 82)
Setting: secondary care
Interventions Indication: prevention of postoperative wound infections
Type of macrolide: azithromycin
Route: per oral
Dose per day: 1000 mg (maximum)
Duration of treatment: 1 day
Total treatment dose: 1000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Reports that the study was supported by Pfizer, who provided the study
medication
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed in blocks of
10 using a computer-generated chart
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo not described.
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Amland 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded to treatment groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment. However, adverse
events reported
Other bias Low risk None were identified.
Andere 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults (macrolide n = 20, placebo n = 20)
Age in years (mean (range)): 32.2 (22 to 35)
Setting: dental care
Interventions Indication: generalised aggressive periodontitis
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 3 days
Total treatment dose: 3000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Ascertainment of adverse events: participant diary
Adverse event: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Funded by Research Funding Agency from Sao Paulo State and National Council for
Science and Technological Development
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
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Andere 2017 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome.
However, clear ascertainment and adverse
events reported
Other bias Low risk None were identified.
Andersen 1998
Methods Design: randomised, placebo-controlled, 4-armed trial
Participants Number assigned: 177 adults (macrolide (daily dose) n = 59, macrolide (weekly dose)
n = 58, placebo n = 60)
Age in years (range): 18 to 55
Setting: 2 villages in western Kenya
Interventions Indication: malaria prophylaxis
Type of macrolide: azithromycin
Route: per oral
Dose per day/week: arm 1: 250 mg/day; arm 2: 1000 mg/week
Duration of treatment: 10 weeks
Total treatment dose: arm 1: 17,500 mg; arm 2: 10,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination/lab tests
Adverse events: data reported. Adverse events are reported as “number of events” and
not as “patients with events”
Antimicrobial resistance: not reported
Death: not reported
Funding sources KenyaMedical Research Institute through the US ArmyMedical Material Development
Activity and Pfizer Central Research. Pfizer provided the study drugs and placebo
Notes Concomitant medication: yes
Note: a 4th group of people were treated with doxycyclin.
Risk of bias
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Andersen 1998 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Separate placebos were used for different
treatment groups to preserve the blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome and
were assessed by a daily symptom question-
naire. Adverse events reported
Other bias Low risk None were identified.
Anderson 1999
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 302 adults and elderly (macrolide n = 150, placebo n = 152)
Age in years (mean ± SD): macrolide: 64 ± 10, placebo: 63 ± 11
Setting: secondary care
Interventions Indication: secondary prevention in people with coronary artery disease and seroposi-
tivity to Chlamydia pneumoniae
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg/day for 3 days, then 500 mg/week for 3 months
Duration of treatment: 93 days
Total treatment dose: 7500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse event: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported in part by a grant from the Deseret Foundation, LDS Hospital, Salt
Lake City, Utah. Azithromycin and placebo purchased from pharmacies
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Anderson 1999 (Continued)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation (alternating blocks of
4 and 6)
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome. Un-
clear ascertainment, but adverse events re-
ported
Other bias Low risk None were identified.
Andremont 1981
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 48 adults (macrolide n = 24, placebo n = 24)
Age in years: N/A
Setting: healthy US residents travelling to Mexico to attend a professional meeting
Interventions Indication: prevention of traveller’s diarrhoea
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 1000 mg
Duration of treatment: mean days of treatment 6 (range 4 to 13 days)
Total treatment dose: 6000 mg (mean)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: states that no adverse events were reported
Antimicrobial resistance: not reported
Death: not reported
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Andremont 1981 (Continued)
Funding sources Study supported by a “contrat de recherche clinique” from Institut Gustave Roussy and
a grant from Roussel-Uclaf Laboratories
Notes Concomitant medication: unclear
Note: gastrointestinal symptoms were reported as the primary outcome in this study and
not reported/regarded as an adverse event
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. However, states
that no adverse events were reported
Other bias Low risk None were identified.
Anthony 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 78 adults and elderly (macrolide n = 39, placebo n = 39)
Age in years (mean ± SD): azithromycin: 65.94 ± 11.77, placebo: 59.75 ± 15.03
Setting: secondary care
Interventions Indication: bronchiectasis
Type of macrolide: azithromycin
Route: per oral
Dose: 1000 mg/week
Duration of treatment: 12 weeks
Total treatment dose: 12,000 mg
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Anthony 2014 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by a grant approved by the Ministry of Health of Malaysia. Study
medication was manufactured and provided by Pfizer Inc
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout in both groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment at each follow-up visit and adverse
events reported
Other bias Low risk None were identified.
Avci 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 adults and elderly (macrolide n = 30, placebo n = 30)
Age in years (mean age ± SD (range)): 50.68 ± 12.92 (18 to 78)
Setting: secondary care
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Avci 2013 (Continued)
Interventions Indication: erythrasma
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 14 days
Total treatment dose: 14,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported. Authors thank supplying companies.
Notes Concomitant medication: no
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment of adverse events at each follow-up
visit and adverse events reported
Other bias Low risk None were identified.
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Bacharier 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 607 children (macrolide n = 307, placebo n = 300)
Age in months (mean ± SD): 41.5 ± 16.5
Setting: 9 US academic medical centres in the National Heart, Lung, and Blood Insti-
tute’s AsthmaNet network
Interventions Indication: recurrent severe lower respiratory tract illness
Type of macrolide: azithromycin
Route: per oral
Dose per day: 12 mg/kg
Duration of treatment: 5 days (per treatment course)
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: spontaneously reporting + clinical examination
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by theNational Heart, Lung, and Blood Institute as part of AsthmaNet.
Several authors have received personal fees and grants from various pharmaceutical com-
panies
Notes Concomitant medication: yes
Note: during the 78-week follow-up included children could use the study treatment
during a maximum of 4 treated respiratory tract infection episodes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo-controlled, double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 17% and 18% withdrew for reasons other
than “early termination” or were lost to fol-
low-up, respectively. Reasons not given
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Bacharier 2015 (Continued)
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Bajaj 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 63 adults (macrolide n = 32, placebo n = 31)
Age in years (range): 30 to 50
Setting: dental care
Interventions Indication: chronic periodontitis in people with type 2 diabetes mellitus
Type of macrolide: clarithromycin
Route: topical
Dose per day: 0.5% gel once
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: states that no adverse events were observed or reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors thankMicro Labs, India, and Purac Biomaterials, theNetherlands,
for providing active drug and placebo
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo gel used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both the participant and the
clinician, who provided treatment
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Bajaj 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment. Authors state that
no adverse events were reported
Other bias Low risk None were identified.
Bala 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): macrolide: 28 ± 10.2, placebo: 35 ± 10.4
Setting: secondary care
Interventions Indication: gastric fluid pH and volume during surgery
Type of macrolide: erythromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 1 day
Total treatment dose: 250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: authors state that “no adverse effects could be attributed to the test
drugs”
Antimicrobial resistance: not reported
Death: not reported
Funding sources Institutional funding
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central randomisation
Allocation concealment (selection bias) Low risk Allocation by statistician off-site
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Bala 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. Authors report
that no adverse events were observed
Other bias Low risk None were identified.
Ballard 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 220 children (macrolide n = 111, placebo n = 109)
Age in weeks (mean ± SD): macrolide: 25.7 ± 1.5, placebo: 26 ± 1.6
Setting: secondary care
Interventions Indication: prevention of bronchopulmonary dysplasia in preterm infants
Type of macrolide: azithromycin
Route: intravenous (study drugs were initially administered intravenously, but switched
to enteral route once the infant reached full enteral feeds)
Dose per day: 10 mg/kg for 7 days, followed by 5 mg/kg for 5 weeks
Duration of treatment: 42 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
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Ballard 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of caretakers and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Audiometry and lab tests performed,
however not complete reporting of adverse
events
Other bias Low risk None were identified.
Banerjee 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 67 adults and elderly (macrolide n = 31, placebo n = 36)
Age in years (mean ± SE): macrolide: 65.1 ± 1.4, placebo: 68.1 ± 1.2
Setting: secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 90 days
Total treatment dose: 45,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + sputum
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Funded by a research grant from Abbott Laboratories Ltd, Maidenhead, UK
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Banerjee 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an
outcome. Participants were contacted and
asked about adverse events regularly, how-
ever no reporting of adverse events in pub-
lished paper
Other bias Low risk None were identified.
Barkhordar 2018
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 96 adults (macrolide n = 48, placebo n = 48)
Age in years (mean ± SD (range)): macrolide: 35.5 ± 12.0 (16 to 62), placebo: 36.1 ±
11.5 (18 to 62)
Setting: secondary care
Interventions Indication: prevention of graft versus host disease in people with acute leukaemia
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 18 days
Total treatment dose: 9000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no (mor-
tality stated as outcome)
Ascertainment of adverse events: unclear
Adverse event:not reported. States that “themedicationwaswell tolerated by all patients”
Antimicrobial resistance: not reported
Death: data reported
Funding sources None reported.
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Barkhordar 2018 (Continued)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, nursing staff, out-
come assessor, and attending physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lowdropout, similar across groups, reasons
given
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Beigelman 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 children (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): 3.8 ± 2.9
Setting: secondary care
Interventions Indication: respiratory syncytial virus bronchiolitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 10 mg/kg once daily for 7 days, followed by 5 mg/kg once daily for an
additional 7 days
Duration of treatment: 14 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: contacting participants’ families 3 times a week during
the treatment period
Adverse events: data reported
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Beigelman 2015 (Continued)
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Washington University Institute of Clinical and Translational Sci-
ences grant from theNational Center for Advancing Translational Sciences and the Chil-
dren’s Discovery Institute of Washington University and St Louis Children’s Hospital.
Supported in part by CTSA grant and Siteman Comprehensive Cancer Center and NCI
Cancer Center support grant
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of all participants, their families,
investigators, and study staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 child lost to follow-up
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment and adverse events
reported
Other bias Low risk None were identified.
Berg 2005
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 473 adults and elderly (macrolide n = 238, placebo n = 235)
Age in years (mean ± SD): macrolide: 64.9 ± 8.7, placebo: 63.8 ± 10.8
Setting: secondary care
Interventions Indication: coronary artery disease
Type of macrolide: clarithromycin
Route: per oral
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Berg 2005 (Continued)
Dose per day: 500 mg
Duration of treatment: 16 days (mean)
Total treatment dose: 8000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: data reported
Death: data reported
Funding sources Unrestricted grant from Abbott Pharmaceuticals
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and research physi-
cian
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and no reporting of
adverse events
Other bias Low risk None were identified.
Bergeron 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 480 adults and elderly (macrolide n = 243, placebo n = 237, excluded
n = 15)
Age in years: median (IQR): macrolide: 57.5 (45.0 to 63.6), placebo: 55.6 (40.3 to 63.
2)
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Bergeron 2017 (Continued)
Setting: secondary care
Interventions Indication: improvement of airflow decline-free survival after allogenic haematopoietic
stem cell transplant
Type of macrolide: azithromycin
Route: per oral
Dose: 250 mg 3 times per week
Duration of treatment: 730 days
Total treatment dose: 78,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Ascertainment of adverse events: participants asked + clinical examination
Adverse event: data reported. Adverse events are reported as “number of events” and not
as “patients with events”
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by the FrenchMinistry of Health, SFGM-TCCapucine association, and SOS
Oxygene
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adverse events reported for all allocated
participants (safety population)
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome, clear
ascertainment. However, only serious ad-
verse events are reported on
Other bias Low risk None were identified.
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Berkhof 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 84 adults and elderly (macrolide n = 42, placebo n = 42)
Age in years (mean ± SD): macrolide: 67 ± 9, placebo: 68 ± 10
Setting: secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: azithromycin
Route: per oral
Dose: 750 mg/week
Duration of treatment: 12 weeks
Total treatment dose: 9000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + lab tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources None stated. However, the authors thank Stichting Astma Bestrijding for financial sup-
port and Teva Pharma for providing the azithromycin tablets
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of investigators, research nurses,
and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Higher dropout in azithro-
mycin group because of adverse events,
however they are reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment and adverse events
reported
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Berkhof 2013 (Continued)
Other bias Low risk None were identified.
Berne 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 68 adults (macrolide n = 32, placebo n = 36)
Age in years (mean): macrolide: 40.0, placebo: 34.1
Setting: secondary care
Interventions Indication: gastric emptying in critically trauma participants
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 1000 mg
Duration of treatment: 2 days
Total treatment dose: 2000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported. Report on 1 participant developing a penicillin-
resistant Streptococcus pneumoniae pneumonia
Death: data reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
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Berne 2002 (Continued)
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Black 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 232 adults (macrolide n = 105, placebo n = 114, excluded n = 13)
Age in years (mean ± SD): macrolide: 40 ± 11.6, placebo: 42 ± 11.9
Setting: secondary care
Interventions Indication: asthma participants infected with Chlamydia pneumoniae
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 42 days
Total treatment dose: 12,600 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Aventis Pharma.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of both participant and examiner/
clinician
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Black 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. Adverse events
reported
Other bias Low risk None were identified.
Bonacini 1993
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 80 adults and elderly (macrolide n = 41, placebo n = 36, excluded n
= 3)
Age in years (median (range)): macrolide: 42 (18 to 80), placebo: 40 (18 to 81)
Setting: secondary care
Interventions Indication: postoperative ileus
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 750 mg
Duration of treatment: 3 days
Total treatment dose: 2250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Bonacini 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. However, 3 assigned partic-
ipants (4%) were excluded from analysis
based on unclear reasons
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. Adverse events
reported
Other bias Low risk None were identified.
Botero 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 70 adults and elderly (macrolide n = 33, placebo n = 37)
Age in years (mean ± SD): macrolide: 55.9 ± 12.6, placebo: 58.2 ± 11.1
Setting: dental care
Interventions Indication: periodontitis in people with diabetes mellitus
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: spontaneously reporting (participants were instructed
to report any side effects)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Partially supported by a grant fromColgate-Palmolive and theUniversidad de Antioquia.
Authors thank supplying companies
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Botero 2013 (Continued)
Allocation concealment (selection bias) Low risk Opaque, sealed, and coded envelopes used
for allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Branden 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 103 adults and elderly (macrolide n = 51, placebo n = 52)
Age in years (mean ± SD): macrolide: 61.1 ± 10.5, placebo: 59.8 ± 13.4
Setting: secondary care
Interventions Indication: chronic Chlamydia pneumoniae-infected participants with longstanding air-
way and/or pharyngeal symptoms
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 15 days in total (5 days treatment, repeated 3 times with 23-
day intervals)
Total treatment dose: 7500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + lab tests
Reporting of adverse events: yes
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Karolinska Institutet, Stockholm, Sweden and the Swedish Heart
and Lung Foundation. Pfizer AB, Sweden supplied the study medication
Notes Concomitant medication: yes
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Branden 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lowdropout. Adverse events leading todis-
continuation reported
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come, standardised ascertainment of ad-
verse events at follow-up visits. Adverse
events clearly presented in a table
Other bias Low risk None were identified.
Brickfield 1986
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 52 adults (macrolide n = 27, placebo n = 25)
Age in years (mean): macrolide: 32.0, placebo: 32.5
Setting: primary care
Interventions Indication: acute bronchitis
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 7 days
Total treatment dose: 6993 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting. However, no contact details for author
Antimicrobial resistance: not reported
Death: not reported
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Brickfield 1986 (Continued)
Funding sources Study supported by a grant from the American Academy of Family Physicians. Authors
acknowledge supplying companies
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent company generated num-
bered, sealed bottles containing tablets of
placebo or erythromycin
Allocation concealment (selection bias) Low risk Participants received a numbered, sealed
bottle with tablets
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant withdrew from each group,
no reasons given.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Brill 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 49 adults and elderly (macrolide n = 25, placebo n = 24)
Age in years (mean ± SD): macrolide: 67.9 ± 8.6, placebo: 68.7 ± 9.8
Setting: participants were recruited from both primary and secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: azithromycin
Route: per oral
Dose: 250 mg 3 times a week
Duration of treatment: 13 weeks
Total treatment dose: 9750 mg
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Brill 2015 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + swabs
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: incomplete reporting, author contacted
Death: not reported
Funding sources Study supported by the National Institute for Health Research (NIHR) under the Pro-
gramme Grants for Applied Research programme and the NIHR Royal Brompton Res-
piratory Biomedical Research Unit.
Many of the authors have received honoraria, consulting, and board membership fees
from pharmaceutical companies. Authors state that the study presents independent re-
search
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Azithromycin was taken 3 times per week,
while placebo was given as 1 tablet per day
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors probably not blinded.
However, only report on AMR data, which
is an objective outcome and not influenced
by blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) High risk Adverse events stated as an outcome and
standardised ascertainment. However, in-
complete reporting of adverse events in-
cluding data on antimicrobial resistance
Other bias Low risk None were identified.
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Brusselle 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 109 adults and elderly (macrolide n = 55, placebo n = 54)
Age in years median (range): macrolide: 53 (19 to 76), placebo: 53 (20 to 74)
Setting: secondary care
Interventions Indication: severe asthma
Type of macrolide: azithromycin
Route: per oral
Dose: 250 mg per day for 5 days, then 250 mg 3 times/week for 25 weeks
Duration of treatment: 26 weeks
Total treatment dose: 20,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported. Adverse events are reported as “number of events” and
not as “patients with events”
Antimicrobial resistance: data reported
Death: not reported
Funding sources The studywas fundedby theAgency for Innovation by Science andTechnology, Flanders,
Belgium
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used a central, web-based tool
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo not described in detail. However,
both active treatment and placebowere for-
mulated at the same pharmacy
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded trial and presumably
matching placebo used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Adverse events resulting in
discontinuation are reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, un-
clear ascertainment. Adverse events re-
ported
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Brusselle 2013 (Continued)
Other bias Low risk None were identified.
Bystedt 1980
Methods Design: randomised, placebo-controlled, 7-armed trial
Participants Number assigned: 40 children, adults, and elderly (macrolide n = 20, placebo n = 20)
Age in years (mean (range)): 29 (17 to 79)
Setting: secondary care
Interventions Indication: impacted mandibular 3rd molars
Type of macrolide: erythromycin stearate
Route: per oral
Dose per day: 500 mg at day 1, then 250 mg x 4 for 7 days
Duration of treatment: 8 days
Total treatment dose: 7500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: incomplete reporting. However, no contact details for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear sequence generation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and staff were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts not reported.
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Bystedt 1980 (Continued)
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come, standardised ascertainment, adverse
events not reported
Other bias Low risk None were identified.
Cameron 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 77 adults (macrolide n = 39, placebo n = 38)
Age in years (mean ± SD): macrolide: 46.4 ± 8.8, placebo: 42.8 ± 9.4
Setting: unclear
Interventions Indication: smokers with chronic asthma
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 84 days
Total treatment dose: 21,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study funded by the Medical Research Council UK and supported financially by NHS
Research Scotland (NRS), through the Scottish Primary Care Research Network
Authors purchased study medication with an educational grant from AstraZeneca. Some
authors were on advisory boards, received consultancy fee or grants for institutions from
pharmaceutical companies
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo
89Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cameron 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events. However, infor-
mation on adverse events was clearly pre-
sented upon contacting authors
Other bias Low risk None were identified.
Carbonell 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 100 adults and elderly (macrolide n = 50, placebo n = 50)
Age in years (mean ± SD): macrolide: 59.3 ± 14.6, placebo: 57.0 ± 13.4
Setting: secondary care
Interventions Indication: endoscopy for acute upper gastrointestinal bleeding
Type of macrolide: erythromycin
Route: intravenous
Dose per day: 250 mg
Duration of treatment: 1 day
Total treatment dose: 250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination
Adverse events: states that no adverse events were observed
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by Assistance Publique Hopitanx de Paris, France. Erythromycin produced
by Abbott France
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Carbonell 2006 (Continued)
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active treatment or placebowasmixedwith
saline before infusion and administered in-
travenously
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout, except 1 participant ran-
domised to erythromycin who was with-
drawn before treatment as he had advanced
hepatocellular carcinoma
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Cercek 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1439 adults and elderly (macrolide n = 716, placebo n = 723)
Age in years (mean ± SE): macrolide: 65.2 ± 0.5, placebo: 64.7 ± 0.5
Setting: secondary care
Interventions Indication: unstable angina or acute myocardial infarction
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg day 1 followed by 250 mg/day for 4 days
Duration of treatment: 5 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: laboratory tests
Reporting of adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Funded by The Heart Foundation at Cedars-Sinai (formerly the Steven S Cohen Heart
Fund) and institutional funds of the participating centres
Notes Concomitant medication: yes
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Cercek 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation
Allocation concealment (selection bias) Low risk Sealed, tamper-evident envelopes used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active drugs and matched placebo deliv-
ered in identical bottles
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded evaluators and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, except
for liver function tests. Adverse events re-
ported
Other bias Low risk None were identified.
Clement 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 82 children (macrolide n = 40, placebo n = 42)
Age in years (mean ± SD): macrolide: 10.9 ± 3.5, placebo: 11.1 ± 3.2
Setting: secondary care
Interventions Indication: cystic fibrosis
Type of macrolide: azithromycin
Route: per oral
Dose: 250 mg if < 40 kg or 500 mg if ≥ 40 kg, 3 days/week
Duration of treatment: 1 year
Total treatment dose: 78,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinical examination/lab tests
Reporting of adverse events: yes
Antimicrobial resistance: data reported
Death: not reported
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Clement 2006 (Continued)
Funding sources Study supported by the Cystic Fibrosis Association Vaincre la Mucoviscidose, Paris,
France
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and study investigators
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment and ad-
verse events presented clearly. However,
liver function measured but not reported
Other bias Low risk None were identified.
Corris 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 48 adults (macrolide n = 25, placebo n = 23)
Age in years (median (IQR)): macrolide: 51.0 (35 to 56), placebo: 51.0 (44 to 59)
Setting: secondary care
Interventions Indication: bronchiolitis obliterans syndrome post-lung transplantation
Type of macrolide: azithromycin
Route: per oral
Dose: 250 mg on alternate days
Duration of treatment: 84 days
Total treatment dose: 10,500 mg
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Corris 2015 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: data reported
Death: no deaths during the study period
Funding sources Study fundedby aMedical ResearchCouncil project grant and aBritish LungFoundation
Trevor Clay Award
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned in a 1:1 ratio using ran-
dom permuted blocks within strata
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo not described in detail. However,
active treatment and placebo were formu-
lated by the same company
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk None lost to follow-up. 1 adverse event
leading to discontinuation reported
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome
and unclear ascertainment. Adverse events
not presented clearly
Other bias Low risk None were identified.
Currier 2000
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 644 adults (macrolide n = 322, placebo n = 321, mistakenly enrolled
n = 1)
Age in years (median): 40
Setting: AIDS clinical trial study sites at university-based outpatient clinics
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Currier 2000 (Continued)
Interventions Indication: mycobacterium avium complex infection in people with AIDS and increased
CD4+ cell counts
Type of macrolide: azithromycin
Route: per oral
Dose: 1200 mg/week
Duration of treatment: 69 weeks (median)
Total treatment dose: 82,800 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by the AIDS Clinical Trials Group and National Institute of Allergy
and Infectious Diseases and in part by Pfizer Inc.
1 of the authors was a representative for Pfizer Inc and reviewed the protocol, statistical
reports, and manuscript
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned in permuted blocks of
4 within each stratification level
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups. Dis-
continuation due to adverse events was
larger in azithromycin group than in
placebo group (8% versus 2%), but this is
reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
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Currier 2000 (Continued)
Other bias Low risk None were identified.
Curry 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 62 children (macrolide n = 32, placebo n = 30)
Age in weeks (mean ± SD): macrolide: 36.3 ± 2.1, placebo: 36.3 ± 1.1
Setting: secondary care
Interventions Indication: infants with gastroschisis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 12 mg/kg
Duration of treatment: 13 days (mean)
Total treatment dose: 377 mg (mean weight used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: laboratory tests and ECG
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources The BAPS Multicentre Research Fellow was funded by Dunhill Medical Trust. Authors
acknowledge supplying company (Rosemont Pharmaceuticals)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of investigators and caretakers
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
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Curry 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome, lab-
oratory tests and ECG performed regu-
larly.However, unclear reporting of adverse
events
Other bias Low risk None were identified.
Czarnetzki 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 132 adults (macrolide n = 66, placebo n = 66)
Age in years (median (IQR)): macrolide: 40.5 (31 to 58), placebo: 45.0 (29 to 55)
Setting: secondary care
Interventions Indication: gastric emptying in people undergoing general anaesthesia for emergency
surgery
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 3 mg/kg
Duration of treatment: 1 day
Total treatment dose: 223.5 mg (mean weight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by institutional funds from the Division of Anestesiology, Geneva
University Hospitals
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Czarnetzki 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Dunlay 1987
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 63 adults (macrolide n = 32, placebo n = 31)
Age in years (mean): macrolide: 43.0, placebo: 44.0
Setting: primary care
Interventions Indication: acute bronchitis
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 10 days
Total treatment dose: 9990 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary used
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported. Authors acknowledge supplying company (Upjohn Company)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Used sequentially numbered, identical
drug containers
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Dunlay 1987 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, physician, and investigators
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, discontinuation due to ad-
verse events reported
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, how-
ever unclear reporting of adverse events as
only reported on how many participants
withdrew due to adverse events
Other bias Low risk None were identified.
Ehsani 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults and elderly (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): macrolide: 61 ± 15, placebo: 62 ± 17
Setting: secondary care
Interventions Indication: upper gastrointestinal bleeding
Type of macrolide: erythromycin
Route: intravenous
Dose per day: 3 mg/kg in 100 mL saline
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Ehsani 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding as placebo not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear if participants and staff were
blinded, however the only reported out-
come is death, which is objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome.
States that adverse events were recorded,
but unclear ascertainment, and adverse
events not reported
Other bias Low risk None were identified.
El-Sadr 2000
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 520 adults (macrolide n = 258, placebo n = 262)
Age in years (mean ± SD): macrolide: 41.7 ± 7.4, placebo: 41.9 ± 8.5
Setting: not specified
Interventions Indication: mycobacterium avium complex infection in people with HIV and increased
CD4+ cell counts
Type of macrolide: azithromycin
Route: per oral
Dose: 1200 mg/week
Duration of treatment: 12.7 months (median in azithromycin group)
Total treatment dose: 66,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by a grant from theNational Institute of Allergy and InfectiousDiseases.
Authors acknowledge supplying company (Pfizer)
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El-Sadr 2000 (Continued)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, discontinuation due to ad-
verse events reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, un-
clear ascertainment. Adverse events pre-
sented clearly
Other bias Low risk None were identified.
Eschenbach 1991
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1181 adults (macrolide n = 605, placebo n = 576)
Age in years (mean ± SD): macrolide: 23.9 ± 5.3, placebo: 23. 6 ± 5.6
Setting: secondary care
Interventions Indication: pregnant women with Ureaplasma urealyticum
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: maximum of 70 days (starting between 26 and 30 weeks’
gestation and continuing through 35 completed weeks of pregnancy. Instructed to take
the medication for 10 weeks or until the end of the 35th week of pregnancy, whichever
came first)
Total treatment dose: 69,930 mg (maximum)
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Eschenbach 1991 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: spontaneously + asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported for babies
Funding sources Study supported by the National Institutes of Health. Authors acknowledge supplying
company (The Upjohn Company)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, and ad-
verse events presented clearly
Other bias Low risk None were identified.
Fonseca-Aten 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 43 children (macrolide n = 22, placebo n = 21)
Age in months (median (range)): macrolide: 112.5 (62 to 187), placebo: 100 (50 to
181)
Setting: emergency department of Children’s Medical Center
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Fonseca-Aten 2006 (Continued)
Interventions Indication: acute exacerbation of recurrent wheezing or asthma
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 15 mg/day, in 2 divided doses (maximum of 1000 mg)
Duration of treatment: 5 days
Total treatment dose: 5000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by Abbott Laboratories and Children’s Medical Center of Dallas Research
Advisory committee
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear sequence generation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo not described, however active
treatment and placebo prepared by the
same company
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No outcomes reported. Children, caretak-
ers, and staff were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Lost to follow-up not reported.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and adverse events
not reported
Other bias Low risk None were identified.
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Frossard 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 105 adults and elderly (macrolide n = 51, placebo n = 54)
Age in years (mean ± SD): macrolide: 59.2 ± 15, placebo: 64.5 ± 16
Setting: secondary care
Interventions Indication: acute upper gastrointestinal bleeding
Type of macrolide: erythromycin
Route: intravenous
Dose per day: 250 mg (mixed with 50 mL saline)
Duration of treatment: 1 day
Total treatment dose: 250 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: spontaneously
Adverse events: data reported
Antimicrobial resistance: not reported
Death: incomplete reporting
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Allocation done off-site at a central phar-
macy.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
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Frossard 2002 (Continued)
Other bias Unclear risk Small, significant age difference between
the 2 groups
Garcia-Burguillo 1996
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 adults (macrolide n = 30, placebo n = 30)
Age in years (mean ± SD): macrolide: 28.3 ± 5.9, placebo: 27.4 ± 6
Setting: secondary care
Interventions Indication: preterm rupture of the amniotic membranes
Type of macrolide: erythromycin ethyl succinate
Route: per oral
Dose per day: 2000 mg
Duration of treatment: 8 days (mean duration of treatment in erythromycin group)
Total treatment dose: 16,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: reported for babies of treated mothers
Funding sources None reported.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear blinding as placebo not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only reported on death in babies, which
is an objective outcome not influenced by
blinding or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
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Garcia-Burguillo 1996 (Continued)
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, adverse events not
reported (only death in babies)
Other bias Low risk None were identified.
Gharpure 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 74 children (macrolide n = 37, placebo n = 37)
Age in years (mean (range)): macrolide: 3.5 (0.1 to 16), placebo: 1.8 (0.1 to 17)
Setting: secondary care
Interventions Indication: tube placement in critically ill children
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 10 mg/kg for every 6 hours (maximum 3 doses)
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: continuous electrocardiogram monitoring and adverse
events defined before study start
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Children’s Research Center of Michigan.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Saline used as placebo and equal amounts.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of children, parents, and staff
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Gharpure 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, report on reason for discon-
tinuation
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come. However, adverse events defined be-
fore study start and reported
Other bias Low risk None were identified.
Giamarellos-Bourboulis 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 200 adults and elderly (macrolide n = 100, placebo n = 100)
Age in years (mean ± SD): macrolide: 58.4 ± 20.7, placebo: 58.4 ± 17.4
Setting: secondary care
Interventions Indication: sepsis associated with ventilator-associated pneumonia
Type of macrolide: clarithromycin
Route: intravenous
Dose per day: 1000 mg
Duration of treatment: 3 days
Total treatment dose: 3000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: clinical examination (lab tests, ECG)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Abbott Laboratories. No information about their role in the study
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequencewas generated by an indepen-
dent biostatistician and stratified by study
site
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Giamarellos-Bourboulis 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk None lost to follow-up. Report on reasons
for discontinuation
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome.
Only serious adverse events reported; info
onQTc interval not presented even though
ECG was performed
Other bias Low risk None were identified.
Giamarellos-Bourboulis 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 600 adults and elderly (macrolide n = 302, placebo n = 298)
Age in years (mean ± SD): macrolide: 67.8 ± 19.3, placebo: 65.9 ± 19.9
Setting: secondary care
Interventions Indication: suspected gram-negative sepsis
Type of macrolide: clarithromycin
Route: intravenous
Dose per day: 1000 mg
Duration of treatment: 4 days
Total treatment dose: 4000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Abbott Laboratories (Hellas) SA.
The first author serves as an advisor of Astellas Hellas and The Medicines Company and
has received honoraria from AbbVie
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sequencewas generated by an indepen-
dent biostatistician and stratified by study
site
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Giamarellos-Bourboulis 2014 (Continued)
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk None lost to follow-up. Report on reasons
for discontinuation
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome
and unclear ascertainment. However, ad-
verse events reported in detail
Other bias Low risk None were identified.
Gibson 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 420 adults and elderly (macrolide n = 213, placebo n = 207)
Age in years (median (IQR)): macrolide: 60.01 (49.58 to 67.98), placebo: 61.02 (50.
62 to 68.74)
Setting: secondary care
Interventions Indication: persistent uncontrolled asthma
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg 3 times per week
Duration of treatment: 336 days
Total treatment dose: 72,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Ascertainment of adverse events: participants asked + clinical examination
Adverse event: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Supported by the National Health and Medical Research Council of Australia and the
John Hunter Hospital Charitable Trust
Notes Concomitant medication: yes
Risk of bias
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Gibson 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk About 20% of participants in each group
were withdrawn, however reasons (includ-
ing adverse events) for withdrawal were
provided
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome and
clear ascertainment. Adverse events re-
ported
Other bias Low risk None were identified.
Glass 1999
Methods Design: randomised, placebo-controlled, 4-armed trial
Participants Number assigned: 80 children and adults (macrolide n = 39, placebo n = 41)
Age in years (mean ± SD): macrolide: 18.8 ± 2.5, placebo: 18.3 ± 1.9
Setting: secondary care
Interventions Indication: acne vulgaris
Type of macrolide: erythromycin
Route: topical
Dose per day: 2% gel twice a day
Duration of treatment: 84 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinician assessment
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None reported.
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Glass 1999 (Continued)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo not described (4 arms in study).
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants or staff or both were
blinded to treatments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment and ad-
verse events reported. However, only re-
port “overall” on participants with adverse
events
Other bias Low risk None were identified.
Gokmen 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 47 children (macrolide n = 24, placebo n = 23)
Gestational age in weeks (median (range)): macrolide: 28.5 (26 to 32), placebo: 27 (25
to 30)
Setting: secondary care
Interventions Indication: preventing feeding intolerance and liver function abnormalities in premature
infants
Type of macrolide: erythromycin
Route: per oral
Dose per day: 12.5 mg/kg (mixed into milk feeds)
Duration of treatment: 14 days
Total treatment dose: N/A
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Gokmen 2012 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: electrocardiography was performed before drug treat-
ment began and after the 1st and 2nd week of treatment to assess the QTc intervals
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None reported.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo solution was given as an equiva-
lent volume of normal saline. All the med-
ications were mixed thoroughly into milk
feeds to mask their appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medicine or placebo addition to the milk
was performed by a dietitian so that the
neonatal nurses were blinded to the partic-
ular intervention in each infant.
Death is an objective outcome, not influ-
enced by blinding or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, none caused by adverse
events
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. State that ECG was performed dur-
ing study period, but no reporting of ECG
measures
Other bias Unclear risk Infants in the macrolide group had higher
gestational age and birthweight than those
assigned placebo
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Grassly 2016
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 754 children (macrolide n = 376, placebo n = 378)
Age in months (mean ± SE): azithromycin: 7.46 ± 0.08, placebo: 7.49 ± 0.08
Setting: healthy infants living in 14 blocks of Vellore district, India
Interventions Indication: improve immune response to oral poliovirus vaccination
Type of macrolide: azithromycin
Route: per oral
Dose per day: 10 mg/kg
Duration of treatment: 3 days
Total treatment dose: 219 mg (mean weight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Bill & Melinda Gates Foundation.
1 author declared unrelated collaborations with pharmaceutical companies
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Children, parents, and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome. How-
ever, unclear ascertainment and incomplete
reporting of adverse events (do not report
on each adverse event separately)
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Grassly 2016 (Continued)
Other bias Low risk None were identified.
Grayston 2005
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 4012 adults and elderly (macrolide n = 2004, placebo n = 2008)
Age in years (mean): macrolide: 65, placebo: 65
Setting: secondary care
Interventions Indication: secondary prevention in people with stable coronary heart disease
Type of macrolide: azithromycin
Route: per oral
Dose: 600 mg/week
Duration of treatment: 1 year
Total treatment dose: 31,200 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported (part of composite primary outcome)
Funding sources Study supported by the National Heart, Lung, and Blood Institute and Pfizer
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, none due to adverse events
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Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Grob 1981
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 91 children (macrolide n = 52, placebo n = 39)
Age in years (range): 0 to 8
Setting: primary care
Interventions Indication: Bordetella pertussis prevention
Type of macrolide: erythromycin ethyl succinate
Route: per oral
Dose per day: 500 mg if aged < 2 years and 1000 mg if aged 2 to 8 years
Duration of treatment: 14 days
Total treatment dose: 14,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study funded by the Medical Research Council.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear sequence generation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout not reported.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and adverse events
not reported
Other bias Low risk None were identified.
Gupta 1997
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 60 adults and elderly (macrolide (3-day course) n = 28, macrolide
(6-day course) n = 12, placebo n = 20)
Age in years (mean ± SD): macrolide (both arms): 58 ± 7, placebo: 60 ± 9
Setting: secondary care
Interventions Indication: male survivors of myocardial infarction
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: arm 1: 3 days, arm 2: 6 days
Total treatment dose: arm 1: 1500 mg, arm 2: 3000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported (note: do not report on “common adverse events”)
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by the British Heart Foundation. Authors acknowledge supplying company
(Pfizer Ltd)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo and azithromycin supplied by the
same company.However, unclear if placebo
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Gupta 1997 (Continued)
matched the single course of azithromycin
(3 days) or the 2 courses (2 x 3 days)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only report on objective outcomes (death/
myocardial infarction) not influenced by
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts.
Selective reporting (reporting bias) High risk Adverse events stated as an outcome. Un-
clear ascertainment. Report on outcomes
for the 2 treatment regimens as 1 group and
do not report on common adverse events
Other bias Low risk None were identified.
Gurfinkel 1999
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 202 adults and elderly (macrolide n = 102, placebo n = 100)
Age in years (mean ± SD): macrolide: 61 ± 12, placebo: 61 ± 12
Setting: secondary care
Interventions Indication: non-Q-wave coronary syndrome
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 30 days
Total treatment dose: 9000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: electrocardiogram
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study funded by the Favaloro Foundation. Authors acknowledge supplying company
(Hoechst Marion Roussel)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Gurfinkel 1999 (Continued)
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and staff blinded to treat-
ments.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come and unclear ascertainment, except
from ECG. However, adverse events re-
ported
Other bias Unclear risk More participants with diabetes were ran-
domised to macrolide group
Hahn 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 45 adults (macrolide n = 24, placebo n = 21)
Age in years (mean ± SD): macrolide: 50 ± 14, placebo: 45 ± 12
Setting: primary care
Interventions Indication: asthma
Type of macrolide: azithromycin
Route: per oral
Dose: 600 mg/day for 3 days, followed by 600 mg weekly
Duration of treatment: 6 weeks
Total treatment dose: 4800 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by the National Institutes of Health, the American Academy of Family
Physicians Foundation Joint Grant Awards Program, the Wisconsin Academy of Family
Physicians, under the auspices of theWisconsinResearchNetwork, theDean Foundation
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Hahn 2006 (Continued)
for Health Research and Education. Study supported by an unrestricted educational
grant from Pfizer
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study physicians, research staff, partici-
pants, and data analysts were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not stated clearly as an out-
come, however standardised ascertainment
and adverse events reported
Other bias Low risk None were identified.
Hahn 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 75 adults (macrolide n = 38, placebo n = 37)
Age in years (mean ± SD): macrolide: 45.7 ± 15.5, placebo: 47.4 ± 14.2
Setting: primary care
Interventions Indication: asthma
Type of macrolide: azithromycin
Route: per oral
Dose: 600 mg/day for 3 days, followed by 600 mg weekly
Duration of treatment: 12 weeks
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked
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Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the Wisconsin Academy of Family Physicians, the American
Academy of Family Physicians Foundation, the Dean Foundation for Health Research
and Education, and private donors provided financial support for direct costs of AZ-
MATICS (AZithroMycin/Asthma: Trial in Community Settings). Authors acknowledge
supplying company (Pfizer Inc)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of staff and participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk 42% lost to follow-up in azithromycin
group versus 30% in placebo group. How-
ever, authors report on adverse events for
92% to 95% of participants in macrolide
group and 92% in placebo group
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Halperin 1999
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 362 children and adults (macrolide n = 170, placebo n = 192)
Age in years (mean): macrolide: 26.6, placebo: 24.9
Setting: community based (households)
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Halperin 1999 (Continued)
Interventions Indication: Bordetella pertussis prevention
Type of macrolide: erythromycin estolate
Route: per oral
Dose per day: 40 mg/kg (max 1000 mg)
Duration of treatment: 10 days
Total treatment dose: 10,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the National Health Research and Development Program, Health
Canada. Authors acknowledge supplying company (Eli Lilly Canada Inc)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and reporting of adverse events
Other bias Low risk None were identified.
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Haxel 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number: 58 adults (macrolide n = 29, placebo n = 29)
Age in years (mean ± SD): macrolide: 45.7 ± 12.8, placebo: 47.7 ± 12.5
Setting: secondary care
Interventions Indication: chronic rhinosinusitis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 90 days
Total treatment dose: 22,500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. More participants dropped
out in macrolide group. However, adverse
events reported
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome. How-
ever, unclear ascertainment and authors
only report on gastrointestinal adverse
events, although it reads as theremight have
been other kinds of adverse events to re-
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Haxel 2015 (Continued)
port (“Adverse events such as gastrointesti-
nal disorders...”)
Other bias Low risk None were identified.
Haye 1998
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 169 adults and elderly (macrolide n = 87, placebo n = 82)
Age in years (mean (range)): macrolide: 40.2 (21 to 70), placebo: 43.2 (18 to 68)
Setting: primary care
Interventions Indication: acute maxillary sinusitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout and no participants discontin-
ued treatment due to adverse events
Selective reporting (reporting bias) Low risk Adverse events not stated clearly as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Heppner 2005
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 292 adults (macrolide n = 190, placebo n = 102)
Age in years (mean ± SD): macrolide: 29.3 ± 8, placebo: 29.1 ± 8
Setting: the remote forest and scrub-covered foothills at the AFRIMS-Kwai River Chris-
tian Hospital field site in western Thailand
Interventions Indication: Plasmodium vivax malaria prophylaxis
Type of macrolide: azithromycin
Route: per oral
Dose per day: loading dose on day 1 of 750 mg, then 250 mg per day
Duration of treatment: 74 days (on average)
Total treatment dose: 19,000 mg (average duration of treatment used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the US Army Medical Materiel Development Activity and by the
Military Infectious Diseases Research Program. Azithromycin and placebowere provided
by Pfizer Central Research
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and trial personnel blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up 28% (macrolide) versus
25% (placebo).However, adverse events re-
ported for > 90% of participants
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Unclear risk 2:1 randomisation design
Hillis 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 141 adults and elderly (macrolide n = 72, placebo n = 69)
Age in years (mean ± SD): macrolide: 66 ± 11, placebo: 65 ± 12
Setting: secondary care
Interventions Indication: survivors of acute coronary syndrome
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 5 days
Total treatment dose: 2500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: data reported, but only those resulting in discontinuation
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the British Heart Foundation.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant dropped out in each group.
Selective reporting (reporting bias) High risk Adverse events not stated clearly as an out-
come. Standardised ascertainment. How-
ever, only adverse events resulting in dis-
continuation were reported on
Other bias Low risk None were identified.
Hodgson 2016
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 44 adults and elderly (macrolide n = 22, placebo n = 22)
Age in years (mean ± SD): macrolide: 59.6 ± 11.0, placebo: 56.9 ± 9.0
Setting: respiratory clinics
Interventions Indication: chronic cough
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg daily for 3 days, followed by 250 mg 3 times/week
Duration of treatment: 59 days
Total treatment dose: 7500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear (ECG and phlebotomy prior to study entry)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by a National Institute for Health Research Biomedical Research fel-
lowship
Notes Concomitant medication: yes
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Hodgson 2016 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups. Rea-
sons given.
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome.
Unclear ascertainment. However, adverse
events reported
Other bias Low risk None were identified.
Hooton 1990
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 87 adults (macrolide n = 36, placebo n = 41)
Age in years (mean ± SD): macrolide: 26 ± 6, placebo: 29 ± 8
Setting: secondary care
Interventions Indication: non-gonococcal urethritis
Type of macrolide: erythromycin estolate
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 21 days
Total treatment dose: 21,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Erythromycin and placebo were provided by The Upjohn Company
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Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table used.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome.
Unclear ascertainment, although follow-up
visits scheduled. Adverse events reported
Other bias Low risk None were identified.
Hyde 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 147 adults (macrolide n = 73, placebo n = 74)
Age in years (mean (range)): macrolide: 44 (25 to 63), placebo: 46 (19 to 64)
Setting: secondary care
Interventions Indication: Mycoplasma pneumoniae prophylaxis
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg on day 1, followed by 250 mg on days 2 to 5
Duration of treatment: 5 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
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Hyde 2001 (Continued)
Funding sources None stated. Authors acknowledge supplying company (Pfizer).
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Residents and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome,
unclear ascertainment. However, adverse
events reported
Other bias Low risk None were identified.
Ikeoka 2007
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 90 adults and elderly (macrolide n = 42, placebo n = 40, excluded n
= 8)
Age in years (mean ± SD): macrolide: 62 ± 10, placebo: 59 ± 9
Setting: secondary care
Interventions Indication: stable coronary disease
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg x 1 for 3 days in week 1, followed by 500 mg x 1 weekly for 12 weeks,
then 500 mg x 1 for 3 days in week 14
Duration of treatment: 14 weeks
Total treatment dose: 9000 mg
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Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated. Authors acknowledge supplying company (Pfizer).
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, block randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not stated clearly as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Jablonowski 1997
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 682 adults (macrolide n = 341, placebo n = 341)
Age in years (range): 20 to 60
Setting: multicentre trial
Interventions Indication: mycobacterium avium-intracellulare complex prophylaxis in HIV-infected
individuals
Type of macrolide: clarithromycin
Route: per oral
130Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jablonowski 1997 (Continued)
Dose per day: 1000 mg
Duration of treatment: N/A
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: no surveillance system was used to study the emergence of
resistant bacteria. However, authors state that there were no reports of infections with
clarithromycin-resistant organisms during the study, and no pneumonia due to a clar-
ithromycin-resistant organism was observed
Death: data reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo was
used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only report on objective outcomes, blind-
ing not relevant
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, adverse events not
reported
Other bias Low risk None were identified.
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Jackson 1999
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 88 adults and elderly (macrolide n = 44, placebo n = 44)
Age in years (mean (range)): 57 (37 to 79)
Setting: unclear
Interventions Indication: coronary artery disease
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg on days 1 and 2, then 250 mg on days 3 to 28
Duration of treatment: 28 days
Total treatment dose: 8000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors acknowledge supplying company (Pfizer Inc)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo not described in detail. However,
active treatment and placebo were formu-
lated by the same company
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, adverse events re-
ported
Other bias Low risk None were identified.
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Jespersen 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 4373 adults and elderly (macrolide n = 2172, placebo n = 2201)
Age in years (mean ± SD): macrolide: 65.4 ± 10.3, placebo: 65.2 ± 10.4
Setting: secondary care
Interventions Indication: stable coronary heart disease
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 14 days
Total treatment dose: 7000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant diary used
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by the Danish Heart Foundation, Copenhagen Hospital Corporation,
Danish Research Council, and 1991 Pharmacy Foundation. Authors acknowledge sup-
plying company (Abbott Laboratories)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded, death
is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk About 1% in each group did not return the
participant diary.
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
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Jespersen 2006 (Continued)
Other bias Low risk None were identified.
Joensen 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 507 adults and elderly (macrolide n = 250, placebo n = 257)
Age in years (mean ± SD): macrolide: 64.8 ± 8.8, placebo: 66.6 ± 10.1
Setting: secondary care
Interventions Indication: peripheral arterial disease
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 28 days
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported (primary outcome)
Funding sources Study supported by theDanish Heart Foundation, the Rosa and Asta Jensen Foundation,
the Danish Medical Research Council, and the Health Department of Viborg County
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Nurses at the department gave participants
a glass of pills (unaware of content)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nurse, other team members, and partici-
pants blinded. Death is an objective out-
come
Incomplete outcome data (attrition bias)
All outcomes
Low risk None lost to follow-up
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Joensen 2008 (Continued)
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Johnston 2016
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 199 adults (macrolide n = 97, placebo n = 102)
Age in years (median (IQR)): macrolide: 39.1 (28.9 to 49.5), placebo: 36.2 (25.4 to
49.3)
Setting: 30 secondary care hospitals and 1 primary centre
Interventions Indication: acute asthma exacerbation
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary used
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study funded by the Efficacy and Mechanisms Evaluation programme of the Medical
Research Council, in partnership with the National Institute for Health Research
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk ID numbers assigned sequentially.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
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Johnston 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many participants included
in safety assessments, numbers not stated.
However, authors report that 80% at-
tended all follow-up visits
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events are reported
Other bias Low risk None were identified.
Jun 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 116 adults and elderly (macrolide n = 58, placebo n = 58)
Age in years (mean ± SD): macrolide: 56.6 ± 10.3, placebo: 59 ± 11.6
Setting: secondary care
Interventions Indication: subtotal gastrectomy
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 125 mg
Duration of treatment: 1 day
Total treatment dose: 125 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Business of Globalization for Science and Technology, Seoul, Re-
public of South Korea
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
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Jun 2014 (Continued)
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both groups received infusion of saline (+/
- antibiotics).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. Some adverse
events reported (nausea, vomiting)
Other bias Low risk None were identified.
Kaehler 2005
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 327 adults and elderly (macrolide n = 165, placebo n = 162)
Age in years (mean ± SD): macrolide: 62 ± 16, placebo: 63 ± 14
Setting: secondary care
Interventions Indication: coronary artery disease
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 42 days
Total treatment dose: 12,600 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Aventis Pharma GmbH, Germany.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Kaehler 2005 (Continued)
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if identical-appearing placebo was
used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No adverse events reported, death is an ob-
jective outcome.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, incomplete report-
ing of adverse events
Other bias Low risk None were identified.
Kaiser 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 269 adults and elderly (macrolide n = 133, placebo n = 132, excluded
n = 4)
Age in years (median (range)): 35 (18 to 93)
Setting: secondary care
Interventions Indication: common cold and acute rhinosinusitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by a grant from Pfizer AG, Switzerland.
Notes Concomitant medication: yes
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Kaiser 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come and unclear ascertainment. However,
gastrointestinal adverse events reported
Other bias Low risk None were identified.
Kalliafas 1996
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 57 adults and elderly (macrolide n = 31, placebo n = 26)
Age in years (mean (range)): macrolide: 54.7 (19 to 84), placebo: 57.8 (19 to 86)
Setting: secondary care
Interventions Indication: critically ill individuals assessed as needing nutrition support
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 200 mg
Duration of treatment: 1 day
Total treatment dose: 200 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
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Kalliafas 1996 (Continued)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table used.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Saline used as placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No reporting of relevant outcomes. Partic-
ipants and clinicians blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, adverse events not
reported
Other bias Low risk None were identified.
Karlsson 2009
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 247 elderly (macrolide n = 122, placebo n = 125)
Age in years (median (IQR)): macrolide: 71 (67 to 74), placebo: 71 (67 to 76)
Setting: secondary care
Interventions Indication: abdominal aortic aneurysms
Type of macrolide: azithromycin
Route: per oral
Dose per day: 600 mg x 1 daily for 3 days, then 600 mg once weekly for 15 weeks
Duration of treatment: 16 weeks
Total treatment dose: 10,800 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
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Karlsson 2009 (Continued)
Funding sources Study supported by County of Gävleborg Research and Development Center, Gore
Swedish Research Foundation, Pfizer AB Sweden, Schyberg medical research fund, and
Zoega medical research fund
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. Death
is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 person in each group was lost to follow-
up.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and only non-spe-
cific adverse events are reported on
Other bias Low risk None were identified.
Kathariya 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 100 adults (macrolide n = 50, placebo n = 50)
Age in years (mean ± SD): macrolide: 39.3 ± 7.4, placebo: 37.4 ± 7.3
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: clarithromycin
Route: topical
Dose per day: 0.5% gel once
Duration of treatment: 1 day
Total treatment dose: N/A
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Kathariya 2014 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: states that no adverse events were observed or reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Self funded project
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Allocation done by a study co-ordinator
not involved in the clinical treatment/as-
sessments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants lost to follow-up in placebo
group: 1 migrated and 1 was unwilling to
continue
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and states that no adverse events were
observed or reported
Other bias Low risk None were identified.
Kaul 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 466 adults (macrolide n = 230, placebo n = 236)
Age in years (mean ± SD): macrolide: 29.1 ± 7.8, placebo: 28.1 ± 7.7
Setting: urban slum area of Nairobi, Kenya
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Kaul 2004 (Continued)
Interventions Indication: prevention of sexually transmitted infections and HIV-1 infection
Type of macrolide: azithromycin
Route: per oral
Dose: 1000 mg once a month
Duration of treatment: 26 months (on average)
Total treatment dose: 26,000 mg (on average)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by the Rockefeller Foundation, the European Commission, the Canada
Research Chairs Program, Ontario HIV Treatment Network, the Canadian Institutes
of Health Research, and the Canadian Infectious Disease Society. Authors acknowledge
supplying company (Pfizer Inc)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Clinic staff assigned study numbers consec-
utively at enrolment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. Death
is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 20% lost to follow-up after 2 years in the
2 groups, but adverse events as a source of
dropout reported
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment. However, adverse
events considered to be possibly or likely
related to treatments are reported on
Other bias Low risk None were identified.
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Keenan 2018
Methods Design: cluster-randomised placebo-controlled trial
Participants Number assigned: 1533 communities (macrolide n = 767 communities (97,047 chil-
dren), placebo n = 766 communities (93,191 children), excluded n = 20 communities,
declined n = 1 community)
Age in months (range): 1 to 59
Setting: communities in Malawi, Niger, and Tanzania
Interventions Indication: mass distribution of antibiotics to reduce mortality
Type of macrolide: azithromycin
Route: per oral
Dose: minimum 20 mg/kg once. Repeated twice yearly
Duration of treatment: 4 years
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Ascertainment of adverse events: parents asked
Adverse event: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by a grant from the Bill & Melinda Gates Foundation. Pfizer provided both
the azithromycin and the placebo
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, observers, and in-
vestigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for exclusion of 20 communities
explained, no communities were lost to fol-
low-up after the initial census
Selective reporting (reporting bias) High risk Unclear if adverse events were stated as an
outcome, standardised ascertainment. Re-
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Keenan 2018 (Continued)
port on very few adverse events in a large
trial population
Other bias Low risk None were identified.
Kenyon 2001a
Methods Design: randomised, placebo-controlled, factorial trial
Participants Number assigned: 3180 adults (macrolide n = 1611, placebo n = 1569)
Age in years (mean ± SD): macrolide: 26.5 ± 6.1, placebo: 26.7 ± 5.7
Setting: secondary care
Interventions Indication: spontaneous preterm labour
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 10 days (or until delivery)
Total treatment dose: 10,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: report on death of babies born to women with preterm labour
Funding sources Study supported by the UKMedical Research Council. Authors acknowledge supplying
company (Parke-Davis)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Each woman was assigned a sequentially
numbered study-drug pack
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, clinicians, and trial staff
blinded.
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Kenyon 2001a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups (note
50% completion at 7 years follow-up)
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and adverse events
not reported
Other bias Low risk None were identified.
Kenyon 2001b
Methods Design: randomised, placebo-controlled, factorial trial
Participants Number assigned: 2422 adults (macrolide n = 1197, placebo n = 1225)
Age in years (mean ± SD): macrolide: 27.5 ± 6.1, placebo: 27.9 ± 6.1
Setting: secondary care
Interventions Indication: preterm pre-labour rupture of foetal membranes
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 10 days (or until delivery)
Total treatment dose: 10,000 (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: report on death of babies born to women with PPROM
Funding sources Study supported by the UKMedical Research Council. Authors acknowledge supplying
company (Parke-Davis)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Each woman was assigned a sequentially
numbered study-drug pack
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Kenyon 2001b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, clinicians, and trial staff
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups (69%
completion at 7 years follow-up)
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment. Most adverse events
presented as a total, and it was not pos-
sible to determine how many there were
in each of the 4 groups (erythromycin,
erythromycin and co-amoxiclav, co-amox-
iclav, or placebo)
Other bias Low risk None were identified.
Kim 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 129 adults and elderly (macrolide n = 64, placebo n = 65)
Age in years (mean ± SD): macrolide: 60.0 ± 10.0, placebo: 59.6 ± 10.1
Setting: secondary care
Interventions Indication: acute coronary syndrome who underwent PCI
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg daily for 3 days before and after PCI, followed by 500 mg/week
Duration of treatment: 3 weeks
Total treatment dose: 4000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (lab tests)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: data reported
Funding sources Not stated
Notes Concomitant medication: yes
Risk of bias
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Kim 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if matching placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No adverse events reported, death is an ob-
jective outcome.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 months follow-up in 95% of partici-
pants.
Selective reporting (reporting bias) High risk Adverse events not stated clearly as an
outcome, unclear ascertainment, adverse
events not reported (only adverse cardiac
outcomes are reported on)
Other bias Low risk None were identified.
King 1996
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 91 adults (macrolide n = 49, placebo n = 42)
Age in years (mean ± SD): macrolide: 36.0 ± 13, placebo: 38.2 ± 14.5
Setting: primary care
Interventions Indication: acute bronchitis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 10 days
Total treatment dose: 10,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
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King 1996 (Continued)
Funding sources Study supported by the Division of Primary Care of the Agency for Health Care Policy
and Research. Authors acknowledge supplying company (Parke-Davis, Morris Plane,
New Jersey)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk > 20% lost to follow-up, unclear from
which groups.
Selective reporting (reporting bias) Low risk Adverse events were stated clearly as an out-
come. Standardised ascertainment and ad-
verse events presented
Other bias Low risk None were reported.
Klebanoff 1995
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 938 women (macrolide n = 469, placebo n = 469)
Age in years: N/A
Setting: secondary care
Interventions Indication: pregnant women colonised with group B streptococci
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 10 weeks or until the end of the 35th week of pregnancy,
whichever came first
Total treatment dose: 69,930 mg (maximum)
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Klebanoff 1995 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: spontaneously
Adverse events: data reported
Antimicrobial resistance: not reported
Death: report on death in babies of mothers treated
Funding sources Study supported by the National Institutes of Health. Authors acknowledge supplying
company (The Upjohn Company)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 1% of women not included in
reporting of adverse events
Selective reporting (reporting bias) Unclear risk Adverse events not stated clearly as an out-
come. Standardised ascertainment. How-
ever, adverse events not presented clearly
Other bias Low risk None were identified.
Kneyber 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 71 children (macrolide n = 32, placebo n = 39)
Age in months (mean (IQR)): macrolide: 3.0 (1.0 to 4.0), placebo: 3.6 (1.0 to 6.0)
Setting: secondary care
Interventions Indication: respiratory syncytial virus lower respiratory tract disease
Type of macrolide: azithromycin
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Kneyber 2008 (Continued)
Route: per oral
Dose per day: 10 mg/kg
Duration of treatment: 3 days
Total treatment dose: 276 mg (mean weight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported. Children,
parents, and clinicians blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 child in placebo group dropped out.
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Kostadima 2004
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 75 adults (macrolide (twice a day) n = 25, macrolide (3 times a day)
n = 25, placebo n = 25)
Age in years (mean ± SD): macrolide (twice a day): 48 ± 16, macrolide (3 times a day):
42 ± 12, placebo: 41 ± 16
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Kostadima 2004 (Continued)
Setting: secondary care
Interventions Indication: asthma
Type of macrolide: clarithromycin
Route: per oral
Dose per day: arm 1: 500 mg, arm 2: 750 mg
Duration of treatment: 8 weeks
Total treatment dose: arm 1: 28,000 mg, arm 2: 42,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (lab tests)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Allocation done by an independent nurse.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that the placebo tabletswere indistin-
guishable from the clarithromycin tablets.
However, there are 2 active groups with 2
or 3 doses/day, unclear how many placebo
tablets/day
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) High risk Adverse events not stated clearly as an
outcome. States that laboratory assessment
was done, however values/changes not re-
ported. Incomplete reporting of adverse
events
Other bias Low risk None were identified.
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Kraft 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 52 adults (macrolide n = 26, placebo n = 26)
Age in years (mean ± SD): 33.4 ± 1.2
Setting: unclear
Interventions Indication: asthma
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 6 weeks
Total treatment dose: 42,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events reported: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the American Lung Association Asthma Research Center Grant and
Abbott Laboratories
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts not reported.
Selective reporting (reporting bias) High risk Adverse events not reported as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
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Kvien 2004
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 152 adults (macrolide n = 81, placebo n = 71)
Age in years (mean ± SD): macrolide: 33.0 ± 9.8, placebo: 34.7 ± 8.9
Setting: secondary care
Interventions Indication: reactive arthritis
Type of macrolide: azithromycin
Route: per oral
Dose: 1000 mg per week (starting after a single 1 g dose of azithromycin)
Duration of treatment: 12 weeks
Total treatment dose: 13,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Pfizer.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout was 30% and 34% in macrolide
and placebo groups, respectively. However,
reasons reported
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
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Kvien 2004 (Continued)
Other bias Low risk None were identified.
Lanza 1998
Methods Design: randomised, placebo-controlled, 4-armed trial
Participants Number assigned: 89 adults and elderly (macrolide n = 60, placebo n = 29)
Age in years (mean (range)): macrolide: 45.0 (28 to 76), placebo: 49.9 (24 to 78)
Setting: “47-Center U.S study”
Interventions Indication: duodenal ulcer
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1500 mg
Duration of treatment: 14 days
Total treatment dose: 21,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study sponsored by Glaxo Wellcome Inc.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adverse events reported for all randomised
participants.
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Lanza 1998 (Continued)
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Unclear risk Uneven distribution of number of partici-
pants in the 2 arms (2:1 allocation)
Leowattana 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 84 adults and elderly (macrolide n = 43, placebo n = 41)
Age in years (mean ± SD): macrolide: 62.9 ± 9.6, placebo: 60.4 ± 12.6
Setting: secondary care
Interventions Indication: secondary prevention of acute coronary syndrome
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 30 days
Total treatment dose: 9000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Siriraj Grant for Research Development and Medical Education.
Authors acknowledge supplying company (Hoechst Marion Roussel)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identically appearing placebo
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Leowattana 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. Death
is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Lildholdt 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 124 children and adults (macrolide n = 53, placebo n = 57, excluded
n = 10)
Age in years (mean (range)): 23.4 (6 to 58)
Setting: secondary care
Interventions Indication: recurrent acute tonsillitis
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg/week
Duration of treatment: 26 weeks
Total treatment dose: 13,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by Pfizer APS, Denmark.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
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Lildholdt 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, unclear in which group
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. However, ad-
verse events are reported
Other bias Low risk None were identified.
Malhotra-Kumar 2007a
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 112 adults (macrolide n = 74, placebo n = 38)
Age in years: (mean (range)): macrolide: 24 (19 to 56), placebo: 24 (18 to 57)
Setting: volunteers were selected from the University of Antwerp, Belgium
Interventions Indication: pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes (only
AMR)
Adverse events ascertainment: clinical examination (oral swabs)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by Abbott Laboratories.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Malhotra-Kumar 2007a (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Volunteers allocated by an administrator
with no further role in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 2 placebo groups (1 for each of the
macrolide arms) were used to ensure com-
plete blinding (Malhotra-Kumar 2007b).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Volunteers and trial staff blinded. Objec-
tive outcomes (data on AMR)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Standardised ascertainment and subse-
quent carriage of resistant bacteria re-
ported.However, no reporting on other ad-
verse events
Other bias Low risk None were identified.
Malhotra-Kumar 2007b
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 112 adults (macrolide n = 74, placebo n = 38)
Age in years (mean (range)): macrolide: 24 (19 to 58), placebo: 24 (18 to 57)
Setting: volunteers were selected from the University of Antwerp, Belgium
Interventions Indication: pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7 days
Total treatment dose: 7000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes (only
AMR)
Adverse events ascertainment: clinical examination (oral swabs)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by Abbott Laboratories.
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Malhotra-Kumar 2007b (Continued)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Volunteers allocated by an administrator
with no further role in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 2 placebo groups (1 for each of the
macrolide arms) were used to ensure com-
plete blinding (Malhotra-Kumar 2007a).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Volunteers and trial staff blinded. Objec-
tive outcomes (data on AMR)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Standardised ascertainment and subse-
quent carriage of resistant bacteria re-
ported.However, no reporting on other ad-
verse events
Other bias Low risk None were identified.
Mandal 1984
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 80 children and adults (macrolide n = 35, placebo n = 37, excluded
n = 8)
Age in years (mean ± SD): macrolide: 31.93 ± 16.59, placebo: 31.18 ± 21.15
Setting: secondary care
Interventions Indication: Campylobacter jejuni infection
Type of macrolide: erythromycin
Route: per oral
Dose per day: 50 mg/kg/child, 1000 mg/adult
Duration of treatment: 5 days
Total treatment dose: 5000 mg (maximum)
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Mandal 1984 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: authors state that “no incidence of adverse drug reaction was recorded”.
Nausea, vomiting, and abdominal pain are reported as a primary outcome and are not
considered to be adverse events
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors acknowledge supplying company (Abbott Laboratories)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded, none
experienced adverse events
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, unclear which group
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and authors state that no adverse
events were noted
Other bias Low risk None were identified.
Mandhane 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 300 children (macrolide n = 150, placebo n = 150)
Age in months (mean ± SD): macrolide: 34.8 ± 13.6, placebo: 30.5 ± 13.9
Setting: secondary care
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Mandhane 2017 (Continued)
Interventions Indication: wheezing
Type of macrolide: azithromycin
Route: per oral
Dose per day: 10 mg/kg for 1 day, then 5 mg/kg for 4 days
Duration of treatment: 5 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Ascertainment of adverse events: participant diary
Adverse event: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by The Lung Association - Alberta and Northwest Territories - TLA-IKON
Pediatric Team Grant
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated stratified block ran-
domisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of children/parents and study in-
vestigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Information on adverse events provided for
93% of participants in each group, reasons
for dropouts given
Selective reporting (reporting bias) Low risk Unclear if adverse events were stated as an
outcome and unclear ascertainment. How-
ever, protocol clearly states times for ad-
verse event monitoring, and adverse events
are reported
Other bias Low risk None were identified.
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Martande 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 70 adults (macrolide n = 35, placebo n = 35)
Age in years (range): 20 to 60
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 5 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors acknowledge supplying company (Micro Labs)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported. Partici-
pants and clinicians blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment. How-
ever, incomplete reporting of adverse events
Other bias Low risk None were identified.
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Martande 2016
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 70 adults (macrolide n = 35, placebo n = 35)
Age in years (mean ± SD): macrolide: 32.6 ± 5.4, placebo: 33.3 ± 7.3
Setting: dental care
Interventions Indication: Aggregatibacter actinomycetemcomitans-associated periodontitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: authors state that “(n)one of the individuals reported any adverse effect
due to the medications”
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors thank supplying companies (Micro Labs, Government College of
Pharmacy, Bangalore, India)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported. Clinicians
and participants blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and authors state that no adverse
events were identified
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Martande 2016 (Continued)
Other bias Low risk None were identified.
Martin 1997
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 414 children and adults (macrolide n = 205, placebo n = 209)
Age in years (mean ± SD): macrolide: 21.5 ± 4.2, placebo: 21.1 ± 4.3
Setting: secondary care
Interventions Indication: pregnant women infected with Chlamydia trachomatis
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: N/A
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported on death in babies of treated mothers
Funding sources Study supported by the National Institute of Child Health and Human Development
and the National Institute of Allergy and Infectious Diseases. Authors acknowledge
supplying company (The Upjohn Company)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
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Martin 1997 (Continued)
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment. How-
ever, adverse events not presented clearly
Other bias Low risk None were identified.
Mathai 2007
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 50 children (macrolide n = 27, placebo n = 23)
Age in weeks (mean): macrolide: 35.5, placebo: 37.2
Setting: secondary care
Interventions Indication: gastric emptying of low-birthweight babies
Type of macrolide: erythromycin
Route: per oral
Dose per day: 6 mg/kg
Duration of treatment: 4 days
Total treatment dose: 47 mg (used mean birthweight in erythromycin group)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinician assessment + clinical examination
Adverse events: authors state that “no side effects of the drug were seen”
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the office of Director General Armed Forces Medical Services
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
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Mathai 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment, and authors state that no adverse
events were identified
Other bias Unclear risk Infants in the erythromycin group had
lower gestational age and birthweight than
those in the placebo group
McCallum 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 97 children (macrolide n = 50, placebo n = 47)
Age in months (median (IQR)): macrolide: 5.3 (3 to 9.4), placebo: 5 (3 to 8.5)
Setting: secondary care
Interventions Indication: bronchiolitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 30 mg/kg
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: clinician assessment
Adverse events: authors state that “there were no adverse events or serious adverse events”
Antimicrobial resistance: not reported
Death: no deaths reported
Funding sources Funded by the National Health and Medical Research Council, the Channel 7 Founda-
tion, and the Financial Markets Foundation for Children
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified block randomisation
Allocation concealment (selection bias) Low risk Sequentially numbered, identical drug
containers
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McCallum 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events stated as a primary outcome,
and adverse eventsmonitored by study staff
every 12 hours until discharge
Other bias Low risk None were identified.
McCallum 2015
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 219 children (macrolide n = 106, placebo n = 113)
Age in months (median (IQR)): macrolide: 5.7 (3 to 10), placebo: 5.6 (3 to 9)
Setting: secondary care
Interventions Indication: bronchiolitis
Type of macrolide: azithromycin
Route: per oral
Dose: 30 mg/kg once weekly
Duration of treatment: 3 weeks
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination (swabs)
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by the National Health and Medical Research Council and by a Centre
for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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McCallum 2015 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Children, parents, and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% and 3% did not attend the day 21
follow-up interview in the macrolide and
placebo groups, respectvely
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
McCormack 1987
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 825 women (macrolide arm 1, n = 174; macrolide arm 2, n = 224;
placebo, n = 427)
Age in years: N/A
Setting: secondary care
Interventions Indication: pregnant women harbouring genital Ureaplasma urealyticum orMycoplasma
hominis, or both
Type of macrolide: arm 1: erythromycin estolate, arm 2: erythromycin stearate
Route: per oral
Dose per day: 1000 mg (both arms)
Duration of treatment: 6 weeks (both arms)
Total treatment dose: 42,000 mg (both arms)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the National Institute of Child Health and Human Development
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McCormack 1987 (Continued)
Notes Concomitant medication: unclear
Note: type of erythromycin used is changed roughly halfway through the study period
(stearate to estolate) due to the reporting of many adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Large dropout in all 3 groups - only about
40% of women completed the study. How-
ever, adverse events presented for 91% of
participants
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come. Standardised ascertainment and ad-
verse events reported
Other bias Low risk None were identified.
McDonald 1985
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 114 adults (macrolide n = N/A, placebo n = N/A)
Age in years: N/A
Setting: primary care
Interventions Indication: non-streptococcal pharyngitis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7 days
Total treatment dose: 7000 mg
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McDonald 1985 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary used
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the National Institute of Allergy and Infectious Diseases
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons given for 16 dropouts, unclear in
what groups. Unclear how many partici-
pants are actually included in the final anal-
ysis
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, how-
ever incomplete reporting of adverse events
Other bias Low risk None were identified.
McGregor 1986
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 58 women (macrolide n = 29, placebo n = 29)
Age in years: N/A
Setting: secondary care
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McGregor 1986 (Continued)
Interventions Indication: idiopathic preterm labour
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 7 days
Total treatment dose: 6993 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by The Upjohn Company, Kalamazoo, Michigan.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Sequentially numbered, identical drug bot-
tles.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active drug and placebo supplied by the
same company.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant lost to follow-up in each
group.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and unclear report-
ing of adverse events
Other bias Low risk None were identified.
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McGregor 1990
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned:235 children and adults (macrolide n=119, placebon=110, excluded
n = 6)
Age in years (mean (range)): macrolide: 23.0 (13 to 37), placebo: 23.2 (16 to 34)
Setting: secondary care
Interventions Indication: impact on cervicovaginal microflora and pregnancy outcomes
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 7 days
Total treatment dose: 6993 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: only intrauterine foetal death is reported on.
Funding sources Funding not stated. The Upjohn Company prepared the treatments
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 participants lost to follow-up (3%), un-
clear in which group
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
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McGregor 1990 (Continued)
Other bias Low risk None were identified.
McGregor 1991
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 65 adults (macrolide n = 28, placebo n = 27, excluded n = 10)
Age in years (mean (range)): macrolide: 25.4 (18 to 41), placebo: 24.2 (18 to 38)
Setting: secondary care
Interventions Indication: preterm premature rupture of the membranes
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: until active labour or for maximum 7 days
Total treatment dose: 6993 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: only foetal or neonatal death reported on.
Funding sources Funding not stated. The Upjohn Company prepared the treatments
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pregnant women and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons stated
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McGregor 1991 (Continued)
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come and unclear ascertainment. However,
adverse events are reported
Other bias Low risk None were identified.
Memis 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults and elderly (macrolide n = 20, placebo n = 20)
Age in years (mean (SD)): macrolide: 47 (22), placebo: 49 (16)
Setting: secondary care
Interventions Indication: effect of preoperative erythromycin on gastric acidity and volume
Type of macrolide: erythromycin
Route: per oral
Dose per day: 200 mg
Duration of treatment: 1 day
Total treatment dose: 200 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: authors state that “there were no side-effects observed in any of the
groups”
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs prepared by the same phar-
macy.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. No rel-
evant outcomes reported
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Memis 2002 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come. Standardised ascertainment for 24
hours after surgery, and authors report that
no adverse events were observed
Other bias Low risk None were identified.
Mercer 1992
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 220 adults (macrolide n = 106, placebo n = 114)
Age in years (mean (SD)): macrolide: 23.7 (5.7), placebo: 24.1 (5.6)
Setting: secondary care
Interventions Indication: preterm premature rupture of the membranes
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: N/A (until delivery)
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: only death in babies of treated mothers reported on.
Funding sources None stated. Boots Pharmaceuticals supplied the treatments.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
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Mercer 1992 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators, participant caregivers, and
participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants lost to follow-up (1%).
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment, and only gastroin-
testinal discomfort mentioned as a possible
adverse event
Other bias Low risk None were identified.
Moller 1990
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 147 children (macrolide n = 69, placebo n = 72, excluded n = 6)
Age in years (range): 1 to 15
Setting: secondary care
Interventions Indication: otitis media with effusion
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 50 mg/kg
Duration of treatment: 14 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events reported: stated that no adverse events were reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
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Moller 1990 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4% dropout, unclear in which group
Selective reporting (reporting bias) Unclear risk Unclear if adverse events were stated as an
outcome, unclear ascertainment. Authors
state that no adverse events were reported
Other bias Low risk None were identified.
Narchi 1993
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 50 adults (macrolide n = 25, placebo n = 25)
Age in years (mean ± SD): macrolide: 33 ± 5, placebo: 36 ± 9
Setting: secondary care
Interventions Indication: gastric acidity and volume in people scheduled for diagnostic laparoscopy
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 500 mg
Duration of treatment: 1 day
Total treatment dose: 500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
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Narchi 1993 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo appears similar.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Neumann 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1010 adults and elderly (macrolide n = 506, placebo n = 504)
Age in years (mean ± SD): macrolide: 64.6 ± 11.4, placebo: 64.3 ± 11.4
Setting: secondary care
Interventions Indication: restenosis after coronary stent replacement
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 28 days
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by funds from theMedical Faculty of Technische UniversitätMünchen.
Aventis provided the study medication and funded participant insurance and cost of
reagents for titre assays
Notes Concomitant medication: yes
Risk of bias
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Neumann 2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. Death
is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and adverse events
not presented
Other bias Low risk None were identified.
Ng 2007
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 182 children (macrolide n = 91, placebo n = 91)
Age in weeks (median (range)): macrolide: 28.6 (27.3 to 30.5), placebo: 28.9 (26.6 to
30.6)
Setting: secondary care
Interventions Indication: parenteral nutrition-associated cholestasis in preterm, very low-birthweight
infants
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 50 mg/kg
Duration of treatment: 14 days
Total treatment dose: 767 mg (mean birthweight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: clinician assessment + clinical examination (ECG, lab
tests)
Adverse events: authors state that “no serious adverse effects were associated with ery-
thromycin treatment”, data on complications reported
Antimicrobial resistance: not reported
Death: data reported
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Ng 2007 (Continued)
Funding sources Supported by Department of Pediatrics, Chinese University of Hong Kong, Research
Grant Council of the Government of Hong Kong SAR and by the HM Lui Memorial
Fund
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both active drug and normal saline
(placebo) were mixed thoroughly into the
milk feeds
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome. Stan-
dardised ascertainment. However, only
complications were reported
Other bias Low risk None were identified.
Nuntnarumit 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 46 children (macrolide n = 23, placebo n = 23)
Age in weeks (median (range)): macrolide: 30 (29 to 32), placebo: 29 (28 to 31)
Setting: secondary care
Interventions Indication: feeding intolerance in preterm infants
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 40 mg/kg/day for 2 days, then 16 mg/kg/day for 5 days
Duration of treatment: 7 days
Total treatment dose: 176 mg (median birthweight in macrolide group used)
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Nuntnarumit 2006 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: clinician assessment + clinical examination (ECG, lab
tests)
Adverse events: authors state that “(n)o significant adverse effects related to erythromycin
were observed”
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported byRamathibodi Fund. Authors acknowledge supplying company (Siam Phar-
maceutical Ltd)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation (by age)
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents, participant-care team, and asses-
sors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome, stan-
dardised ascertainment, however only com-
plications reported
Other bias Low risk None were identified.
O’Connor 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 7747 adults and elderly (macrolide n = 3879, placebo n = 3868)
Age in years (mean): 62
Setting: clinical practices in North America, Europe, Argentina, and India
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O’Connor 2003 (Continued)
Interventions Indication: coronary artery disease and known Chlamydia pneumoniae exposure
Type of macrolide: azithromycin
Route: per oral
Dose per day: 600 mg/day for 3 days during week 1, then 600 mg/week during weeks
2 to 12
Duration of treatment: 84 days
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study was sponsored by Pfizer Global Research and Development
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Identical drug containers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, clinical site
monitors, and the sponsor project team
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Adverse events resulting in
discontinuation are reported
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come, standardised ascertainment. Authors
only report on gastrointestinal complaints,
not lab tests. Adverse events are reported as
%, not numbers, assume that this is out of
the total analysed
Other bias Low risk None were identified.
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Oei 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 50 children (macrolide n = 25, placebo n = 25)
Gestational age in weeks (mean (range)): macrolide: 28.6 (24 to 32), placebo: 29.3 (27
to 32)
Setting: secondary care
Interventions Indication: feeding intolerance in preterm infants
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 10 mg/day
Duration of treatment: 10 days
Total treatment dose: 123 mg (mean birthweight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: authors state that no adverse events were noted during the trial. Vomiting
is reported as a primary outcome and is not considered to be an adverse event
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated. Authors acknowledge supplying company (Abbott Australasia Ltd)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome,
unclear ascertainment. However, authors
state that no adverse events were noted
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Oei 2001 (Continued)
Other bias Low risk None were identified.
Ogrendik 2007
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 81 adults (macrolide n = 41, placebo n = 40)
Age in years (mean ± SD): macrolide: 42 ± 9, placebo: 38 ± 10
Setting: secondary care
Interventions Indication: rheumatoid arthritis
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 6 months
Total treatment dose: 90,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: reported that no deaths occurred
Funding sources Supported by Sanovel, Istanbul
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, most discontinued because
of lack of efficacy of treatments
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Ogrendik 2007 (Continued)
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. Standardised ascertainment, only
most frequently reported adverse events re-
ported (5% cut-off )
Other bias Low risk None were identified.
Ogrendik 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 100 adults (macrolide n = 50, placebo n = 50)
Age in years (mean ± SD): macrolide: 49 ± 7, placebo: 45 ± 8
Setting: secondary care
Interventions Indication: rheumatoid arthritis
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 6 months
Total treatment dose: 54,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: reported that no deaths occurred
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
Low risk Participants and clinicians blinded.
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Ogrendik 2011 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, most discontinued because
of lack of efficacy of treatments
Selective reporting (reporting bias) Low risk Unclear if adverse events were stated as an
outcome. Standardised ascertainment, only
most frequently reported adverse events re-
ported (5% cut-off )
Other bias Low risk None were identified.
Oldfield 1998
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 182 adults (macrolide n = 89, placebo n = 93)
Age in years (mean (range)): macrolide: 41.1 (24 to 63), placebo: 38.2 (24 to 61)
Setting: unclear
Interventions Indication: prevention ofMycobacterium avium complex infection in people with AIDS
Type of macrolide: azithromycin
Route: per oral
Dose: 1200 mg once a week
Duration of treatment: 400 days (mean duration of therapy in macrolide group)
Total treatment dose: 68,571 mg (used mean days in macrolide group)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked + clinical examination (biaural audio-
grams)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by Pfizer and the Military Medical Consortium for Applied Retroviral Re-
search
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
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Oldfield 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and staff
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many are analysed for vari-
ous outcomes. Reported n = 90 in adverse
events section, although only 89 people
were randomised
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and reporting of adverse events
Other bias Low risk None were identified.
Ozdemir 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 74 children (macrolide n = 37, placebo, n = 37)
Gestational age in years (mean ± SD): macrolide: 27.4 ± 1.3, placebo: 27.3 ± 1.8
Setting: secondary care
Interventions Indication: prevention of bronchopulmonary dysplasia in Ureaplasma urealyticum-pos-
itive preterm infants
Type of macrolide: clarithromycin
Route: intravenous
Dose per day: 20 mg/kg
Duration of treatment: 10 days
Total treatment dose: 198 mg (mean birthweight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted. Author reply: “We didn’t see
any adverse events in both groups”
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
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Ozdemir 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only objective outcomes (death) reported
on.
Incomplete outcome data (attrition bias)
All outcomes
Low risk None lost to follow-up
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Paknejad 2010
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults (macrolide n = 20, placebo n = 20)
Age in years (min to max): 18.0 to 46.7
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
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Paknejad 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lowdropout, unclear which group, reasons
given
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Pandhi 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 70 children and adults (macrolide n = 35, placebo n = 35)
Age in years (mean ± SD): macrolide: 23.00 ± 8.96, placebo: 23.66 ± 8.35
Setting: secondary care
Interventions Indication: pityriasis rosea
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg (maximum)
Duration of treatment: 5 days
Total treatment dose: 2500 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
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Pandhi 2014 (Continued)
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Parchure 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults and elderly (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): macrolide: 56 ± 9, placebo: 54 ± 10
Setting: secondary care
Interventions Indication: coronary artery disease and antibodies positive to Chlamydia pneumoniae
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg for 3 days, then 500 mg once a week for an additional 4 weeks
Duration of treatment: 5 weeks
Total treatment dose: 3500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
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Parchure 2002 (Continued)
Funding sources Supported by the British Heart Foundation
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Patole 2000
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 73 children (macrolide n = 36, placebo n = 37)
Gestational age in weeks (median (IQR)): macrolide: 29 (27 to 30), placebo: 30 (27
to 31)
Setting: secondary care
Interventions Indication: full enteral feeds in preterm infants
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 48 mg/kg
Duration of treatment: until full feeds or maximum of 14 days
Total treatment dose: 230 mg (mean birthweight in macrolide group and median time
taken to full feeds used)
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Patole 2000 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, however no contact information for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources Authors acknowledge Abbott Australasia.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Sealed, coded envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Paul 1998
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 437 women (macrolide n = 219, placebo n = 218)
Age in years: N/A
Setting: secondary care
Interventions Indication: low birthweight and preterm delivery
Type of macrolide: erythromycin stearate
Route: per oral
Dose per day: 1000 mg
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Paul 1998 (Continued)
Duration of treatment: 6 weeks
Total treatment dose: 42,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 27%and 24%excluded from the final anal-
ysis in the macrolide and placebo groups,
respectively; 29 lost to follow-up. Reasons
not given
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Petersen 1997
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 212 adults (macrolide n = 93, placebo n = 93, excluded n = 26)
Age in years (median): macrolide: 25, placebo: 26
Setting: primary care
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Petersen 1997 (Continued)
Interventions Indication: pharyngitis not caused by group A Streptococcus
Type of macrolide: erythromycin base
Route: per oral
Dose per day: 999 mg
Duration of treatment: 10 days
Total treatment dose: 9990 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary used
Adverse events: data reported on day 1, 3, and 6
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by Henry J Kaiser Foundation and The Upjohn Company
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar between groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported. Re-
ported on adverse events as %, not num-
bers, assume that this is out of the total
analysed
Other bias Low risk None were identified.
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Peterson 1996
Methods Design: randomised, placebo-controlled, 4-armed trial
Participants Number assigned: 89 adults and elderly (macrolide n = 55, placebo n = 34)
Age in years (mean (range)): macrolide: 51.7 (26 to 77), placebo: 48.4 (22 to 76)
Setting: secondary care
Interventions Indication: duodenal ulcer
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1500 mg
Duration of treatment: 14 days
Total treatment dose: 21,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: physical + clinical examination (lab tests)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Glaxo Wellcome Inc.
Notes Concomitant medication: yes
Note: this is a 4-armed randomised controlled trial (placebo, clarithromycin, ranitidine
bismuth citrate, ranitidine bismuth citrate + clarithromycin). Importantly, the partici-
pants in both the macrolide and the placebo group received a placebo at some time to
ensure blinding in all groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts due to adverse events reported.
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Peterson 1996 (Continued)
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Unclear risk Participants were assigned in a 2:1 ratio.
Pierce 1996
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 682 adults and elderly (macrolide n = 341, placebo n = 341)
Age in years (mean (range)): macrolide: 37.5 (22 to 60), placebo: 37.6 (20 to 65)
Setting: unclear
Interventions Indication: prevention of disseminatedMycobacterium avium complex infection in peo-
ple with AIDS
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 315 days (mean duration of treatment inmacrolide group used)
Total treatment dose: 315,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: data reported
Death: data reported
Funding sources Supported by a grant from Abbott Laboratories
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
Low risk Participants and staff blinded.
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Pierce 1996 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Few participants lost to follow-up. With-
drawal due to adverse events reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome. Un-
clear ascertainment, but clear statement
about the approach used to summarise ad-
verse events. Adverse events reported in de-
tail. Authors only present adverse events as
% - calculations done on all participants
enrolled/treated
Other bias Low risk None were identified.
Pinto 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 185 children (macrolide n = 88, placebo n = 97)
Age in months (mean ± SD): macrolide: 3.08 ± 2.23, placebo: 3.12 ± 2.29
Setting: secondary care
Interventions Indication: acute bronchiolitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 10 mg/kg
Duration of treatment: 7 days
Total treatment dose: 394 mg (current weight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
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Pinto 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No relevant outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant in placebo group lost to fol-
low-up.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Pradeep 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD (range)): macrolide: 35.2 ± 6.0 (26 to 45), placebo: 37.3 ± 5.
7 (29 to 48)
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 3 days
Total treatment dose: 3000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Stated that project is self funded
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
199Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pradeep 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examiner and participant blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% and 5% of participants were lost to
follow-up in the macrolide and placebo
groups, respectively
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Pradeep 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 61 adults (macrolide n = 31, placebo n = 30)
Age in years (range): 30 to 50
Setting: dental care
Interventions Indication: chronic periodontitis in smokers
Type of macrolide: azithromycin
Route: topical
Dose per day: 0.5% gel
Duration of treatment: 1 day
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Authors acknowledge Micro Labs and Purac Biomaterials for providing
samples of gel and antibiotics
Notes Concomitant medication: unclear
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Pradeep 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo gel not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No adverse events reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, but in-
complete reporting of adverse events
Other bias Low risk None were identified.
Rajaei 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 94 children and adults (macrolide n = 38, placebo n = 42, excluded
n = 12)
Age in years (mean ± SD): macrolide: 23.87 ± 4.99, placebo: 22.59 ± 5.06
Setting: secondary care
Interventions Indication: idiopathic preterm labor
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1600 mg
Duration of treatment: 10 days
Total treatment dose: 16,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
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Rajaei 2006 (Continued)
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No adverse events reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 participants had no follow-up, and a fur-
ther 3 stopped medication (9%). Reasons
not given, unclear in which group
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, but in-
complete reporting of adverse event
Other bias Low risk None were identified.
Reignier 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 48 adults and elderly (macrolide n = 25, placebo n = 23)
Age in years (mean ± SD): macrolide: 70 ± 2, placebo: 66 ± 3
Setting: secondary care
Interventions Indication: enteral feeding in mechanically ventilated, critically ill individuals
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 1000 mg
Duration of treatment: 5 days
Total treatment dose: 5000 mg
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Reignier 2002 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded. Death is an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Low risk None were identified.
Robins-Browne 1983
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 78 children (macrolide n = 39, placebo n = 39)
Age in months: (mean): macrolide: 9.1, placebo: 7.4
Setting: secondary care
Interventions Indication: acute non-specific gastroenteritis
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 40 mg/kg
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Robins-Browne 1983 (Continued)
Duration of treatment: 5 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported (only at baseline)
Death: data reported
Funding sources Study supported by the South AfricanMedical ResearchCouncil, theUniversity ofNatal,
and Abbott Laboratories
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Sequentially numbered, identical drug
containers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Paediatricians, nurses, and children/par-
ents blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar between groups. Rea-
sons given.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and no reporting of
adverse events
Other bias Low risk None were identified.
Roca 2016a
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 829 adults (macrolide n = 414, placebo n = 415)
Age in years (median (IQR)): macrolide: 26.0 (22.0 to 30.0), placebo: 25.0 (22.0 to
30.0)
Setting: secondary care
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Roca 2016a (Continued)
Interventions Indication: bacterial carriage in mothers and their offspring
Type of macrolide: azithromycin
Route: per oral
Dose per day: 2000 mg
Duration of treatment: 1 day
Total treatment dose: 2000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: data reported
Death: data reported
Funding sources Study supported by the UKMedical Research Council, the UKDepartment for Interna-
tional Development, and the EDCTP2 programme supported by the European Union
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Mothers and clinicians blinded. Death and
AMR objective outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% and 4% dropouts in the macrolide and
placebo groups, respectively
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome, stan-
dardised ascertainment, but incomplete re-
porting of adverse events (complete after
author reply)
Other bias Low risk None were identified.
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Roy 1998
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 94 children (macrolide n = 46, placebo n = 48)
Age in months (mean ± SD): macrolide: 43.5 ± 12.2, placebo: 43.6 ± 10.6
Setting: secondary care
Interventions Indication: cholera
Type of macrolide: erythromycin
Route: per oral
Dose per day: 50 mg/kg
Duration of treatment: 3 days
Total treatment dose: 1560 mg (mean weight in macrolide group used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (lab tests)
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by the International Centre for Diarrhoeal Disease Research, Bangladesh
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Dropouts not reported. However, it seems
like all participants are included in the final
analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk No adverse events reported.
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, but no
adverse events reported
Other bias Low risk None were identified.
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Rozman 1984
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 282 participants (macrolide n = 146, placebo n = 136)
Age in years: N/A
Setting: unclear
Interventions Indication: acne
Type of macrolide: erythromycin
Route: topical
Dose per day: 1% gel/cream twice a day
Duration of treatment: 3 months
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7% dropout, unclear in which group. Rea-
sons unclear
Selective reporting (reporting bias) Low risk Adverse events not stated as an outcome,
unclear ascertainment. However, adverse
events reported
Other bias Low risk None were identified.
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Sadreddini 2009
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 108 adults and elderly (macrolide n = 54, placebo n = 54)
Age in years (mean ± SD): macrolide: 55.71 ± 11.19, placebo: 52.73 ± 10.25
Setting: secondary care
Interventions Indication: knee effusion due to osteoarthritis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 800 mg
Duration of treatment: 12 weeks
Total treatment dose: 67,200 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% and 2% dropout in the macrolide and
placebo groups, respectively
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come and unclear ascertainment. However,
adverse events reported
Other bias Low risk None were identified.
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Saiman 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 185 children and adults (macrolide n = 87, placebo n = 98)
Age in years (mean ± SD): macrolide: 20.2 ± 7.9, placebo: 20.6 ± 8.6
Setting: secondary care
Interventions Indication: people with cystic fibrosis chronically infected with Pseudomonas aeroginosa
Type of macrolide: azithromycin
Route: per oral
Dose per week: 1500 mg (maximum)
Duration of treatment: 168 days
Total treatment dose: 36,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by the Cystic Fibrosis Foundation. Authors acknowledge supplying
company (Pfizer Pharmaceuticals)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated randomisa-
tion.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active treatment and placebo supplied
from the same company and packed iden-
tically
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% and 6% lost to follow-up in the
macrolide and placebo groups, respectively.
Reasons given
Selective reporting (reporting bias) High risk Adverse events stated as an outcome. Stan-
dardised ascertainment, adverse events re-
ported. However, adverse events were only
reported if at least 15% of participants in
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Saiman 2003 (Continued)
the macrolide group experienced the ad-
verse event
Other bias Low risk None were identified.
Saiman 2010
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 263 children (macrolide n = 131, placebo n = 132)
Age in years (mean ± SD): macrolide: 10.7 ± 3.25, placebo: 10.6 ± 3.10
Setting: secondary care
Interventions Indication: cystic fibrosis (uninfected with Pseudomonas aeruginosa)
Type of macrolide: azithromycin
Route: per oral
Dose per week: 1500 mg (maximum)
Duration of treatment: 168 days
Total treatment dose: 36,000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study funded by CF Foundation Therapeutics Inc. Authors acknowledge supplying
company (Pfizer)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised computer-generated randomi-
sation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study personnel and participants were
blinded.
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Saiman 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups
Selective reporting (reporting bias) High risk Adverse events stated as an outcome, stan-
dardised ascertainment, and reporting of
adverse events. However, adverse events
were only reported on if at least 10% of
participants in either of the groups experi-
enced the adverse event
Other bias Low risk None were identified.
Sampaio 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): macrolide: 44.40 ± 7.42, placebo: 43.52 ± 5.90
Setting: dental care
Interventions Indication: chronic periodontitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 5 days
Total treatment dose: 2500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
Brazil
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Independent person did the allocation.
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Sampaio 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examiners, participants, and biostatisti-
cians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Sander 2002
Methods Design: randomised, placebo-controlled, 4-armed trial
Participants Number assigned: 272 adults and elderly (macrolide n = 136, placebo n = 136)
Age in years (range): 61 to 69
Setting: secondary care
Interventions Indication: carotid atherosclerosis
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 30 days
Total treatment dose: 9000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated.
Notes Concomitant medication: yes
Note: within the 2 groups (macrolide versus placebo) Chlamydia pneumoniae positive
and negative are presented as 1 group - i.e. 2 arms instead of 4 arms
Risk of bias
Bias Authors’ judgement Support for judgement
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Sander 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and clinicians.
Only report on objective outcome (death)
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 5% dropout during the 4-year follow-up.
All reported as deaths
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, no reporting of ad-
verse events
Other bias Low risk None were identified.
Schalen 1993
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 106 adults (macrolide n = 53, placebo n = 53)
Age in years (mean): macrolide: 33.6, placebo: 38.3
Setting: secondary care
Interventions Indication: acute laryngitis
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 5 days
Total treatment dose: 5000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by Abbott Scandinavia AB, Sweden.
Notes Concomitant medication: unclear
Risk of bias
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Schalen 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. No rel-
evant outcome reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7%dropout, unclear which group. Reasons
given.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, no reporting of ad-
verse events
Other bias Low risk None were identified.
Schwameis 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1371 adults (macrolide n = 685, placebo n = 686)
Age in years (mean ± SD): macrolide: 44.2 ± 15.3, placebo: 43.7 ± 14.8
Setting: unclear
Interventions Indication: prevention of Lyme borreliosis in people bitten by European ticks
Type of macrolide: azithromycin
Route: topical
Dose per day: N/A (10% gel twice per day)
Duration of treatment: 3 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Ixodes AG.
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Schwameis 2017 (Continued)
Notes Concomitant medication: unclear
Note: trial stopped early as a futility analysis showed that the prespecified primary end-
point was not reached in the intention-to-treat population
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and trial staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adverse events reported for all allocated
participants.
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Seemungal 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 109 adults and elderly (macrolide n = 53, placebo n = 56)
Age in years (mean ± SD): macrolide: 66.54 ± 8.10, placebo: 67.79 ± 9.08
Setting: secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: erythromycin stearate
Route: per oral
Dose per day: 500 mg
Duration of treatment: 1 year
Total treatment dose: 182,500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary + clinical examination/lab tests
Adverse events: data reported
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Seemungal 2008 (Continued)
Antimicrobial resistance: data reported
Death: data reported
Funding sources Supported by the British Lung Foundation
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 17% and 18% dropout in the macrolide
and placebo groups, respectively. However,
reasons given
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Serisier 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 117 adults and elderly (macrolide n = 59, placebo n = 58)
Age in years (mean ± SD): macrolide: 63.5 ± 9.5, placebo: 61.1 ± 10.5
Setting: secondary care
Interventions Indication: non-cystic fibrosis bronchiectasis
Type of macrolide: erythromycin ethylsuccinate
Route: per oral
Dose per day: 800 mg
Duration of treatment: 336 days
Total treatment dose: 268,800 mg
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Serisier 2013 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: clinical examination (laboratory tests, audiometry)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: reported that no deaths occurred
Funding sources Study funded by Mater Adult Respiratory Research Trust Fund.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, trial supervisors, and all staff
directly involved in participant care were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Adverse events resulting in
discontinuation are reported
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, adverse events re-
ported
Other bias Low risk None were identified.
Shafuddin 2015
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 191 adults and elderly (macrolide n = 97, placebo n = 94)
Age in years (mean ± SD): macrolide: 67.6 ± 7.85, placebo: 66.7 ± 8.7
Setting: secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
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Shafuddin 2015 (Continued)
Duration of treatment: 84 days
Total treatment dose: 25,200 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant diary + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Sanofi-Aventis Australia Pty.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation sequence not described.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and active treatment supplied by
same company.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Shanson 1985
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 109 adults and elderly (macrolide n = 56, placebo n = 53)
Age in years (range): 18 to 78
Setting: dental care
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Shanson 1985 (Continued)
Interventions Indication: prophylaxis of streptococcal bacteraemia after dental extraction
Type of macrolide: erythromycin stearate
Route: per oral
Dose per day: 1500 mg
Duration of treatment: 1 day
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant diary used
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by a grant from Abbott Laboratories
Notes Concomitant medication: yes
Note: randomised participantswere also allocated alternatively for differentmeasurement
methods for adverse events (1 with leading questions about adverse events and 1 without)
. However, adverse events are reported as a total
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Coded envelopes were used with identi-
cal-appearing content. Allocation done by
nurse
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome,
standardised ascertainments, and adverse
events reported
Other bias Low risk None were identified.
219Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Simpson 2008
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 46 adults and elderly (macrolide n = 23, placebo n = 23)
Age in years (mean (range)): macrolide: 60 (27 to 80), placebo: 55 (27 to 77)
Setting: secondary care
Interventions Indication: refractory asthma
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 8 weeks
Total treatment dose: 56,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by the National Health and Medical Research Council of Australia
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. No ad-
verse events reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant in placebo group was with-
drawn as the participant did not complete
first week treatment
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment. How-
ever, incomplete reporting of adverse events
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Simpson 2008 (Continued)
Other bias Low risk None were identified.
Sinisalo 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 152 adults and elderly (macrolide n = 74, placebo n = 74, excluded
n = 4)
Age in years (mean ± SD): macrolide: 64 ± 10, placebo: 63 ± 11
Setting: secondary care
Interventions Indication: unstable angina or non-Q-wave myocardial infarction
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 85 days
Total treatment dose: 42,500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (ECG, lab tests)
Adverse events reported: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by the Aarno Koskelo Foundation and the Finnish Foundation for Cardiovas-
cular Research. Authors acknowledge Abbott Laboratories for supplying trial medication
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Noparticipantswere lost to follow-up.Rea-
sons for dropouts given
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Sinisalo 2002 (Continued)
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come, however standardised ascertainment
and reporting of adverse events
Other bias Low risk None were identified.
Sirinavin 2003
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 191 children and adults (macrolide n = 95, placebo n = 96)
Age in years (mean (range)): macrolide: 25 (15 to 55), placebo: 22 (15 to 48)
Setting: 4 food factories in Thailand
Interventions Indication: eradication of non-typhoidal Salmonella
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 5 days
Total treatment dose: 2500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination (swabs)
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Supported by Bureau of General Communicable Diseases, Department of Disease Con-
trol, Ministry of Public Health, Nonthaburi, Thailand
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if matching placebo used. Two
placebo groups in lieu of 2 different antibi-
otic regimens (azithromycin, norfloxacin)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participant and trial investiga-
tors were blinded for assessment of adverse
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Sirinavin 2003 (Continued)
events. Data onAMR should be considered
an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 19% of participants missed more than 1
follow-up visit, however reasons given
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Smith 2000
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 150 adults and elderly (macrolide n = 75, placebo n = 75)
Age in years (mean ± SD): macrolide: 63.2 ± 12.6, placebo: 61.4 ± 11.7
Setting: secondary care
Interventions Indication: postoperative ileus after colorectal surgery
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 800 mg
Duration of treatment: 5 days (maximum)
Total treatment dose: 4000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (ECG)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
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Smith 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, reasons given.
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Smith 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 46 adults (macrolide n = 23, placebo n = 21, excluded n = 2)
Age in years (mean ± SD): macrolide: 41.87 ± 7.09, placebo: 43.57 ± 10.22
Setting: dental care
Interventions Indication: periodontitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (lab tests)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: incomplete reporting, author contacted
Death: not reported
Funding sources Study supported by Pfizer Ltd Sandwich.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
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Smith 2002 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4% dropout, reasons given
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, how-
ever incomplete reporting of adverse
events, including AMR
Other bias Low risk None were identified.
Sorensen 1992
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 432 children and adults (macrolide n = 216, placebo n = 216)
Age in years (median (range)): macrolide: 28 (14 to 46), placebo: 27 (14 to 46)
Setting: secondary care
Interventions Indication: prevention of postabortal pelvic inflammatory disease
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7.5 days
Total treatment dose: 7500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, however no contact details for author
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated. Abbott supplied treatments.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Sorensen 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active treatment and placebo supplied by
the same company.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Women and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Reasons given.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, incomplete report-
ing of adverse events
Other bias Low risk None were identified.
Taylor 1999
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 225 adults (macrolide n = 148, placebo n = 77)
Age in years (median (range)): macrolide: 27 (18 to 52), placebo: 26 (20 to 50)
Setting: army soldiers and civilians in Indonesia
Interventions Indication: malaria prophylaxis
Type of macrolide: azithromycin
Route: per oral
Dose per day: loading dose on day 1 of 750 mg, then 250 mg per day
Duration of treatment: 141 days
Total treatment dose: 35,750 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked + clinical examination (lab tests)
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by the US Army Medical Materiel Development Activity and the US Naval
Medical Research and Development Command. Authors acknowledge supplying com-
pany (Pfizer Central Research)
Notes Concomitant medication: yes
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Taylor 1999 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Sequentially numbered, identical drug
containers.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and trial staff blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 21% and 17% dropout in the macrolide
and placebo groups, respectively. Rea-
sons (including withdrawal due to adverse
events) given. However, unclear how many
people adverse events data were based on,
and numbers change throughout the re-
porting
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an
outcome, however standardised ascertain-
ment. Incomplete reporting of adverse
events
Other bias Unclear risk 2:1 allocation to macrolide and placebo
group.
Tita 2016
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 2013 adults (macrolide n = 1019, placebo n = 994)
Age in years (mean ± SD): macrolide: 28.2 ± 6.1, placebo: 28.4 ± 6.5
Setting: secondary care
Interventions Indication: non-elective Caesarean delivery
Type of macrolide: azithromycin
Route: intravenous
Dose per day: 500 mg
Duration of treatment: 1 hour
Total treatment dose: 500 mg
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Tita 2016 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: medical records review and participant asked
Adverse events: data reported
Antimicrobial resistance: data reported
Death: data reported
Funding sources Supported by a grant from the Eunice Kennedy Shriver National Institute of Child
Health and Human Development
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo saline
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Women and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodropouts for reporting of adverse events
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
are reported
Other bias Low risk None were identified.
Uzun 2014
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 92 adults and elderly (macrolide n = 47, placebo n = 45)
Age in years (mean ± SD): macrolide: 64.7 ± 10.2, placebo: 64.9 ± 10.2
Setting: secondary care
Interventions Indication: chronic obstructive pulmonary disease
Type of macrolide: azithromycin
Route: per oral
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Uzun 2014 (Continued)
Dose: 500 mg 3 times a week
Duration of treatment: 52 weeks
Total treatment dose: 78,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination (lab tests, swabs)
Adverse events: data reported
Antimicrobial resistance: data reported
Death: data reported
Funding sources Supported by SoLong Trust
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and trial staff were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13% and 16% withdrew in the macrolide
and placebo groups, respectively. However,
reasons given, including adverse events
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Vainas 2005
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 509 adults and elderly (macrolide n = 257, placebo n = 252)
Age in years (mean ± SD): macrolide: 64.4 ± 9.9, placebo: 65.5 ± 9.7
Setting: secondary care
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Vainas 2005 (Continued)
Interventions Indication: peripheral arterial disease
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 3 days
Total treatment dose: 1500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary used
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by the Netherlands Heart Foundation
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, attending surgeons, and the
co-ordinating scientist blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% and 95% completed treatments in the
macrolide and placebo groups, respectively.
Reasons for dropouts given
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
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Valery 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 89 children (macrolide n = 45, placebo n = 44)
Age in years (mean ± SD): macrolide: 3.99 ± 2.14, placebo: 4.22 ± 2.30
Setting: community clinics in central and northern Australia, and urban Maori and
Pacific Island children from a tertiary paediatric hospital in Auckland, New Zealand
Interventions Indication: bronchiectasis
Type of macrolide: azithromycin
Route: per oral
Dose: 30 mg/kg (max 600 mg) once weekly
Duration of treatment: 24 months (maximum)
Total treatment dose: 62,400 (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked + clinical examination (swabs)
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Supported by theNationalHealth andMedical ResearchCouncil of Australia andHealth
Research Council, New Zealand
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Sequentially numbered, double-sealed,
opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, families, health professionals,
and study personnel blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11% and 21% dropouts in the macrolide
and placebo groups, respectively. However,
reasons given
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Valery 2013 (Continued)
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Vammen 2001
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 92 elderly (macrolide n = 43, placebo n = 49)
Age in years (mean ± SD): macrolide: 72 ± 3.7, placebo: 73 ± 3.7
Setting: secondary care
Interventions Indication: abdominal aortic aneurysms
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: annual 4 weeks’ treatment. Followed/treated annually for a
mean of 5.27 years
Total treatment dose: 44,268 mg (mean follow-up used)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: unclear
Adverse events: stated that no participants stopped their medication due to side effects
and that no adverse events were observed
Antimicrobial resistance: not reported
Death: data reported
Funding sources Supported by the Danish Heart Foundation, the Foundation of Asta and Rosa Jensen,
and the Health Department of Viborg County
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Unclear risk Alocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
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Vammen 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout. Stated that no participants
stopped their medication due to side effects
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome. Un-
clear ascertainment, but reported that no
adverse events were observed
Other bias Low risk None were identified.
Van Delden 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 92 adults and elderly (macrolide n = 47, placebo n = 45)
Age in years (mean ± SD): macrolide: 59.3 ± 16.98, placebo: 59.7 ± 15.18
Setting: secondary care
Interventions Indication: prevention of Pseudomonas aeruginosa ventilator-associated pneumonia
Type of macrolide: azithromycin
Route: intravenous
Dose per day: 300 mg
Duration of treatment: 20 days (maximum)
Total treatment dose: 6000 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: spontaneously
Adverse events: data reported
Antimicrobial resistance: stated that azithromycin did lead to an increase in minimum
inhibitory concentration when comparing initial and last P aeruginosa isolate.
Death: data reported
Funding sources Study supported by Anbics Corporation, the Swiss Ministry of Technolog, and the Swiss
National Science Foundation
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation.
Allocation concealment (selection bias) Low risk Central allocation.
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Van Delden 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo (saline).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator, staff, participants, and moni-
tor blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout, similar across groups.
Selective reporting (reporting bias) Low risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported
Other bias Low risk None were identified.
Van den Broek 2009
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 2297 children and adults (macrolide n = 1149, placebo n = 1148)
Age in years (mean ± SD): azithromycin: 22.8 ± 5.1, placebo: 23.0 ± 5.2
Setting: 3 rural and 1 peri-urban antenatal clinic in southern Malawi
Interventions Indication: preterm birth
Type of macrolide: azithromycin
Route: per oral
Dose: 1000 mg given 1 time between 16 to 24 weeks and 1 time between 28 to 32 weeks
Duration of treatment: N/A
Total treatment dose: 2000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Reporting of adverse events: yes
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study funded byWellcome Trust. Authors acknowledge supplying company (Pfizer) and
state that Pfizer had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Van den Broek 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo not described in detail, however
drug andplacebowere supplied by the same
pharmaceutical company
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, study midwives,
and trial statistician
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Similar dropouts across groups. Unclear
reasons for loss to follow-up: “Missed visit,
could not be traced, declined to continue
and did not attend”. Possibly missed re-
porting on some adverse events as discon-
tinuation due to adverse events was not re-
ported
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. However, ad-
verse events reported
Other bias Low risk None were identified.
Veskitkul 2017
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 children (macrolide n = 20, placebo n = 20)
Age in years (median (range)): macrolide: 5.8 (5.0 to 9.2), placebo: 5.9 (5.0 to 12.3)
Setting: secondary care
Interventions Indication: recurrent acute rhinosinusitis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 5 mg/kg/day for 3 days/week
Duration of treatment: 12 months
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Ascertainment of adverse events: participants/parents asked
Adverse event: stated that “adverse events were not reported in either group”
Antimicrobial resistance: not reported
Death: not reported
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Veskitkul 2017 (Continued)
Funding sources Supported by a Siriraj Grant for Research Development from the Faculty of Medicine,
Siriraj Hospital, Bangkok, Thailand
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Allocation not described in detail.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
Selective reporting (reporting bias) Low risk Unclear if adverse events were stated as an
outcome. However, standardised ascertain-
ment and reported on (no) adverse events
Other bias Low risk None were identified.
Videler 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 adults and elderly (macrolide n = 29, placebo n = 31)
Age in years (median (range)): macrolide: 49 (20 to 70), placebo: 49 (20 to 70)
Setting: secondary care
Interventions Indication: chronic rhinosinusitis
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg once a day for 3 days for the first week, then once a week for 11 weeks
Duration of treatment: 12 weeks
Total treatment dose: 7000 mg
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Videler 2011 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked + clinical examination (swabs)
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources None stated. Authors acknowledge Pliva Hrvatska d.o.o., Zagreb, Croatia for supplying
treatments
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13% and 10% dropout at follow-up 2
weeks after treatment finished in the
macrolide and placebo groups, respectively.
However, reasons given
Selective reporting (reporting bias) Unclear risk Adverse events not clearly stated as an out-
come. Standardised ascertainment and ad-
verse events reported.However, lab tests for
liver function were performed but the re-
sults were not provided
Other bias Low risk None were identified.
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Vos 2011
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 83 adults (macrolide n = 40, placebo n = 43)
Age in years (median (range)): macrolide: 56.1 (47.7 to 61.2), placebo: 55.1 (44.2 to
59.4)
Setting: secondary care
Interventions Indication: prevention of bronchiolitis obliterans syndrome post-lung transplantation
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg daily for 5 days, followed by 250 mg 3 times a week for 2 years
Duration of treatment: 2 years
Total treatment dose: 79,250 mg (maximum)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 70% and 41.9% completed 2 years’ treat-
ment in the macrolide and placebo groups,
respectively. However, reasons given for
discontinuation/entering open-label treat-
ment
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an out-
come. Standardised ascertainment, and ad-
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Vos 2011 (Continued)
verse events reported
Other bias Low risk None were identified.
Wallwork 2006
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 64 participants (macrolide n = 29, placebo n = 35)
Age in years: N/A
Setting: secondary care
Interventions Indication: chronic rhinosinusitis
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 150 mg
Duration of treatment: 3 months
Total treatment dose: 13,500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: clinical examination (swabs)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: authors state that “no macrolide-resistant organisms were
noted to develop”
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded.
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Wallwork 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7% and 9%withdrew in themacrolide and
placebo groups, respectively. Reasons given
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Unclear ascertainment, only swabs
mentioned. Reported solely on adverse
events leading to discontinuation
Other bias Low risk None were identified.
Walsh 1998
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 1985 adults (macrolide n = 996, placebo n = 989)
Age in years (mean ± SD): macrolide: 30.4 ± 6.3, placebo: 30.5 ± 6.5
Setting: 11 clinics in Los Angeles County, USA. Clinics represented several provider
types
Interventions Indication: intrauterine device insertion
Type of macrolide: azithromycin
Route: per oral
Dose per day: 500 mg
Duration of treatment: 1 day
Total treatment dose: 500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources Supported by theNational Institute ofChildHealth andHumanDevelopment,National
Institutes of Health
Notes Concomitant medication: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Sequentially numbered, identical, opaque,
sealed pill bottles
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Walsh 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinicians, research personnel, and partic-
ipants blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2% lost to follow-up in both groups.
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Wang 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 45 adults and elderly (macrolide n = 23, placebo n = 22)
Age in years (mean (range)): macrolide: 60 (27 to 80), placebo: 55 (27 to 80)
Setting: secondary care
Interventions Indication: non-eosinophilic refractory asthma
Type of macrolide: clarithromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 56 days
Total treatment dose: 56,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participants asked
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
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Wang 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if participants and clinicians were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant dropped out, reason unclear.
Selective reporting (reporting bias) High risk Adverse events not clearly stated as an out-
come. Standardised ascertainment. How-
ever, no reporting about adverse events
Other bias Low risk None were identified.
Wiesli 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 40 adults and elderly (macrolide n = 20, placebo n = 20)
Age in years (mean ± SD): macrolide: 72.4 ± 7.7, placebo: 70.3 ± 9.1
Setting: secondary care
Interventions Indication: peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive
men
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 28 days
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported
Funding sources Study supported by Aventis Pharma AG, Switzerland and the Lixmar foundation,
Switzerland
Notes Concomitant medication: yes
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Wiesli 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinicians and participants blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Adverse events not stated as an outcome
and unclear ascertainment. However, ad-
verse events are reported
Other bias Low risk None were identified.
Wilson 1977
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 51 adults (macrolide n = 26, placebo n = 25)
Age in years: N/A
Setting: healthy volunteers at the Baylor College of Medicine
Interventions Indication: nasal carriage of Staphylococcus aureus
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7 days
Total treatment dose: 7000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
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Wilson 1977 (Continued)
Funding sources Study supported by the EI duPont de Nemours and Company and theNational Institute
of Allergy and Infectious Diseases
Notes Concomitant medication: unclear
Note: a third group of people were treated with josamycin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Placebo not identical appearing, orange vs
pink tablet.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who was blinded. Data on AMR
assessed as an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 4 dropouts in the 3 arms be-
foremedicationwas given, unclear inwhich
groups
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Wilson 1979
Methods Design: randomised, placebo-controlled, 3-armed trial
Participants Number assigned: 57 adults (macrolide n = 27, placebo n = 30)
Age in years (range): 18 to 43
Setting: healthy volunteers at the Baylor College of Medicine
Interventions Indication: nasal carriage of Staphylococcus aureus
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1000 mg
Duration of treatment: 7 days
Total treatment dose: 7000 mg
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Wilson 1979 (Continued)
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant diary + clinical examination/lab tests
Adverse events: data reported
Antimicrobial resistance: data reported
Death: not reported
Funding sources Study supported by Schering Laboratories, The Council for Tobacco Research, and the
National Institutes of Health
Notes Concomitant medication: unclear
Note: a third group of people were treated with rosaramicin.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unclear if placebo was identical appearing.
Authors state only that the placebo was
identical in appearance to the rosaramicin
capsules (the third arm)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who was blinded. Data on AMR
assessed as an objective outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13% and 3% dropout in themacrolide and
placebo groups, respectively. Reasons given
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Winkler 1988
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 43 pregnant women (macrolide n = 20, placebo n = 23)
Age in years: N/A
Setting: secondary care
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Winkler 1988 (Continued)
Interventions Indication: preterm delivery
Type of macrolide: erythromycin
Route: per oral
Dose per day: 1200 mg
Duration of treatment: 7 days
Total treatment dose: 8400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: not reported
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear if placebo was identical appearing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts not reported.
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and adverse events
not reported
Other bias Low risk None were identified.
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Wolter 2002
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 60 adults (macrolide n = 30, placebo n = 30)
Age in years (mean (range)): 27.9 (18 to 44)
Setting: secondary care
Interventions Indication: cystic fibrosis
Type of macrolide: azithromycin
Route: per oral
Dose per day: 250 mg
Duration of treatment: 90 days
Total treatment dose: 22,500 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources Study supported by the John P KellyMater Research Foundation and theMaterHospital
Private Practice Fund. Authors thank supplying company (Pfizer)
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation.
Allocation concealment (selection bias) Low risk Randomised by independent pharmacy
staff, and participants were automatically
dispensed the next allocated treatment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants, clinicians, and
statistician. No relevant outcomes reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 participants (25%) and 9 participants
(30%) did not complete the treatment in
the macrolide and placebo groups, respec-
tively.However, adverse events are reported
for 3 participants, while the remainder
dropped out due tonon-compliance or per-
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Wolter 2002 (Continued)
sonal request
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment, and incomplete re-
porting of adverse events
Other bias Unclear risk The placebo group contained more men,
and they were also taller, heavier, and had
a better lung function
Wong 2012
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 141 adults and elderly (macrolide n = 71, placebo n = 70)
Age in years (mean ± SD): macrolide: 60.9 ± 13.6, placebo: 59.0 ± 13.3
Setting: secondary care
Interventions Indication: non-cystic fibrosis bronchiectasis
Type of macrolide: azithromycin
Route: per oral
Dose: 500 mg 3 times a week
Duration of treatment: 6 months
Total treatment dose: 39,000 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: reported on participants diagnosed with macrolide-resistant
Streptococcus pneumoniae following macrolide treatment
Death: not reported
Funding sources Study funded by theHealth ResearchCouncil of NewZealand and the AucklandDistrict
Health Board Charitable Trust
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Central allocation
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Wong 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, clinicians, and investigators
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% in macrolide group versus 10% in
placebo group withdrew. However, reasons
for dropout are clearly presented
Selective reporting (reporting bias) Unclear risk Adverse events stated as an outcome, stan-
dardised ascertainment, and adverse events
reported. Note that only adverse events
with an incidence of more than 2.5% in
either group were presented
Other bias Low risk None were identified.
Yang 2013
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 180 children, adults, and elderly (macrolide n = 89, placebo n = 91)
Age in years (mean (range)): 41 (9 to 87)
Setting: secondary care
Interventions Indication: bacterial conjunctivitis
Type of macrolide: azithromycin
Route: topical
Dose: a 1% drop of gel twice a day for 2 days, then 1 drop once a day for the next 3 to
7 days
Duration of treatment: 7 days
Total treatment dose: N/A
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: yes
Adverse events ascertainment: participants asked + clinical examination (swabs)
Adverse events: incomplete reporting, author contacted
Antimicrobial resistance: not reported
Death: not reported
Funding sources None stated.
Notes Concomitant medication: unclear
Risk of bias
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Yang 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded. No
outcomes reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Selective reporting (reporting bias) High risk Adverse events stated as an outcome, stan-
dardised ascertainment. However, incom-
plete reporting of adverse events
Other bias Low risk None were identified.
Yeo 1993
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 128 adults and elderly (macrolide n = 58, placebo n = 60)
Age in years (mean ± SD): macrolide: 65.6 ± 1.6, placebo: 63.7 ± 1.4
Setting: secondary care
Interventions Indication: gastric emptying after pancreaticoduodenectomy
Type of macrolide: erythromycin lactobionate
Route: intravenous
Dose per day: 800 mg
Duration of treatment: 8 days
Total treatment dose: 6400 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: unclear
Adverse events ascertainment: participant asked
Adverse events: data reported
Antimicrobial resistance: not reported
Death: no deaths reported
Funding sources None stated.
Notes Concomitant medication: yes
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Yeo 1993 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described in de-
tail.
Allocation concealment (selection bias) Unclear risk Allocation not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nursing staff, physicians, and participants
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 participants (8%) excluded from analy-
sis, unclear which group. However, reasons
given
Selective reporting (reporting bias) Low risk Adverse events not clearly stated as an
outcome. However, standardised ascertain-
ment and adverse events reported
Other bias Low risk None were identified.
Zahn 2003
Methods Design: randomised, placebo-controlled, parallel-group trial
Participants Number assigned: 872 adults and elderly (macrolide n = 433, placebo n = 439)
Age in years (mean (IQR)): macrolide: 60.4 (51.3 to 69.1), placebo: 61.0 (52.2 to 68.
6)
Setting: secondary care
Interventions Indication: acute myocardial infarction
Type of macrolide: roxithromycin
Route: per oral
Dose per day: 300 mg
Duration of treatment: 42 days
Total treatment dose: 12,600 mg
Outcomes Adverse events stated as an outcome in trial registration/protocol/paper: no
Adverse events ascertainment: unclear
Adverse events: data reported
Antimicrobial resistance: not reported
Death: data reported (death is reported as a primary outcome)
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Zahn 2003 (Continued)
Funding sources Supported by Aventis Pharma GmbH
Notes Concomitant medication: yes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical-appearing placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and clinicians blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 18% and 11% dropouts in the macrolide
and placebo groups, respectively. Reasons
given
Selective reporting (reporting bias) High risk Adverse events not stated as an outcome,
unclear ascertainment. Only adverse events
resulting in discontinuation were reported
Other bias Low risk None were identified.
AMR: antimicrobial resistance
ECG: electrocardiogram
IQR: interquartile range
N/A: not applicable
PCI: percutaneous coronary intervention
PPROM: preterm pre-labour rupture of membrane
SD: standard deviation
SE: standard error
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aboud 2009 Participants in treatment group were randomised to receive both a macrolide (erythromycin) and metron-
idazole
Ballard 2007 Too-small sample size. 19 infants were allocated to macrolide treatment and 16 infants were allocated to
placebo
Batieha 2002 Quasi-randomised trial. Participants were allocated by alternate assignment to either macrolide or placebo
group
Doan 2017 Only report on pharmacodynamic outcomes (microbiome)
Ferahbas 2004 Cross-over trial. Adverse events were only reported after cross-over
Figueiredo-Mello 2018 Participants in the intervention group were allocated to 1 of 2 types of macrolides (clarithromycin or
azithromycin). However, it was not possible to identify those participants treated with clarithromycin and
those treated with azithromycin
Gong 2014 Too-small sample size. Only 17 participants were allocated in each arm
Makkar 2016 Not possible to extract data on participants only treated with placebo. Participants allocated to placebo also
received erythromycin if feed failure
Nielsen 2016 Too-small sample size. Only 12 participants were allocated in each arm
Parker 2017 Only report on pharmacodynamic outcomes (microbiome)
Pazoki-Toroudi 2010 Not placebo controlled. Participants allocated to topical macrolide gel were treated for 12 weeks, while
participants allocated to topical placebo gel were treated for 4 weeks
Rasi 2008 Not placebo controlled. Participants allocated to macrolides were treated with tablets, while participants
allocated to placebo were treated with an emollient cream
Sharma 2000 Quasi-randomised trial. Participants were allocated by alternate assignment to either macrolide treatment
or placebo
Stokholm 2016 Asthma-like episodes, not participants, randomised to either macrolide treatment or placebo
Weber 1993 Not placebo controlled. Participants allocated to macrolides were treated with a cream, while participants
allocated to placebo were treated with tablets
Yamamoto 1992 Participants were not randomly assigned to treatment or placebo group
Zhang 2006 Quasi-randomised trial. Participants were allocated by alternate assignment to either macrolide treatment
or placebo
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Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12617000531314
Methods Randomised, placebo-controlled clinical trial
Participants Adults with chronic periodontitis
Interventions Arm 1: azithromycin (+ non-surgical periodontal scaling and root planing + use of mouthwashes)
Arm 2: placebo (+ non-surgical periodontal scaling and root planing + use of mouthwash)
Outcomes Adverse events, antimicrobial resistance, and death
Notes
ChiCTR-INR-17013272
Methods Randomised, placebo-controlled clinical trial
Participants Women having Caesarean section
Interventions Arm 1: azithromycin (+ usual antibiotic regimen = cefuroxime)
Arm 2: placebo (+ usual antibiotic regimen = cefuroxime)
Outcomes Adverse events, antimicrobial resistance, and death
Notes
ChiCTR-IOR-16008820
Methods Randomised, placebo-controlled clinical trial
Participants Adults with chronic obstructive pulmonary disease
Interventions Arm 1: erythromycin
Arm 2: placebo
Outcomes Adverse events, antimicrobial resistance, and death
Notes
CTRI/2017/07/009017
Methods Randomised, placebo-controlled clinical trial
Participants Children with acute diarrhoea
Interventions Arm 1: azithromycin
Arm 2: placebo
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CTRI/2017/07/009017 (Continued)
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
Dicko 2016
Methods Randomised, placebo-controlled clinical trial
Participants African children
Interventions Arm 1: azithromycin (+ usual malaria prevention = sulfadoxine/pyrimethamine + amodiaquine)
Arm 2: placebo (+ usual malaria prevention = sulfadoxine/pyrimethamine + amodiaquine)
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
EUCTR2011-004351-39-IT
Methods Randomised, placebo-controlled clinical trial
Participants Adolescents and adults with primary immunodeficiency and chronic obstructive pulmonary disease
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
EUCTR2012-002792-34-GB
Methods Randomised, placebo-controlled clinical trial
Participants Adults and elderly with bronchiectasis
Interventions Arm 1: erythromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
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EUCTR2015-004306-42-SI
Methods Randomised, placebo-controlled clinical trial
Participants Adults with chronic periodontitis
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
Gregersen 2017
Methods Randomised, placebo-controlled clinical trial
Participants Adults and elderly with multiple myeloma
Interventions Arm 1: clarithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes Extended abstract identified. However, we could not identify a peer-reviewed publication of this study
IRCT2015052322383N1
Methods Randomised, placebo-controlled clinical trial
Participants Adults residing in endemic area of leptospirosis and working in the paddy field
Interventions Arm 1: azithromycin
Arm 2: doxycycline
Arm 3: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
KCT0002373
Methods Randomised, placebo-controlled clinical trial
Participants Ureaplasma-positive preterm infants
Interventions Arm 1: azithromycin
Arm 2: placebo
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KCT0002373 (Continued)
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
Milito 2017
Methods Randomised, placebo-controlled clinical trial
Participants Children and adults with primary antibody deficiency and chronic obstructive pulmonary disease with recurrent
exacerbations
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT01270074
Methods Randomised, placebo-controlled clinical trial
Participants Children with cystic fibrosis
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT01778634
Methods Randomised, placebo-controlled clinical trial
Participants Preterm infants with indwelling intravenous line for drug administration
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes Study results posted on ClinicalTrials.gov in May 2018. However, we could not identify a peer-reviewed publication
of this study
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NCT02003911
Methods Randomised, placebo-controlled clinical trial
Participants Children hospitalised with acute asthma exacerbations
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT02307825
Methods Randomised, placebo-controlled clinical trial
Participants Adults with chronic rhinosinusitis
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT02336516
Methods Randomised, placebo-controlled clinical trial
Participants Children diagnosed with postdiarrhoeal haemolytic and uraemic syndrome
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT02677701
Methods Randomised, placebo-controlled clinical trial
Participants Children and adults with cystic fibrosis and chronic airway infection with Pseudomonas aeruginosa
Interventions Arm 1: azithromycin + tobramycin
Arm 2: placebo + tobramycin
Outcomes Adverse events including data on antimicrobial resistance and death
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NCT02677701 (Continued)
Notes
NCT02756403
Methods Randomised, placebo-controlled clinical trial
Participants Women having a first trimester abortion
Interventions Arm 1: azithromycin
Arm 2: doxycycline
Arm 3: metronidazole
Arm 4: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT02911935
Methods Randomised, placebo-controlled clinical trial
Participants Children hospitalised with respiratory syncytial virus bronchiolitis
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT02960503
Methods Randomised, placebo-controlled clinical trial
Participants Adults with sickle cell disease
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
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NCT03130114
Methods Randomised, placebo-controlled clinical trial
Participants Children with severe diarrhoea
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT03233880
Methods Randomised, placebo-controlled clinical trial
Participants Healthy primigravidae: prevention of pre-eclampsia
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT03248297
Methods Randomised, placebo-controlled clinical trial
Participants High-risk labouring women in low-income countries
Interventions Arm 1: azithromycin
Arm 2: azithromycin + amoxicillin
Arm 3: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT03341273
Methods Randomised, placebo-controlled clinical trial
Participants Adults with a suspected lower respiratory tract infection
Interventions Arm 1: azithromycin (+ procalcitonin test)
Arm 2: placebo (+ procalcitonin test)
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NCT03341273 (Continued)
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
NCT03345992
Methods Randomised, placebo-controlled clinical trial
Participants Adults with sepsis and respiratory and multiple organ dysfunction syndrome
Interventions Arm 1: clarithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
Ramsey 2017
Methods Randomised, placebo-controlled clinical trial
Participants Children with cystic fibrosis with early Pseudomonas aeruginosa
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
RBR-9pqqpb
Methods Randomised, placebo-controlled clinical trial
Participants Adults with eosinophilic nasosinusinal polyposis
Interventions Arm 1: azithromycin
Arm 2: placebo
Outcomes Adverse events including data on antimicrobial resistance and death
Notes
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Characteristics of ongoing studies [ordered by study ID]
Chang 2012
Trial name or title A randomised, double-blind, placebo-controlled trial of azithromycin versus amoxicillin-clavulanic acid to
treat mild to moderate respiratory exacerbations in children with non-cystic fibrosis bronchiectasis, study one
Methods Randomised, double-blind, double-dummy, placebo-controlled, parallel-group trial
Participants Children aged less than 18 years, diagnosed with non-cystic fibrosis bronchiectasis
Interventions Arm 1: oral azithromycin 5 mg/kg x 1 for 14 days
Arm 2: oral amoxicillin-clavulanic acid 22.5 mg/kg x 2 for 14 days
Arm 3: oral placebo for 14 days
Outcomes Adverse events including data on antimicrobial resistance
Starting date 15 March 2012
Contact information annechang@ausdoctors.net
Notes Author reply in April 2018: Dr Anne Chang reports that the trial has completed recruitment and data are
being analysed. No publication yet
Trial registration: Australia and New Zealand Clinical Trials Register ACTRN12612000011886
Gonzalez-Martinez 2017
Trial name or title Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and ado-
lescents (BREATHE trial): study protocol for a randomised controlled trial
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Children and adolescents aged 6 to 19 years, diagnosed with HIV-associated chronic lung disease
Interventions Arm 1: oral azithromycin (10 to 19.9 kg, 250 mg; 20 to 29.9 kg, 500 mg; 30 to 39.9 kg, 750 mg; > 40 kg,
1250 mg) once a week for 12 months
Arm 2: oral placebo for 12 months
Outcomes Adverse events including data on antimicrobial resistance and death
Starting date June 2016
Contact information rashida.ferrand@lshtm.ac.uk
Notes Author reply in June 2018: Dr Rashida Ferrand reports that the trial will be completed shortly and that they
plan to publish the results in 2019
Trial registration: ClinicalTrials.gov NCT02426112
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Kobbernagel 2016
Trial name or title Randomised controlled trial to determine the efficacy and safety of azithromycin maintenance for 6 months
in participants with primary ciliary dyskinesia - a double-blind, parallel-group study
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Children and adults aged 7 to 50 years, diagnosed with primary ciliary dyskinesia
Interventions Arm 1: oral azithromycin 250 mg/500 mg (according to body weight) x 1, 3 times a week for 6 months
Arm 2: oral placebo for 6 months
Outcomes Adverse events including data on antimicrobial resistance
Starting date 26 August 2014
Contact information helene kobber@hotmail.com
Notes Author reply in April 2018: Dr Helene Kobbernagel reports that the trial has completed recruitment and
data are being analysed. No publication yet
Trial registration: EU Clinical Trials Register EudraCT 2013-004664-58
Mosquera 2016
Trial name or title The anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Children aged 6 months to 6 years with chronic lung disease secondary to bronchopulmonary dysplasia
Interventions Arm 1: oral azithromycin 5 mg/kg x 1, 3 times a week for 3 to 6 months
Arm 2: oral placebo for 3 to 6 months
Outcomes Adverse events
Starting date October 2015
Contact information Richardo.A.Mosquera@uth.tmc.edu
Notes Author reply in April 2018: Dr Richardo Mosquera reports that the trial has completed recruitment and
data are being analysed. No publication yet
Trial registration: ClinicalTrials.gov NCT02544984
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Pavlinac 2017
Trial name or title Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children: a protocol for a ran-
domised, double-blind, placebo-controlled trial (the Toto Bora trial)
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Children aged 1 to 59 months discharged from hospitals
Interventions Arm 1: oral azithromycin, 10 mg/kg on day 1, followed by 5 mg/kg for days 2 to 5
Arm 2: oral placebo for 5 days
Outcomes Adverse events including data on antimicrobial resistance and death
Starting date 28 June 2016
Contact information ppav@uw.edu
Notes Author reply in June 2018: Dr Patricia Pavlinac reports that they are still recruiting patients and anticipate
publishing results in late 2019/late 2020
Trial registration: ClinicalTrials.gov NCT02414399
Vermeersch 2016
Trial name or title Belgian trial with azithromycin during acute COPD exacerbations
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Adults aged 18 years or older hospitalised for an acute exacerbation in chronic obstructive pulmonary disease
(COPD)
Interventions Arm 1: oral azithromycin: 500 mg x 1 for 3 days, followed by 250 mg once every 2 days for the remainder
of the 90-day treatment period
Arm 2: oral placebo for 90 days
Outcomes Adverse events including data on deaths
Starting date 1 August 2014
Contact information wim.janssens@uzleuven.be
Notes Author reply in April 2018: Dr Wim Janssens reports that the trial has completed recruitment and data are
being analysed. No publication yet
Trial registration: ClinicalTrials.gov NCT02135354
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D A T A A N D A N A L Y S E S
Comparison 1. Cardiac disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac disorders 7 1715 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.54, 1.40]
Comparison 2. Ear and labyrinth disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hearing loss 4 1369 Odds Ratio (M-H, Random, 95% CI) 1.30 [1.00, 1.70]
Comparison 3. Gastrointestinal disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea 28 14983 Odds Ratio (M-H, Random, 95% CI) 1.61 [1.37, 1.90]
2 Nausea - subgroup analysis by
macrolide
26 10572 Odds Ratio (M-H, Random, 95% CI) 1.67 [1.39, 2.00]
2.1 Azithromycin 10 5437 Odds Ratio (M-H, Random, 95% CI) 1.66 [1.27, 2.16]
2.2 Erythromycin 13 4625 Odds Ratio (M-H, Random, 95% CI) 1.58 [1.23, 2.04]
2.3 Roxithromycin 3 510 Odds Ratio (M-H, Random, 95% CI) 3.29 [1.15, 9.43]
3 Nausea - subgroup analysis by
route of administration
28 14983 Odds Ratio (M-H, Random, 95% CI) 1.61 [1.37, 1.90]
3.1 Intravenous 3 396 Odds Ratio (M-H, Random, 95% CI) 3.04 [0.69, 13.51]
3.2 Peroral 25 14587 Odds Ratio (M-H, Random, 95% CI) 1.57 [1.35, 1.81]
4 Vomiting 15 5328 Odds Ratio (M-H, Random, 95% CI) 1.27 [1.04, 1.56]
5 Vomiting - subgroup analysis by
macrolide
13 5147 Odds Ratio (M-H, Random, 95% CI) 1.26 [1.00, 1.60]
5.1 Azithromycin 6 2692 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.76, 1.49]
5.2 Erythromycin 7 2455 Odds Ratio (M-H, Random, 95% CI) 1.46 [1.07, 1.98]
6 Vomiting - subgroup analysis by
route of administration
15 5328 Odds Ratio (M-H, Random, 95% CI) 1.27 [1.04, 1.56]
6.1 Intravenous 5 2354 Odds Ratio (M-H, Random, 95% CI) 1.21 [0.88, 1.66]
6.2 Peroral 10 2974 Odds Ratio (M-H, Random, 95% CI) 1.32 [0.97, 1.78]
7 Nausea and vomiting 8 1053 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.60, 1.42]
8 Abdominal pain 23 7776 Odds Ratio (M-H, Random, 95% CI) 1.66 [1.22, 2.26]
9 Abdominal pain - subgroup
analysis by macrolide
20 7506 Odds Ratio (M-H, Random, 95% CI) 1.68 [1.21, 2.34]
9.1 Azithromycin 14 6072 Odds Ratio (M-H, Random, 95% CI) 1.47 [1.01, 2.13]
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9.2 Erythromycin 6 1434 Odds Ratio (M-H, Random, 95% CI) 3.16 [1.14, 8.75]
10 Diarrhoea 37 23754 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.34, 2.16]
11 Diarrhoea - subgroup analysis
by macrolide
37 23754 Odds Ratio (M-H, Random, 95% CI) 1.70 [1.34, 2.16]
11.1 Azithromycin 22 15144 Odds Ratio (M-H, Random, 95% CI) 1.96 [1.37, 2.81]
11.2 Clarithromycin 4 4540 Odds Ratio (M-H, Random, 95% CI) 2.09 [1.70, 2.56]
11.3 Erythromycin 8 3711 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.94, 1.98]
11.4 Roxithromycin 3 359 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.38, 2.07]
12 Gastrointestinal disorders not
otherwise specified
23 3295 Odds Ratio (M-H, Random, 95% CI) 2.16 [1.56, 3.00]
13 Gastrointestinal disorders not
otherwise specified - subgroup
analysis by macrolide
22 3238 Odds Ratio (M-H, Random, 95% CI) 2.19 [1.56, 3.09]
13.1 Azithromycin 13 2396 Odds Ratio (M-H, Random, 95% CI) 1.77 [1.30, 2.42]
13.2 Erythromycin 9 842 Odds Ratio (M-H, Random, 95% CI) 4.00 [1.83, 8.74]
Comparison 4. Nervous system disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dizziness 3 376 Odds Ratio (M-H, Random, 95% CI) 1.83 [0.85, 3.95]
2 Headache 12 1386 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.58, 1.11]
3 Taste disturbance 5 932 Odds Ratio (M-H, Random, 95% CI) 4.95 [1.64, 14.93]
Comparison 5. Skin and subcutaneous tissue disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Itching 4 1388 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.73, 1.67]
2 Rash 8 5314 Odds Ratio (M-H, Random, 95% CI) 1.13 [0.91, 1.41]
Comparison 6. General disorders and administration site conditions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever 7 2451 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.54, 1.00]
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Comparison 7. Hepatobiliary disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hepatobiliary disorders 4 443 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.27, 4.09]
Comparison 8. Infections and infestations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood infection 4 356 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.52, 1.34]
2 Respiratory tract infections 11 11062 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.62, 0.80]
3 Skin and soft tissue infections 3 263 Odds Ratio (M-H, Random, 95% CI) 1.57 [0.53, 4.64]
Comparison 9. Investigations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in liver enzymes 6 1187 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.73, 3.37]
Comparison 10. Metabolism and nutrition disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Appetite lost 5 2183 Odds Ratio (M-H, Random, 95% CI) 1.10 [0.84, 1.43]
Comparison 11. Respiratory, thoracic, and mediastinal disorders
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cough 6 1587 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.40, 0.80]
2 Respiratory symptoms not
otherwise specified
8 2176 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.25]
3 Wheezing 3 484 Odds Ratio (M-H, Random, 95% CI) 2.20 [0.74, 6.52]
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Comparison 12. Deaths
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Deaths - overall 52 216246 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.06]
2 Deaths - subgroup analysis by
type of macrolide
52 216246 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.06]
2.1 Azithromycin 24 204719 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.85, 1.10]
2.2 Clarithromycin 8 7216 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.59, 1.24]
2.3 Erythromycin 10 718 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.38, 1.40]
2.4 Roxithromycin 10 3593 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.76, 1.41]
3 Deaths - subgroup analysis by
route of administration
51 214875 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.06]
3.1 Intravenous 8 1334 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.63, 1.10]
3.2 Peroral 43 213541 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.10]
Analysis 1.1. Comparison 1 Cardiac disorders, Outcome 1 Cardiac disorders.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 1 Cardiac disorders
Outcome: 1 Cardiac disorders
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albert 2011 29/558 33/559 52.5 % 0.87 [ 0.52, 1.46 ]
Berkhof 2013 2/42 1/42 3.7 % 2.05 [ 0.18, 23.51 ]
Gupta 1997 4/40 2/20 6.7 % 1.00 [ 0.17, 5.98 ]
Kim 2004 17/64 14/65 27.5 % 1.32 [ 0.59, 2.96 ]
Smith 2000 0/75 4/75 2.6 % 0.11 [ 0.01, 1.99 ]
Vammen 2001 0/43 4/49 2.6 % 0.12 [ 0.01, 2.22 ]
Vos 2011 1/40 4/43 4.4 % 0.25 [ 0.03, 2.34 ]
Total (95% CI) 862 853 100.0 % 0.87 [ 0.54, 1.40 ]
Total events: 53 (Macrolide), 62 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 6.60, df = 6 (P = 0.36); I2 =9%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 2.1. Comparison 2 Ear and labyrinth disorders, Outcome 1 Hearing loss.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 2 Ear and labyrinth disorders
Outcome: 1 Hearing loss
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albert 2011 142/558 110/559 88.2 % 1.39 [ 1.05, 1.85 ]
Altenburg 2013 5/43 4/40 3.6 % 1.18 [ 0.29, 4.76 ]
Hahn 2012 1/38 2/37 1.2 % 0.47 [ 0.04, 5.45 ]
Saiman 2003 8/44 12/50 7.0 % 0.70 [ 0.26, 1.92 ]
Total (95% CI) 683 686 100.0 % 1.30 [ 1.00, 1.70 ]
Total events: 156 (Macrolide), 128 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.34, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
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Analysis 3.1. Comparison 3 Gastrointestinal disorders, Outcome 1 Nausea.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 1 Nausea
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 6/43 6/40 1.6 % 0.92 [ 0.27, 3.12 ]
Black 2001 13/105 5/114 2.0 % 3.08 [ 1.06, 8.96 ]
Branden 2004 5/51 1/52 0.5 % 5.54 [ 0.62, 49.22 ]
Brickfield 1986 5/27 9/25 1.5 % 0.40 [ 0.11, 1.44 ]
Czarnetzki 2015 15/66 2/66 1.0 % 9.41 [ 2.06, 43.06 ]
Eschenbach 1991 194/586 142/548 11.0 % 1.41 [ 1.09, 1.83 ]
Gibson 2017 31/213 20/207 4.9 % 1.59 [ 0.88, 2.90 ]
Grayston 2005 284/2004 198/2008 12.6 % 1.51 [ 1.24, 1.83 ]
Hahn 2012 10/38 3/37 1.2 % 4.05 [ 1.01, 16.15 ]
Halperin 1999 18/144 8/166 2.8 % 2.82 [ 1.19, 6.70 ]
Haye 1998 7/87 1/82 0.6 % 7.09 [ 0.85, 58.93 ]
Hodgson 2016 1/21 1/21 0.3 % 1.00 [ 0.06, 17.12 ]
Jackson 1999 4/44 1/44 0.5 % 4.30 [ 0.46, 40.12 ]
Jespersen 2006 127/2155 93/2175 10.6 % 1.40 [ 1.07, 1.84 ]
Jun 2014 11/56 3/58 1.3 % 4.48 [ 1.18, 17.05 ]
Klebanoff 1995 149/466 112/466 10.3 % 1.49 [ 1.11, 1.98 ]
Martin 1997 68/205 44/209 7.1 % 1.86 [ 1.20, 2.90 ]
McCormack 1987 77/360 75/391 8.8 % 1.15 [ 0.80, 1.64 ]
McGregor 1990 32/119 14/110 4.0 % 2.52 [ 1.26, 5.04 ]
Ogrendik 2007 5/41 4/40 1.2 % 1.25 [ 0.31, 5.04 ]
Ogrendik 2011 6/50 4/50 1.3 % 1.57 [ 0.41, 5.93 ]
Petersen 1997 14/93 9/93 2.7 % 1.65 [ 0.68, 4.04 ]
Sadreddini 2009 4/51 2/53 0.8 % 2.17 [ 0.38, 12.40 ]
Saiman 2003 29/87 16/98 4.0 % 2.56 [ 1.28, 5.14 ]
Saiman 2010 11/131 12/129 2.9 % 0.89 [ 0.38, 2.11 ]
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Serisier 2013 0/59 3/58 0.3 % 0.13 [ 0.01, 2.64 ]
Shafuddin 2015 13/97 1/94 0.6 % 14.39 [ 1.84, 112.39 ]
Smith 2000 17/75 18/75 3.5 % 0.93 [ 0.44, 1.98 ]
Total (95% CI) 7474 7509 100.0 % 1.61 [ 1.37, 1.90 ]
Total events: 1156 (Macrolide), 807 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 41.48, df = 27 (P = 0.04); I2 =35%
Test for overall effect: Z = 5.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Gastrointestinal disorders, Outcome 2 Nausea - subgroup analysis by macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 2 Nausea - subgroup analysis by macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Altenburg 2013 6/43 6/40 2.0 % 0.92 [ 0.27, 3.12 ]
Branden 2004 5/51 1/52 0.7 % 5.54 [ 0.62, 49.22 ]
Gibson 2017 31/213 20/207 5.8 % 1.59 [ 0.88, 2.90 ]
Grayston 2005 284/2004 198/2008 12.9 % 1.51 [ 1.24, 1.83 ]
Hahn 2012 10/38 3/37 1.6 % 4.05 [ 1.01, 16.15 ]
Haye 1998 7/87 1/82 0.7 % 7.09 [ 0.85, 58.93 ]
Hodgson 2016 1/21 1/21 0.4 % 1.00 [ 0.06, 17.12 ]
Jackson 1999 4/44 1/44 0.6 % 4.30 [ 0.46, 40.12 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Saiman 2003 29/87 16/98 4.7 % 2.56 [ 1.28, 5.14 ]
Saiman 2010 11/131 12/129 3.5 % 0.89 [ 0.38, 2.11 ]
Subtotal (95% CI) 2719 2718 32.9 % 1.66 [ 1.27, 2.16 ]
Total events: 388 (Macrolide), 259 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.38, df = 9 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.74 (P = 0.00018)
2 Erythromycin
Brickfield 1986 5/27 9/25 1.8 % 0.40 [ 0.11, 1.44 ]
Czarnetzki 2015 15/66 2/66 1.3 % 9.41 [ 2.06, 43.06 ]
Eschenbach 1991 194/586 142/548 11.6 % 1.41 [ 1.09, 1.83 ]
Halperin 1999 18/144 8/166 3.5 % 2.82 [ 1.19, 6.70 ]
Jun 2014 11/56 3/58 1.7 % 4.48 [ 1.18, 17.05 ]
Klebanoff 1995 149/466 112/466 11.0 % 1.49 [ 1.11, 1.98 ]
Martin 1997 68/205 44/209 8.0 % 1.86 [ 1.20, 2.90 ]
McCormack 1987 77/360 75/391 9.6 % 1.15 [ 0.80, 1.64 ]
McGregor 1990 32/119 14/110 4.8 % 2.52 [ 1.26, 5.04 ]
Petersen 1997 14/93 9/93 3.3 % 1.65 [ 0.68, 4.04 ]
Sadreddini 2009 4/51 2/53 1.0 % 2.17 [ 0.38, 12.40 ]
Serisier 2013 0/59 3/58 0.4 % 0.13 [ 0.01, 2.64 ]
Smith 2000 17/75 18/75 4.2 % 0.93 [ 0.44, 1.98 ]
Subtotal (95% CI) 2307 2318 62.2 % 1.58 [ 1.23, 2.04 ]
Total events: 604 (Macrolide), 441 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 24.11, df = 12 (P = 0.02); I2 =50%
Test for overall effect: Z = 3.54 (P = 0.00041)
3 Roxithromycin
Black 2001 13/105 5/114 2.5 % 3.08 [ 1.06, 8.96 ]
Ogrendik 2011 6/50 4/50 1.7 % 1.57 [ 0.41, 5.93 ]
Shafuddin 2015 13/97 1/94 0.8 % 14.39 [ 1.84, 112.39 ]
Subtotal (95% CI) 252 258 4.9 % 3.29 [ 1.15, 9.43 ]
Total events: 32 (Macrolide), 10 (Placebo)
Heterogeneity: Tau2 = 0.35; Chi2 = 3.34, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 5278 5294 100.0 % 1.67 [ 1.39, 2.00 ]
Total events: 1024 (Macrolide), 710 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 41.00, df = 25 (P = 0.02); I2 =39%
Test for overall effect: Z = 5.45 (P < 0.00001)
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for subgroup differences: Chi2 = 1.76, df = 2 (P = 0.41), I2 =0.0%
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Analysis 3.3. Comparison 3 Gastrointestinal disorders, Outcome 3 Nausea - subgroup analysis by route of
administration.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 3 Nausea - subgroup analysis by route of administration
Study or subgroup Macrolides Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intravenous
Czarnetzki 2015 15/66 2/66 1.0 % 9.41 [ 2.06, 43.06 ]
Jun 2014 11/56 3/58 1.3 % 4.48 [ 1.18, 17.05 ]
Smith 2000 17/75 18/75 3.5 % 0.93 [ 0.44, 1.98 ]
Subtotal (95% CI) 197 199 5.9 % 3.04 [ 0.69, 13.51 ]
Total events: 43 (Macrolides), 23 (Placebo)
Heterogeneity: Tau2 = 1.35; Chi2 = 9.49, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Peroral
Altenburg 2013 6/43 6/40 1.6 % 0.92 [ 0.27, 3.12 ]
Black 2001 13/105 5/114 2.0 % 3.08 [ 1.06, 8.96 ]
Branden 2004 5/51 1/52 0.5 % 5.54 [ 0.62, 49.22 ]
Brickfield 1986 5/27 9/25 1.5 % 0.40 [ 0.11, 1.44 ]
Eschenbach 1991 194/586 142/548 11.0 % 1.41 [ 1.09, 1.83 ]
Gibson 2017 31/213 20/207 4.9 % 1.59 [ 0.88, 2.90 ]
Grayston 2005 284/2004 198/2008 12.6 % 1.51 [ 1.24, 1.83 ]
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(. . . Continued)
Study or subgroup Macrolides Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hahn 2012 10/38 3/37 1.2 % 4.05 [ 1.01, 16.15 ]
Halperin 1999 18/144 8/166 2.8 % 2.82 [ 1.19, 6.70 ]
Haye 1998 7/87 1/82 0.6 % 7.09 [ 0.85, 58.93 ]
Hodgson 2016 1/21 1/21 0.3 % 1.00 [ 0.06, 17.12 ]
Jackson 1999 4/44 1/44 0.5 % 4.30 [ 0.46, 40.12 ]
Jespersen 2006 127/2155 93/2175 10.6 % 1.40 [ 1.07, 1.84 ]
Klebanoff 1995 149/466 112/466 10.3 % 1.49 [ 1.11, 1.98 ]
Martin 1997 68/205 44/209 7.1 % 1.86 [ 1.20, 2.90 ]
McCormack 1987 77/360 75/391 8.8 % 1.15 [ 0.80, 1.64 ]
McGregor 1990 32/119 14/110 4.0 % 2.52 [ 1.26, 5.04 ]
Ogrendik 2007 5/41 4/40 1.2 % 1.25 [ 0.31, 5.04 ]
Ogrendik 2011 6/50 4/50 1.3 % 1.57 [ 0.41, 5.93 ]
Petersen 1997 14/93 9/93 2.7 % 1.65 [ 0.68, 4.04 ]
Sadreddini 2009 4/51 2/53 0.8 % 2.17 [ 0.38, 12.40 ]
Saiman 2003 29/87 16/98 4.0 % 2.56 [ 1.28, 5.14 ]
Saiman 2010 11/131 12/129 2.9 % 0.89 [ 0.38, 2.11 ]
Serisier 2013 0/59 3/58 0.3 % 0.13 [ 0.01, 2.64 ]
Shafuddin 2015 13/97 1/94 0.6 % 14.39 [ 1.84, 112.39 ]
Subtotal (95% CI) 7277 7310 94.1 % 1.57 [ 1.35, 1.81 ]
Total events: 1113 (Macrolides), 784 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 31.76, df = 24 (P = 0.13); I2 =24%
Test for overall effect: Z = 6.05 (P < 0.00001)
Total (95% CI) 7474 7509 100.0 % 1.61 [ 1.37, 1.90 ]
Total events: 1156 (Macrolides), 807 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 41.48, df = 27 (P = 0.04); I2 =35%
Test for overall effect: Z = 5.81 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 3.4. Comparison 3 Gastrointestinal disorders, Outcome 4 Vomiting.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 4 Vomiting
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bonacini 1993 3/41 2/36 1.2 % 1.34 [ 0.21, 8.52 ]
Cameron 2013 2/39 0/38 0.4 % 5.13 [ 0.24, 110.52 ]
Clement 2006 2/40 0/42 0.4 % 5.52 [ 0.26, 118.61 ]
Eschenbach 1991 102/586 76/548 27.9 % 1.31 [ 0.95, 1.81 ]
Gharpure 2001 3/37 1/37 0.7 % 3.18 [ 0.31, 32.04 ]
Hahn 2012 2/38 2/37 1.0 % 0.97 [ 0.13, 7.29 ]
McCormack 1987 55/360 39/391 17.3 % 1.63 [ 1.05, 2.52 ]
McGregor 1990 15/119 4/110 3.0 % 3.82 [ 1.23, 11.90 ]
Ogrendik 2007 3/41 2/40 1.2 % 1.50 [ 0.24, 9.49 ]
Ogrendik 2011 3/50 2/50 1.2 % 1.53 [ 0.24, 9.59 ]
Reignier 2002 0/20 3/20 0.4 % 0.12 [ 0.01, 2.53 ]
Saiman 2003 14/87 15/98 6.0 % 1.06 [ 0.48, 2.35 ]
Saiman 2010 22/131 31/129 9.7 % 0.64 [ 0.35, 1.18 ]
Smith 2000 11/75 11/75 4.7 % 1.00 [ 0.40, 2.47 ]
Tita 2016 77/1019 61/994 25.0 % 1.25 [ 0.88, 1.77 ]
Total (95% CI) 2683 2645 100.0 % 1.27 [ 1.04, 1.56 ]
Total events: 314 (Macrolide), 249 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.95, df = 14 (P = 0.38); I2 =6%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Gastrointestinal disorders, Outcome 5 Vomiting - subgroup analysis by
macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 5 Vomiting - subgroup analysis by macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Cameron 2013 2/39 0/38 0.6 % 5.13 [ 0.24, 110.52 ]
Clement 2006 2/40 0/42 0.6 % 5.52 [ 0.26, 118.61 ]
Hahn 2012 2/38 2/37 1.3 % 0.97 [ 0.13, 7.29 ]
Saiman 2003 14/87 15/98 7.4 % 1.06 [ 0.48, 2.35 ]
Saiman 2010 22/131 31/129 11.3 % 0.64 [ 0.35, 1.18 ]
Tita 2016 77/1019 61/994 23.1 % 1.25 [ 0.88, 1.77 ]
Subtotal (95% CI) 1354 1338 44.3 % 1.06 [ 0.76, 1.49 ]
Total events: 119 (Macrolide), 109 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.63, df = 5 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Erythromycin
Bonacini 1993 3/41 2/36 1.6 % 1.34 [ 0.21, 8.52 ]
Eschenbach 1991 102/586 76/548 24.8 % 1.31 [ 0.95, 1.81 ]
Gharpure 2001 3/37 1/37 1.0 % 3.18 [ 0.31, 32.04 ]
McCormack 1987 55/360 39/391 17.8 % 1.63 [ 1.05, 2.52 ]
McGregor 1990 15/119 4/110 4.0 % 3.82 [ 1.23, 11.90 ]
Reignier 2002 0/20 3/20 0.6 % 0.12 [ 0.01, 2.53 ]
Smith 2000 11/75 11/75 5.9 % 1.00 [ 0.40, 2.47 ]
Subtotal (95% CI) 1238 1217 55.7 % 1.46 [ 1.07, 1.98 ]
Total events: 189 (Macrolide), 136 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.10, df = 6 (P = 0.31); I2 =15%
Test for overall effect: Z = 2.39 (P = 0.017)
Total (95% CI) 2592 2555 100.0 % 1.26 [ 1.00, 1.60 ]
Total events: 308 (Macrolide), 245 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 14.88, df = 12 (P = 0.25); I2 =19%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 1.84, df = 1 (P = 0.17), I2 =46%
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Analysis 3.6. Comparison 3 Gastrointestinal disorders, Outcome 6 Vomiting - subgroup analysis by route of
administration.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 6 Vomiting - subgroup analysis by route of administration
Study or subgroup Macrolides Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intravenous
Bonacini 1993 3/41 2/36 1.2 % 1.34 [ 0.21, 8.52 ]
Gharpure 2001 3/37 1/37 0.7 % 3.18 [ 0.31, 32.04 ]
Reignier 2002 0/20 3/20 0.4 % 0.12 [ 0.01, 2.53 ]
Smith 2000 11/75 11/75 4.7 % 1.00 [ 0.40, 2.47 ]
Tita 2016 77/1019 61/994 25.0 % 1.25 [ 0.88, 1.77 ]
Subtotal (95% CI) 1192 1162 32.0 % 1.21 [ 0.88, 1.66 ]
Total events: 94 (Macrolides), 78 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.10, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Peroral
Cameron 2013 2/39 0/38 0.4 % 5.13 [ 0.24, 110.52 ]
Clement 2006 2/40 0/42 0.4 % 5.52 [ 0.26, 118.61 ]
Eschenbach 1991 102/586 76/548 27.9 % 1.31 [ 0.95, 1.81 ]
Hahn 2012 2/38 2/37 1.0 % 0.97 [ 0.13, 7.29 ]
McCormack 1987 55/360 39/391 17.3 % 1.63 [ 1.05, 2.52 ]
McGregor 1990 15/119 4/110 3.0 % 3.82 [ 1.23, 11.90 ]
Ogrendik 2007 3/41 2/40 1.2 % 1.50 [ 0.24, 9.49 ]
Ogrendik 2011 3/50 2/50 1.2 % 1.53 [ 0.24, 9.59 ]
Saiman 2003 14/87 15/98 6.0 % 1.06 [ 0.48, 2.35 ]
Saiman 2010 22/131 31/129 9.7 % 0.64 [ 0.35, 1.18 ]
Subtotal (95% CI) 1491 1483 68.0 % 1.32 [ 0.97, 1.78 ]
Total events: 220 (Macrolides), 171 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.71, df = 9 (P = 0.23); I2 =23%
Test for overall effect: Z = 1.77 (P = 0.076)
Total (95% CI) 2683 2645 100.0 % 1.27 [ 1.04, 1.56 ]
Total events: 314 (Macrolides), 249 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.95, df = 14 (P = 0.38); I2 =6%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 3.7. Comparison 3 Gastrointestinal disorders, Outcome 7 Nausea and vomiting.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 7 Nausea and vomiting
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heppner 2005 11/170 6/94 17.9 % 1.01 [ 0.36, 2.84 ]
Lanza 1998 2/60 2/29 4.7 % 0.47 [ 0.06, 3.48 ]
Mandhane 2017 22/140 29/139 50.4 % 0.71 [ 0.38, 1.30 ]
McGregor 1991 2/28 0/27 2.0 % 5.19 [ 0.24, 113.22 ]
Narchi 1993 2/22 1/22 3.1 % 2.10 [ 0.18, 25.01 ]
Peterson 1996 0/55 2/34 2.0 % 0.12 [ 0.01, 2.52 ]
Uzun 2014 3/47 2/45 5.6 % 1.47 [ 0.23, 9.21 ]
Wong 2012 9/71 5/70 14.4 % 1.89 [ 0.60, 5.94 ]
Total (95% CI) 593 460 100.0 % 0.92 [ 0.60, 1.42 ]
Total events: 51 (Macrolide), 47 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.31, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Gastrointestinal disorders, Outcome 8 Abdominal pain.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 8 Abdominal pain
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 8/43 1/40 1.8 % 8.91 [ 1.06, 74.89 ]
Amer 2006 2/25 0/24 0.9 % 5.21 [ 0.24, 114.41 ]
Avci 2013 8/30 0/30 1.0 % 23.04 [ 1.26, 420.37 ]
Bonacini 1993 2/41 2/36 2.0 % 0.87 [ 0.12, 6.53 ]
Clement 2006 11/40 8/42 5.1 % 1.61 [ 0.57, 4.55 ]
Czarnetzki 2015 20/66 4/66 4.6 % 6.74 [ 2.16, 21.06 ]
Gibson 2017 38/213 30/207 9.0 % 1.28 [ 0.76, 2.16 ]
Grayston 2005 370/2004 216/2008 11.6 % 1.88 [ 1.57, 2.25 ]
Hahn 2012 11/38 4/37 4.1 % 3.36 [ 0.96, 11.76 ]
Halperin 1999 10/144 2/166 3.0 % 6.12 [ 1.32, 28.41 ]
Heppner 2005 41/170 21/94 8.3 % 1.10 [ 0.61, 2.01 ]
Hodgson 2016 2/21 1/21 1.4 % 2.11 [ 0.18, 25.17 ]
Lanza 1998 2/60 2/29 2.0 % 0.47 [ 0.06, 3.48 ]
Lildholdt 2003 14/53 0/57 1.1 % 42.22 [ 2.45, 728.45 ]
Mandhane 2017 23/140 34/139 8.4 % 0.61 [ 0.34, 1.10 ]
McCormack 1987 59/360 56/391 10.1 % 1.17 [ 0.79, 1.74 ]
Ogrendik 2007 4/41 3/40 3.0 % 1.33 [ 0.28, 6.38 ]
Ogrendik 2011 7/50 2/50 2.8 % 3.91 [ 0.77, 19.83 ]
Pandhi 2014 3/35 0/35 1.0 % 7.65 [ 0.38, 153.75 ]
Sadreddini 2009 3/51 1/53 1.6 % 3.25 [ 0.33, 32.32 ]
Saiman 2003 26/87 31/98 8.1 % 0.92 [ 0.49, 1.72 ]
Saiman 2010 17/131 20/129 7.5 % 0.81 [ 0.40, 1.63 ]
Wong 2012 5/71 1/70 1.7 % 5.23 [ 0.59, 45.94 ]
Total (95% CI) 3914 3862 100.0 % 1.66 [ 1.22, 2.26 ]
Total events: 686 (Macrolide), 439 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 52.28, df = 22 (P = 0.00029); I2 =58%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Gastrointestinal disorders, Outcome 9 Abdominal pain - subgroup analysis by
macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 9 Abdominal pain - subgroup analysis by macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Altenburg 2013 8/43 1/40 2.0 % 8.91 [ 1.06, 74.89 ]
Amer 2006 2/25 0/24 1.0 % 5.21 [ 0.24, 114.41 ]
Clement 2006 11/40 8/42 5.6 % 1.61 [ 0.57, 4.55 ]
Gibson 2017 38/213 30/207 9.7 % 1.28 [ 0.76, 2.16 ]
Grayston 2005 370/2004 216/2008 12.3 % 1.88 [ 1.57, 2.25 ]
Hahn 2012 11/38 4/37 4.5 % 3.36 [ 0.96, 11.76 ]
Heppner 2005 41/170 21/94 9.0 % 1.10 [ 0.61, 2.01 ]
Hodgson 2016 2/21 1/21 1.5 % 2.11 [ 0.18, 25.17 ]
Lildholdt 2003 14/53 0/57 1.2 % 42.22 [ 2.45, 728.45 ]
Mandhane 2017 23/140 34/139 9.0 % 0.61 [ 0.34, 1.10 ]
Pandhi 2014 3/35 0/35 1.1 % 7.65 [ 0.38, 153.75 ]
Saiman 2003 26/87 31/98 8.7 % 0.92 [ 0.49, 1.72 ]
Saiman 2010 17/131 20/129 8.1 % 0.81 [ 0.40, 1.63 ]
Wong 2012 5/71 1/70 1.9 % 5.23 [ 0.59, 45.94 ]
Subtotal (95% CI) 3071 3001 75.7 % 1.47 [ 1.01, 2.13 ]
Total events: 571 (Macrolide), 367 (Placebo)
Heterogeneity: Tau2 = 0.21; Chi2 = 33.99, df = 13 (P = 0.001); I2 =62%
Test for overall effect: Z = 2.02 (P = 0.043)
2 Erythromycin
Avci 2013 8/30 0/30 1.2 % 23.04 [ 1.26, 420.37 ]
Bonacini 1993 2/41 2/36 2.2 % 0.87 [ 0.12, 6.53 ]
Czarnetzki 2015 20/66 4/66 5.0 % 6.74 [ 2.16, 21.06 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Halperin 1999 10/144 2/166 3.4 % 6.12 [ 1.32, 28.41 ]
McCormack 1987 59/360 56/391 10.8 % 1.17 [ 0.79, 1.74 ]
Sadreddini 2009 3/51 1/53 1.8 % 3.25 [ 0.33, 32.32 ]
Subtotal (95% CI) 692 742 24.3 % 3.16 [ 1.14, 8.75 ]
Total events: 102 (Macrolide), 65 (Placebo)
Heterogeneity: Tau2 = 0.93; Chi2 = 15.80, df = 5 (P = 0.01); I2 =68%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 3763 3743 100.0 % 1.68 [ 1.21, 2.34 ]
Total events: 673 (Macrolide), 432 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 49.61, df = 19 (P = 0.00015); I2 =62%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Chi2 = 1.94, df = 1 (P = 0.16), I2 =48%
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Analysis 3.10. Comparison 3 Gastrointestinal disorders, Outcome 10 Diarrhoea.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 10 Diarrhoea
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 9/43 1/40 1.0 % 10.32 [ 1.24, 85.71 ]
Amer 2006 2/25 0/24 0.5 % 5.21 [ 0.24, 114.41 ]
Andere 2017 2/20 0/20 0.5 % 5.54 [ 0.25, 123.08 ]
Black 2001 6/105 10/114 2.8 % 0.63 [ 0.22, 1.80 ]
Branden 2004 16/51 2/52 1.7 % 11.43 [ 2.47, 52.89 ]
Cameron 2013 4/39 3/38 1.7 % 1.33 [ 0.28, 6.40 ]
Clement 2006 3/40 4/42 1.7 % 0.77 [ 0.16, 3.68 ]
Eschenbach 1991 94/586 64/548 5.4 % 1.44 [ 1.03, 2.03 ]
Gibson 2017 72/213 39/207 5.0 % 2.20 [ 1.40, 3.45 ]
Grassly 2016 92/376 63/378 5.3 % 1.62 [ 1.13, 2.32 ]
Grayston 2005 724/2004 446/2008 5.9 % 1.98 [ 1.72, 2.28 ]
Hahn 2012 12/38 5/37 2.5 % 2.95 [ 0.92, 9.47 ]
Halperin 1999 29/144 14/166 4.0 % 2.74 [ 1.38, 5.42 ]
Haye 1998 11/87 5/82 2.6 % 2.23 [ 0.74, 6.72 ]
Heppner 2005 14/170 17/94 3.8 % 0.41 [ 0.19, 0.87 ]
Hodgson 2016 4/21 2/21 1.3 % 2.24 [ 0.36, 13.78 ]
Hyde 2001 6/73 5/74 2.3 % 1.24 [ 0.36, 4.24 ]
Jackson 1999 8/44 8/44 2.7 % 1.00 [ 0.34, 2.95 ]
Jespersen 2006 292/2155 151/2175 5.8 % 2.10 [ 1.71, 2.58 ]
Klebanoff 1995 60/466 42/466 5.1 % 1.49 [ 0.98, 2.26 ]
Lanza 1998 4/60 2/29 1.4 % 0.96 [ 0.17, 5.60 ]
Mandhane 2017 42/140 44/139 4.7 % 0.93 [ 0.56, 1.54 ]
McCormack 1987 23/360 23/391 4.4 % 1.09 [ 0.60, 1.98 ]
McGregor 1990 6/119 0/110 0.6 % 12.66 [ 0.70, 227.35 ]
O’Connor 2003 313/3866 54/3856 5.5 % 6.20 [ 4.63, 8.31 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ogrendik 2007 2/41 1/40 0.8 % 2.00 [ 0.17, 22.97 ]
Ogrendik 2011 3/50 2/50 1.3 % 1.53 [ 0.24, 9.59 ]
Petersen 1997 4/93 11/93 2.4 % 0.34 [ 0.10, 1.09 ]
Saiman 2003 20/87 8/98 3.3 % 3.36 [ 1.39, 8.09 ]
Saiman 2010 6/131 11/129 2.9 % 0.51 [ 0.18, 1.44 ]
Sampaio 2011 2/20 0/20 0.5 % 5.54 [ 0.25, 123.08 ]
Uzun 2014 9/47 1/45 1.1 % 10.42 [ 1.26, 86.05 ]
Videler 2011 2/29 2/31 1.1 % 1.07 [ 0.14, 8.17 ]
Wiesli 2002 2/20 1/20 0.8 % 2.11 [ 0.18, 25.35 ]
Wilson 1977 9/26 5/25 2.2 % 2.12 [ 0.59, 7.54 ]
Wong 2012 13/71 4/70 2.5 % 3.70 [ 1.14, 11.97 ]
Yeo 1993 6/58 9/60 2.6 % 0.65 [ 0.22, 1.97 ]
Total (95% CI) 11918 11836 100.0 % 1.70 [ 1.34, 2.16 ]
Total events: 1926 (Macrolide), 1059 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 140.51, df = 36 (P<0.00001); I2 =74%
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Gastrointestinal disorders, Outcome 11 Diarrhoea - subgroup analysis by
macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 11 Diarrhoea - subgroup analysis by macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Altenburg 2013 9/43 1/40 1.0 % 10.32 [ 1.24, 85.71 ]
Amer 2006 2/25 0/24 0.5 % 5.21 [ 0.24, 114.41 ]
Branden 2004 16/51 2/52 1.7 % 11.43 [ 2.47, 52.89 ]
Cameron 2013 4/39 3/38 1.7 % 1.33 [ 0.28, 6.40 ]
Clement 2006 3/40 4/42 1.7 % 0.77 [ 0.16, 3.68 ]
Gibson 2017 72/213 39/207 5.0 % 2.20 [ 1.40, 3.45 ]
Grassly 2016 92/376 63/378 5.3 % 1.62 [ 1.13, 2.32 ]
Grayston 2005 724/2004 446/2008 5.9 % 1.98 [ 1.72, 2.28 ]
Hahn 2012 12/38 5/37 2.5 % 2.95 [ 0.92, 9.47 ]
Haye 1998 11/87 5/82 2.6 % 2.23 [ 0.74, 6.72 ]
Heppner 2005 14/170 17/94 3.8 % 0.41 [ 0.19, 0.87 ]
Hodgson 2016 4/21 2/21 1.3 % 2.24 [ 0.36, 13.78 ]
Hyde 2001 6/73 5/74 2.3 % 1.24 [ 0.36, 4.24 ]
Jackson 1999 8/44 8/44 2.7 % 1.00 [ 0.34, 2.95 ]
Mandhane 2017 42/140 44/139 4.7 % 0.93 [ 0.56, 1.54 ]
O’Connor 2003 313/3866 54/3856 5.5 % 6.20 [ 4.63, 8.31 ]
Saiman 2003 20/87 8/98 3.3 % 3.36 [ 1.39, 8.09 ]
Saiman 2010 6/131 11/129 2.9 % 0.51 [ 0.18, 1.44 ]
Sampaio 2011 2/20 0/20 0.5 % 5.54 [ 0.25, 123.08 ]
Uzun 2014 9/47 1/45 1.1 % 10.42 [ 1.26, 86.05 ]
Videler 2011 2/29 2/31 1.1 % 1.07 [ 0.14, 8.17 ]
Wong 2012 13/71 4/70 2.5 % 3.70 [ 1.14, 11.97 ]
Subtotal (95% CI) 7615 7529 59.7 % 1.96 [ 1.37, 2.81 ]
Total events: 1384 (Macrolide), 724 (Placebo)
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.39; Chi2 = 108.72, df = 21 (P<0.00001); I2 =81%
Test for overall effect: Z = 3.68 (P = 0.00024)
2 Clarithromycin
Andere 2017 2/20 0/20 0.5 % 5.54 [ 0.25, 123.08 ]
Jespersen 2006 292/2155 151/2175 5.8 % 2.10 [ 1.71, 2.58 ]
Lanza 1998 4/60 2/29 1.4 % 0.96 [ 0.17, 5.60 ]
Ogrendik 2007 2/41 1/40 0.8 % 2.00 [ 0.17, 22.97 ]
Subtotal (95% CI) 2276 2264 8.6 % 2.09 [ 1.70, 2.56 ]
Total events: 300 (Macrolide), 154 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 7.08 (P < 0.00001)
3 Erythromycin
Eschenbach 1991 94/586 64/548 5.4 % 1.44 [ 1.03, 2.03 ]
Halperin 1999 29/144 14/166 4.0 % 2.74 [ 1.38, 5.42 ]
Klebanoff 1995 60/466 42/466 5.1 % 1.49 [ 0.98, 2.26 ]
McCormack 1987 23/360 23/391 4.4 % 1.09 [ 0.60, 1.98 ]
McGregor 1990 6/119 0/110 0.6 % 12.66 [ 0.70, 227.35 ]
Petersen 1997 4/93 11/93 2.4 % 0.34 [ 0.10, 1.09 ]
Wilson 1977 9/26 5/25 2.2 % 2.12 [ 0.59, 7.54 ]
Yeo 1993 6/58 9/60 2.6 % 0.65 [ 0.22, 1.97 ]
Subtotal (95% CI) 1852 1859 26.8 % 1.36 [ 0.94, 1.98 ]
Total events: 231 (Macrolide), 168 (Placebo)
Heterogeneity: Tau2 = 0.12; Chi2 = 14.58, df = 7 (P = 0.04); I2 =52%
Test for overall effect: Z = 1.63 (P = 0.10)
4 Roxithromycin
Black 2001 6/105 10/114 2.8 % 0.63 [ 0.22, 1.80 ]
Ogrendik 2011 3/50 2/50 1.3 % 1.53 [ 0.24, 9.59 ]
Wiesli 2002 2/20 1/20 0.8 % 2.11 [ 0.18, 25.35 ]
Subtotal (95% CI) 175 184 4.9 % 0.88 [ 0.38, 2.07 ]
Total events: 11 (Macrolide), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 11918 11836 100.0 % 1.70 [ 1.34, 2.16 ]
Total events: 1926 (Macrolide), 1059 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 140.51, df = 36 (P<0.00001); I2 =74%
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Chi2 = 6.93, df = 3 (P = 0.07), I2 =57%
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Analysis 3.12. Comparison 3 Gastrointestinal disorders, Outcome 12 Gastrointestinal disorders not
otherwise specified.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 12 Gastrointestinal disorders not otherwise specified
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alger 1991 9/39 1/44 2.0 % 12.90 [ 1.55, 107.25 ]
Anderson 1999 31/150 12/152 7.7 % 3.04 [ 1.49, 6.18 ]
Anthony 2014 3/39 1/39 1.7 % 3.17 [ 0.31, 31.86 ]
Beigelman 2015 7/19 8/20 4.2 % 0.88 [ 0.24, 3.18 ]
Berkhof 2013 5/42 6/42 4.3 % 0.81 [ 0.23, 2.89 ]
Dunlay 1987 4/32 0/31 1.1 % 9.95 [ 0.51, 192.99 ]
Hahn 2006 5/24 2/21 2.7 % 2.50 [ 0.43, 14.51 ]
Haxel 2015 5/29 0/29 1.1 % 13.24 [ 0.70, 251.60 ]
Hooton 1990 18/34 3/35 3.9 % 12.00 [ 3.07, 46.83 ]
Ikeoka 2007 5/42 0/40 1.1 % 11.88 [ 0.64, 222.25 ]
Johnston 2016 25/97 20/102 8.1 % 1.42 [ 0.73, 2.78 ]
Kaiser 2001 32/133 14/132 8.0 % 2.67 [ 1.35, 5.28 ]
Kaul 2004 22/230 18/236 8.2 % 1.28 [ 0.67, 2.46 ]
King 1996 13/49 2/42 3.2 % 7.22 [ 1.52, 34.21 ]
Kvien 2004 30/81 12/71 7.3 % 2.89 [ 1.34, 6.23 ]
Mercer 1992 7/106 8/114 5.4 % 0.94 [ 0.33, 2.68 ]
Pradeep 2011 1/20 0/20 0.9 % 3.15 [ 0.12, 82.16 ]
Seemungal 2008 8/53 8/56 5.3 % 1.07 [ 0.37, 3.08 ]
Shanson 1985 29/56 10/53 6.6 % 4.62 [ 1.94, 10.97 ]
Uzun 2014 4/47 7/45 4.2 % 0.50 [ 0.14, 1.86 ]
Vainas 2005 15/257 10/252 6.9 % 1.50 [ 0.66, 3.40 ]
Vos 2011 3/40 1/43 1.7 % 3.41 [ 0.34, 34.17 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wilson 1979 7/27 5/30 4.2 % 1.75 [ 0.48, 6.35 ]
Total (95% CI) 1646 1649 100.0 % 2.16 [ 1.56, 3.00 ]
Total events: 288 (Macrolide), 148 (Placebo)
Heterogeneity: Tau2 = 0.23; Chi2 = 38.05, df = 22 (P = 0.02); I2 =42%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Gastrointestinal disorders, Outcome 13 Gastrointestinal disorders not
otherwise specified - subgroup analysis by macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 3 Gastrointestinal disorders
Outcome: 13 Gastrointestinal disorders not otherwise specified - subgroup analysis by macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Anderson 1999 31/150 12/152 8.0 % 3.04 [ 1.49, 6.18 ]
Anthony 2014 3/39 1/39 1.9 % 3.17 [ 0.31, 31.86 ]
Beigelman 2015 7/19 8/20 4.4 % 0.88 [ 0.24, 3.18 ]
Berkhof 2013 5/42 6/42 4.5 % 0.81 [ 0.23, 2.89 ]
Hahn 2006 5/24 2/21 2.9 % 2.50 [ 0.43, 14.51 ]
Ikeoka 2007 5/42 0/40 1.2 % 11.88 [ 0.64, 222.25 ]
Johnston 2016 25/97 20/102 8.3 % 1.42 [ 0.73, 2.78 ]
Kaiser 2001 32/133 14/132 8.2 % 2.67 [ 1.35, 5.28 ]
Kaul 2004 22/230 18/236 8.4 % 1.28 [ 0.67, 2.46 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kvien 2004 30/81 12/71 7.5 % 2.89 [ 1.34, 6.23 ]
Uzun 2014 4/47 7/45 4.4 % 0.50 [ 0.14, 1.86 ]
Vainas 2005 15/257 10/252 7.1 % 1.50 [ 0.66, 3.40 ]
Vos 2011 3/40 1/43 1.9 % 3.41 [ 0.34, 34.17 ]
Subtotal (95% CI) 1201 1195 68.7 % 1.77 [ 1.30, 2.42 ]
Total events: 187 (Macrolide), 111 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.19, df = 12 (P = 0.23); I2 =21%
Test for overall effect: Z = 3.60 (P = 0.00032)
2 Erythromycin
Alger 1991 9/39 1/44 2.1 % 12.90 [ 1.55, 107.25 ]
Dunlay 1987 4/32 0/31 1.2 % 9.95 [ 0.51, 192.99 ]
Haxel 2015 5/29 0/29 1.2 % 13.24 [ 0.70, 251.60 ]
Hooton 1990 18/34 3/35 4.1 % 12.00 [ 3.07, 46.83 ]
King 1996 13/49 2/42 3.5 % 7.22 [ 1.52, 34.21 ]
Mercer 1992 7/106 8/114 5.7 % 0.94 [ 0.33, 2.68 ]
Seemungal 2008 1/20 0/20 1.0 % 3.15 [ 0.12, 82.16 ]
Shanson 1985 8/53 8/56 5.6 % 1.07 [ 0.37, 3.08 ]
Wilson 1979 29/56 10/53 6.8 % 4.62 [ 1.94, 10.97 ]
Subtotal (95% CI) 418 424 31.3 % 4.00 [ 1.83, 8.74 ]
Total events: 94 (Macrolide), 32 (Placebo)
Heterogeneity: Tau2 = 0.69; Chi2 = 18.04, df = 8 (P = 0.02); I2 =56%
Test for overall effect: Z = 3.47 (P = 0.00052)
Total (95% CI) 1619 1619 100.0 % 2.19 [ 1.56, 3.09 ]
Total events: 281 (Macrolide), 143 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 37.99, df = 21 (P = 0.01); I2 =45%
Test for overall effect: Z = 4.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.57, df = 1 (P = 0.06), I2 =72%
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Analysis 4.1. Comparison 4 Nervous system disorders, Outcome 1 Dizziness.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 4 Nervous system disorders
Outcome: 1 Dizziness
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Branden 2004 3/51 1/52 11.2 % 3.19 [ 0.32, 31.70 ]
Jackson 1999 2/44 2/44 14.7 % 1.00 [ 0.13, 7.43 ]
Saiman 2003 14/87 9/98 74.1 % 1.90 [ 0.78, 4.63 ]
Total (95% CI) 182 194 100.0 % 1.83 [ 0.85, 3.95 ]
Total events: 19 (Macrolide), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Nervous system disorders, Outcome 2 Headache.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 4 Nervous system disorders
Outcome: 2 Headache
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 0/43 2/40 1.1 % 0.18 [ 0.01, 3.80 ]
Cameron 2013 2/39 1/38 1.7 % 2.00 [ 0.17, 23.02 ]
Clement 2006 2/40 0/42 1.1 % 5.52 [ 0.26, 118.61 ]
Hodgson 2016 1/21 0/21 1.0 % 3.15 [ 0.12, 81.74 ]
Hooton 1990 1/34 2/35 1.7 % 0.50 [ 0.04, 5.79 ]
Jackson 1999 2/44 4/44 3.4 % 0.48 [ 0.08, 2.75 ]
Mandhane 2017 8/140 14/139 12.8 % 0.54 [ 0.22, 1.33 ]
Ogrendik 2007 7/41 6/40 7.4 % 1.17 [ 0.36, 3.83 ]
Ogrendik 2011 6/50 5/50 6.6 % 1.23 [ 0.35, 4.32 ]
Saiman 2003 28/87 31/98 27.2 % 1.03 [ 0.55, 1.91 ]
Saiman 2010 30/131 40/129 34.2 % 0.66 [ 0.38, 1.15 ]
Sampaio 2011 1/20 2/20 1.7 % 0.47 [ 0.04, 5.69 ]
Total (95% CI) 690 696 100.0 % 0.81 [ 0.58, 1.11 ]
Total events: 88 (Macrolide), 107 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.95, df = 11 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Nervous system disorders, Outcome 3 Taste disturbance.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 4 Nervous system disorders
Outcome: 3 Taste disturbance
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lanza 1998 7/60 0/29 11.0 % 8.27 [ 0.46, 149.99 ]
Ogrendik 2007 19/41 1/40 17.4 % 33.68 [ 4.22, 268.98 ]
Pierce 1996 38/341 7/341 36.4 % 5.98 [ 2.63, 13.60 ]
Pradeep 2011 2/20 1/20 13.8 % 2.11 [ 0.18, 25.35 ]
Sampaio 2011 3/20 3/20 21.4 % 1.00 [ 0.18, 5.67 ]
Total (95% CI) 482 450 100.0 % 4.95 [ 1.64, 14.93 ]
Total events: 69 (Macrolide), 12 (Placebo)
Heterogeneity: Tau2 = 0.70; Chi2 = 7.47, df = 4 (P = 0.11); I2 =46%
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Skin and subcutaneous tissue disorders, Outcome 1 Itching.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 5 Skin and subcutaneous tissue disorders
Outcome: 1 Itching
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 2/43 3/40 5.0 % 0.60 [ 0.10, 3.80 ]
Heppner 2005 9/170 5/94 13.5 % 1.00 [ 0.32, 3.06 ]
McCormack 1987 27/360 26/399 54.7 % 1.16 [ 0.67, 2.03 ]
Rozman 1984 15/146 12/136 26.8 % 1.18 [ 0.53, 2.63 ]
Total (95% CI) 719 669 100.0 % 1.11 [ 0.73, 1.67 ]
Total events: 53 (Macrolide), 46 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Skin and subcutaneous tissue disorders, Outcome 2 Rash.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 5 Skin and subcutaneous tissue disorders
Outcome: 2 Rash
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Altenburg 2013 8/43 4/40 2.9 % 2.06 [ 0.57, 7.45 ]
Bonacini 1993 3/41 1/36 0.9 % 2.76 [ 0.27, 27.82 ]
Gibson 2017 11/213 10/207 6.2 % 1.07 [ 0.45, 2.58 ]
Grayston 2005 122/2004 116/2008 69.8 % 1.06 [ 0.81, 1.37 ]
Hahn 2012 3/36 1/34 0.9 % 3.00 [ 0.30, 30.35 ]
Heppner 2005 19/170 5/94 4.6 % 2.24 [ 0.81, 6.21 ]
Mandhane 2017 26/140 26/139 13.2 % 0.99 [ 0.54, 1.81 ]
Seemungal 2008 3/53 2/56 1.4 % 1.62 [ 0.26, 10.10 ]
Total (95% CI) 2700 2614 100.0 % 1.13 [ 0.91, 1.41 ]
Total events: 195 (Macrolide), 165 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.42, df = 7 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 General disorders and administration site conditions, Outcome 1 Fever.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 6 General disorders and administration site conditions
Outcome: 1 Fever
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bonacini 1993 1/41 3/36 1.7 % 0.28 [ 0.03, 2.77 ]
Clement 2006 2/40 3/42 2.6 % 0.68 [ 0.11, 4.33 ]
Grassly 2016 100/376 107/378 30.6 % 0.92 [ 0.67, 1.26 ]
Heppner 2005 63/170 32/94 19.5 % 1.14 [ 0.67, 1.93 ]
Roca 2016a 8/414 24/415 11.0 % 0.32 [ 0.14, 0.72 ]
Saiman 2003 24/87 36/98 15.9 % 0.66 [ 0.35, 1.22 ]
Saiman 2010 30/131 41/129 18.6 % 0.64 [ 0.37, 1.11 ]
Total (95% CI) 1259 1192 100.0 % 0.73 [ 0.54, 1.00 ]
Total events: 228 (Macrolide), 246 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.19, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Hepatobiliary disorders, Outcome 1 Hepatobiliary disorders.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 7 Hepatobiliary disorders
Outcome: 1 Hepatobiliary disorders
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aly 2007 2/30 4/30 28.1 % 0.46 [ 0.08, 2.75 ]
Black 2001 6/105 1/114 23.2 % 6.85 [ 0.81, 57.87 ]
Nuntnarumit 2006 3/23 2/23 26.5 % 1.58 [ 0.24, 10.44 ]
Yeo 1993 1/58 4/60 22.2 % 0.25 [ 0.03, 2.27 ]
Total (95% CI) 216 227 100.0 % 1.04 [ 0.27, 4.09 ]
Total events: 12 (Macrolide), 11 (Placebo)
Heterogeneity: Tau2 = 0.91; Chi2 = 5.63, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Infections and infestations, Outcome 1 Blood infection.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 8 Infections and infestations
Outcome: 1 Blood infection
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Aly 2007 11/30 15/30 21.2 % 0.58 [ 0.21, 1.62 ]
Berne 2002 6/32 7/36 15.3 % 0.96 [ 0.28, 3.21 ]
Ng 2007 26/91 27/91 55.0 % 0.95 [ 0.50, 1.80 ]
Nuntnarumit 2006 3/23 4/23 8.5 % 0.71 [ 0.14, 3.61 ]
Total (95% CI) 176 180 100.0 % 0.83 [ 0.52, 1.34 ]
Total events: 46 (Macrolide), 53 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Infections and infestations, Outcome 2 Respiratory tract infections.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 8 Infections and infestations
Outcome: 2 Respiratory tract infections
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albert 2011 26/558 41/559 6.6 % 0.62 [ 0.37, 1.02 ]
Altenburg 2013 1/43 2/40 0.3 % 0.45 [ 0.04, 5.19 ]
Anthony 2014 3/39 4/39 0.7 % 0.73 [ 0.15, 3.50 ]
Berne 2002 13/32 18/36 1.8 % 0.68 [ 0.26, 1.79 ]
Cameron 2013 5/39 5/38 1.0 % 0.97 [ 0.26, 3.67 ]
Clement 2006 14/40 16/42 2.1 % 0.88 [ 0.36, 2.15 ]
El-Sadr 2000 16/258 20/262 3.7 % 0.80 [ 0.40, 1.58 ]
Gibson 2017 42/213 65/207 8.5 % 0.54 [ 0.34, 0.84 ]
Grassly 2016 81/376 76/378 13.7 % 1.09 [ 0.77, 1.55 ]
O’Connor 2003 247/3866 362/3856 59.8 % 0.66 [ 0.56, 0.78 ]
Wong 2012 9/71 12/70 1.9 % 0.70 [ 0.28, 1.79 ]
Total (95% CI) 5535 5527 100.0 % 0.70 [ 0.62, 0.80 ]
Total events: 457 (Macrolide), 621 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.95, df = 10 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.30 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
297Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.3. Comparison 8 Infections and infestations, Outcome 3 Skin and soft tissue infections.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 8 Infections and infestations
Outcome: 3 Skin and soft tissue infections
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berne 2002 2/32 2/36 28.7 % 1.13 [ 0.15, 8.55 ]
Cameron 2013 3/39 1/38 22.0 % 3.08 [ 0.31, 31.04 ]
Yeo 1993 4/58 3/60 49.3 % 1.41 [ 0.30, 6.58 ]
Total (95% CI) 129 134 100.0 % 1.57 [ 0.53, 4.64 ]
Total events: 9 (Macrolide), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Investigations, Outcome 1 Change in liver enzymes.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 9 Investigations
Outcome: 1 Change in liver enzymes
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ballard 2011 16/111 13/109 19.7 % 1.24 [ 0.57, 2.73 ]
Black 2001 6/105 1/114 8.5 % 6.85 [ 0.81, 57.87 ]
McCormack 1987 16/161 3/165 14.9 % 5.96 [ 1.70, 20.87 ]
Ng 2007 11/91 23/91 19.7 % 0.41 [ 0.18, 0.89 ]
Sinisalo 2002 11/74 10/74 18.3 % 1.12 [ 0.44, 2.82 ]
Uzun 2014 21/47 13/45 18.9 % 1.99 [ 0.84, 4.72 ]
Total (95% CI) 589 598 100.0 % 1.56 [ 0.73, 3.37 ]
Total events: 81 (Macrolide), 63 (Placebo)
Heterogeneity: Tau2 = 0.62; Chi2 = 17.49, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Metabolism and nutrition disorders, Outcome 1 Appetite lost.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 10 Metabolism and nutrition disorders
Outcome: 1 Appetite lost
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eschenbach 1991 91/586 79/548 42.8 % 1.09 [ 0.79, 1.51 ]
Heppner 2005 15/170 13/94 10.4 % 0.60 [ 0.27, 1.33 ]
Martin 1997 43/205 29/209 21.8 % 1.65 [ 0.98, 2.76 ]
Petersen 1997 25/93 25/93 14.9 % 1.00 [ 0.52, 1.91 ]
Saiman 2003 13/87 15/98 10.0 % 0.97 [ 0.43, 2.18 ]
Total (95% CI) 1141 1042 100.0 % 1.10 [ 0.84, 1.43 ]
Total events: 187 (Macrolide), 161 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.75, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 1 Cough.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 11 Respiratory, thoracic, and mediastinal disorders
Outcome: 1 Cough
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clement 2006 0/40 2/42 1.2 % 0.20 [ 0.01, 4.30 ]
Grassly 2016 15/376 19/378 20.3 % 0.79 [ 0.39, 1.57 ]
Heppner 2005 30/170 20/94 23.6 % 0.79 [ 0.42, 1.49 ]
Hodgson 2016 1/21 5/21 2.3 % 0.16 [ 0.02, 1.51 ]
Saiman 2003 64/87 80/98 20.0 % 0.63 [ 0.31, 1.26 ]
Saiman 2010 63/131 91/129 32.6 % 0.39 [ 0.23, 0.64 ]
Total (95% CI) 825 762 100.0 % 0.57 [ 0.40, 0.80 ]
Total events: 173 (Macrolide), 217 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.82, df = 5 (P = 0.32); I2 =14%
Test for overall effect: Z = 3.24 (P = 0.0012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
301Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 11.2. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 2 Respiratory
symptoms not otherwise specified.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 11 Respiratory, thoracic, and mediastinal disorders
Outcome: 2 Respiratory symptoms not otherwise specified
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bergeron 2017 27/234 31/231 14.7 % 0.84 [ 0.48, 1.46 ]
Berkhof 2013 7/42 8/42 3.6 % 0.85 [ 0.28, 2.60 ]
Bonacini 1993 2/41 1/36 0.7 % 1.79 [ 0.16, 20.66 ]
Grassly 2016 81/376 76/378 36.1 % 1.09 [ 0.77, 1.55 ]
Johnston 2016 20/97 28/102 10.4 % 0.69 [ 0.36, 1.32 ]
Kvien 2004 10/81 9/71 4.8 % 0.97 [ 0.37, 2.54 ]
Saiman 2003 38/87 36/98 12.8 % 1.34 [ 0.74, 2.41 ]
Saiman 2010 45/131 42/129 16.8 % 1.08 [ 0.65, 1.81 ]
Total (95% CI) 1089 1087 100.0 % 1.02 [ 0.82, 1.25 ]
Total events: 230 (Macrolide), 231 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.18, df = 7 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Respiratory, thoracic, and mediastinal disorders, Outcome 3 Wheezing.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 11 Respiratory, thoracic, and mediastinal disorders
Outcome: 3 Wheezing
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Beigelman 2015 2/19 1/20 15.0 % 2.24 [ 0.19, 26.91 ]
Saiman 2003 15/87 4/98 39.2 % 4.90 [ 1.56, 15.38 ]
Saiman 2010 10/131 9/129 45.8 % 1.10 [ 0.43, 2.81 ]
Total (95% CI) 237 247 100.0 % 2.20 [ 0.74, 6.52 ]
Total events: 27 (Macrolide), 14 (Placebo)
Heterogeneity: Tau2 = 0.44; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Deaths, Outcome 1 Deaths - overall.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 12 Deaths
Outcome: 1 Deaths - overall
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albert 2011 18/558 21/559 2.2 % 0.85 [ 0.45, 1.62 ]
Aly 2007 5/30 6/30 0.6 % 0.80 [ 0.22, 2.97 ]
Anderson 1999 5/150 4/152 0.5 % 1.28 [ 0.34, 4.85 ]
Anthony 2014 2/39 0/39 0.1 % 5.27 [ 0.24, 113.35 ]
Ballard 2011 20/111 24/109 2.1 % 0.78 [ 0.40, 1.51 ]
Barkhordar 2018 11/48 10/48 1.0 % 1.13 [ 0.43, 2.98 ]
Berg 2005 10/238 9/235 1.1 % 1.10 [ 0.44, 2.76 ]
Bergeron 2017 95/234 66/231 5.3 % 1.71 [ 1.16, 2.52 ]
Berne 2002 2/32 2/36 0.2 % 1.13 [ 0.15, 8.55 ]
Cercek 2003 23/716 29/723 2.8 % 0.79 [ 0.45, 1.39 ]
Currier 2000 3/322 7/321 0.5 % 0.42 [ 0.11, 1.65 ]
Ehsani 2013 0/20 1/20 0.1 % 0.32 [ 0.01, 8.26 ]
El-Sadr 2000 5/258 5/262 0.6 % 1.02 [ 0.29, 3.55 ]
Giamarellos-Bourboulis 2008 43/100 60/100 2.8 % 0.50 [ 0.29, 0.88 ]
Giamarellos-Bourboulis 2014 56/302 51/298 4.7 % 1.10 [ 0.73, 1.68 ]
Gokmen 2012 0/24 1/23 0.1 % 0.31 [ 0.01, 7.91 ]
Grayston 2005 143/2004 132/2008 10.3 % 1.09 [ 0.85, 1.40 ]
Gupta 1997 1/40 1/20 0.1 % 0.49 [ 0.03, 8.22 ]
Gurfinkel 1999 2/102 5/100 0.4 % 0.38 [ 0.07, 2.01 ]
Hahn 2006 0/24 1/21 0.1 % 0.28 [ 0.01, 7.22 ]
Ikeoka 2007 2/42 0/40 0.1 % 5.00 [ 0.23, 107.43 ]
Jablonowski 1997 1/341 7/341 0.2 % 0.14 [ 0.02, 1.15 ]
Jespersen 2006 212/2172 172/2200 12.4 % 1.28 [ 1.03, 1.57 ]
Joensen 2008 28/250 26/257 2.8 % 1.12 [ 0.64, 1.97 ]
Kaehler 2005 1/165 1/162 0.1 % 0.98 [ 0.06, 15.83 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Karlsson 2009 5/122 8/125 0.7 % 0.63 [ 0.20, 1.97 ]
Kaul 2004 1/230 2/236 0.2 % 0.51 [ 0.05, 5.67 ]
Keenan 2018 2404/97047 2616/93191 25.7 % 0.88 [ 0.83, 0.93 ]
Kim 2004 2/64 2/65 0.2 % 1.02 [ 0.14, 7.44 ]
Leowattana 2001 1/43 1/41 0.1 % 0.95 [ 0.06, 15.75 ]
Neumann 2001 16/506 13/504 1.7 % 1.23 [ 0.59, 2.59 ]
Ng 2007 2/91 4/91 0.3 % 0.49 [ 0.09, 2.74 ]
Nuntnarumit 2006 2/23 0/23 0.1 % 5.47 [ 0.25, 120.37 ]
Oei 2001 1/24 1/24 0.1 % 1.00 [ 0.06, 16.97 ]
Oldfield 1998 38/85 38/86 2.5 % 1.02 [ 0.56, 1.87 ]
Ozdemir 2011 2/37 4/37 0.3 % 0.47 [ 0.08, 2.75 ]
Pierce 1996 107/333 137/334 7.2 % 0.68 [ 0.50, 0.93 ]
Reignier 2002 6/20 8/20 0.6 % 0.64 [ 0.17, 2.38 ]
Robins-Browne 1983 1/39 1/39 0.1 % 1.00 [ 0.06, 16.58 ]
Sander 2002 4/136 5/136 0.5 % 0.79 [ 0.21, 3.02 ]
Schwameis 2017 0/685 1/686 0.1 % 0.33 [ 0.01, 8.20 ]
Seemungal 2008 0/53 1/56 0.1 % 0.35 [ 0.01, 8.68 ]
Shafuddin 2015 3/97 5/94 0.5 % 0.57 [ 0.13, 2.45 ]
Sinisalo 2002 4/74 1/74 0.2 % 4.17 [ 0.46, 38.24 ]
Uzun 2014 0/47 2/45 0.1 % 0.18 [ 0.01, 3.92 ]
Vainas 2005 20/257 25/252 2.4 % 0.77 [ 0.41, 1.42 ]
Vammen 2001 3/43 2/49 0.3 % 1.76 [ 0.28, 11.08 ]
Van Delden 2012 9/47 6/45 0.8 % 1.54 [ 0.50, 4.74 ]
Van den Broek 2009 7/1149 3/1148 0.5 % 2.34 [ 0.60, 9.07 ]
Vos 2011 5/15 8/13 0.4 % 0.31 [ 0.07, 1.47 ]
Wiesli 2002 1/20 2/20 0.2 % 0.47 [ 0.04, 5.69 ]
Zahn 2003 28/431 26/437 2.9 % 1.10 [ 0.63, 1.91 ]
Total (95% CI) 110040 106206 100.0 % 0.96 [ 0.87, 1.06 ]
Total events: 3360 (Macrolide), 3563 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 57.03, df = 51 (P = 0.26); I2 =11%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Deaths, Outcome 2 Deaths - subgroup analysis by type of macrolide.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 12 Deaths
Outcome: 2 Deaths - subgroup analysis by type of macrolide
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Azithromycin
Albert 2011 18/558 21/559 2.2 % 0.85 [ 0.45, 1.62 ]
Anderson 1999 5/150 4/152 0.5 % 1.28 [ 0.34, 4.85 ]
Anthony 2014 2/39 0/39 0.1 % 5.27 [ 0.24, 113.35 ]
Ballard 2011 20/111 24/109 2.1 % 0.78 [ 0.40, 1.51 ]
Barkhordar 2018 11/48 10/48 1.0 % 1.13 [ 0.43, 2.98 ]
Bergeron 2017 95/234 66/231 5.3 % 1.71 [ 1.16, 2.52 ]
Cercek 2003 23/716 29/723 2.8 % 0.79 [ 0.45, 1.39 ]
Currier 2000 3/322 7/321 0.5 % 0.42 [ 0.11, 1.65 ]
El-Sadr 2000 5/258 5/262 0.6 % 1.02 [ 0.29, 3.55 ]
Grayston 2005 143/2004 132/2008 10.3 % 1.09 [ 0.85, 1.40 ]
Gupta 1997 1/40 1/20 0.1 % 0.49 [ 0.03, 8.22 ]
Hahn 2006 0/24 1/21 0.1 % 0.28 [ 0.01, 7.22 ]
Ikeoka 2007 2/42 0/40 0.1 % 5.00 [ 0.23, 107.43 ]
Karlsson 2009 5/122 8/125 0.7 % 0.63 [ 0.20, 1.97 ]
Kaul 2004 1/230 2/236 0.2 % 0.51 [ 0.05, 5.67 ]
Keenan 2018 2404/97047 2616/93191 25.7 % 0.88 [ 0.83, 0.93 ]
Kim 2004 2/64 2/65 0.2 % 1.02 [ 0.14, 7.44 ]
Oldfield 1998 38/85 38/86 2.5 % 1.02 [ 0.56, 1.87 ]
Schwameis 2017 0/685 1/686 0.1 % 0.33 [ 0.01, 8.20 ]
Uzun 2014 0/47 2/45 0.1 % 0.18 [ 0.01, 3.92 ]
Vainas 2005 20/257 25/252 2.4 % 0.77 [ 0.41, 1.42 ]
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Van Delden 2012 9/47 6/45 0.8 % 1.54 [ 0.50, 4.74 ]
Van den Broek 2009 7/1149 3/1148 0.5 % 2.34 [ 0.60, 9.07 ]
Vos 2011 5/15 8/13 0.4 % 0.31 [ 0.07, 1.47 ]
Subtotal (95% CI) 104294 100425 59.4 % 0.97 [ 0.85, 1.10 ]
Total events: 2819 (Macrolide), 3011 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 25.88, df = 23 (P = 0.31); I2 =11%
Test for overall effect: Z = 0.53 (P = 0.59)
2 Clarithromycin
Berg 2005 10/238 9/235 1.1 % 1.10 [ 0.44, 2.76 ]
Giamarellos-Bourboulis 2008 43/100 60/100 2.8 % 0.50 [ 0.29, 0.88 ]
Giamarellos-Bourboulis 2014 56/302 51/298 4.7 % 1.10 [ 0.73, 1.68 ]
Jablonowski 1997 1/341 7/341 0.2 % 0.14 [ 0.02, 1.15 ]
Jespersen 2006 212/2172 172/2200 12.4 % 1.28 [ 1.03, 1.57 ]
Ozdemir 2011 2/37 4/37 0.3 % 0.47 [ 0.08, 2.75 ]
Pierce 1996 107/333 137/334 7.2 % 0.68 [ 0.50, 0.93 ]
Sinisalo 2002 4/74 1/74 0.2 % 4.17 [ 0.46, 38.24 ]
Subtotal (95% CI) 3597 3619 28.9 % 0.86 [ 0.59, 1.24 ]
Total events: 435 (Macrolide), 441 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 22.42, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 0.82 (P = 0.41)
3 Erythromycin
Aly 2007 5/30 6/30 0.6 % 0.80 [ 0.22, 2.97 ]
Berne 2002 2/32 2/36 0.2 % 1.13 [ 0.15, 8.55 ]
Ehsani 2013 0/20 1/20 0.1 % 0.32 [ 0.01, 8.26 ]
Gokmen 2012 0/24 1/23 0.1 % 0.31 [ 0.01, 7.91 ]
Ng 2007 2/91 4/91 0.3 % 0.49 [ 0.09, 2.74 ]
Nuntnarumit 2006 2/23 0/23 0.1 % 5.47 [ 0.25, 120.37 ]
Oei 2001 1/24 1/24 0.1 % 1.00 [ 0.06, 16.97 ]
Reignier 2002 6/20 8/20 0.6 % 0.64 [ 0.17, 2.38 ]
Robins-Browne 1983 1/39 1/39 0.1 % 1.00 [ 0.06, 16.58 ]
Seemungal 2008 0/53 1/56 0.1 % 0.35 [ 0.01, 8.68 ]
Subtotal (95% CI) 356 362 2.3 % 0.73 [ 0.38, 1.40 ]
Total events: 19 (Macrolide), 25 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.91, df = 9 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 Roxithromycin
Gurfinkel 1999 2/102 5/100 0.4 % 0.38 [ 0.07, 2.01 ]
Joensen 2008 28/250 26/257 2.8 % 1.12 [ 0.64, 1.97 ]
Kaehler 2005 1/165 1/162 0.1 % 0.98 [ 0.06, 15.83 ]
Leowattana 2001 1/43 1/41 0.1 % 0.95 [ 0.06, 15.75 ]
Neumann 2001 16/506 13/504 1.7 % 1.23 [ 0.59, 2.59 ]
Sander 2002 4/136 5/136 0.5 % 0.79 [ 0.21, 3.02 ]
Shafuddin 2015 3/97 5/94 0.5 % 0.57 [ 0.13, 2.45 ]
Vammen 2001 3/43 2/49 0.3 % 1.76 [ 0.28, 11.08 ]
Wiesli 2002 1/20 2/20 0.2 % 0.47 [ 0.04, 5.69 ]
Zahn 2003 28/431 26/437 2.9 % 1.10 [ 0.63, 1.91 ]
Subtotal (95% CI) 1793 1800 9.4 % 1.03 [ 0.76, 1.41 ]
Total events: 87 (Macrolide), 86 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.24, df = 9 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
Total (95% CI) 110040 106206 100.0 % 0.96 [ 0.87, 1.06 ]
Total events: 3360 (Macrolide), 3563 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 57.03, df = 51 (P = 0.26); I2 =11%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 1.25, df = 3 (P = 0.74), I2 =0.0%
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
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Analysis 12.3. Comparison 12 Deaths, Outcome 3 Deaths - subgroup analysis by route of administration.
Review: Adverse events in people taking macrolide antibiotics versus placebo for any indication
Comparison: 12 Deaths
Outcome: 3 Deaths - subgroup analysis by route of administration
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intravenous
Ballard 2011 20/111 24/109 2.1 % 0.78 [ 0.40, 1.51 ]
Berne 2002 2/32 2/36 0.2 % 1.13 [ 0.15, 8.55 ]
Ehsani 2013 0/20 1/20 0.1 % 0.32 [ 0.01, 8.26 ]
Giamarellos-Bourboulis 2008 43/100 60/100 2.9 % 0.50 [ 0.29, 0.88 ]
Giamarellos-Bourboulis 2014 56/302 51/298 4.8 % 1.10 [ 0.73, 1.68 ]
Ozdemir 2011 2/37 4/37 0.3 % 0.47 [ 0.08, 2.75 ]
Reignier 2002 6/20 8/20 0.6 % 0.64 [ 0.17, 2.38 ]
Van Delden 2012 9/47 6/45 0.8 % 1.54 [ 0.50, 4.74 ]
Subtotal (95% CI) 669 665 11.8 % 0.83 [ 0.63, 1.10 ]
Total events: 138 (Macrolide), 156 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.97, df = 7 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Peroral
Albert 2011 18/558 21/559 2.3 % 0.85 [ 0.45, 1.62 ]
Aly 2007 5/30 6/30 0.6 % 0.80 [ 0.22, 2.97 ]
Anderson 1999 5/150 4/152 0.6 % 1.28 [ 0.34, 4.85 ]
Anthony 2014 2/39 0/39 0.1 % 5.27 [ 0.24, 113.35 ]
Barkhordar 2018 11/48 10/48 1.0 % 1.13 [ 0.43, 2.98 ]
Berg 2005 10/238 9/235 1.2 % 1.10 [ 0.44, 2.76 ]
Bergeron 2017 95/234 66/231 5.4 % 1.71 [ 1.16, 2.52 ]
Cercek 2003 23/716 29/723 2.9 % 0.79 [ 0.45, 1.39 ]
Currier 2000 3/322 7/321 0.5 % 0.42 [ 0.11, 1.65 ]
El-Sadr 2000 5/258 5/262 0.6 % 1.02 [ 0.29, 3.55 ]
Gokmen 2012 0/24 1/23 0.1 % 0.31 [ 0.01, 7.91 ]
Grayston 2005 143/2004 132/2008 10.3 % 1.09 [ 0.85, 1.40 ]
Gupta 1997 1/40 1/20 0.1 % 0.49 [ 0.03, 8.22 ]
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gurfinkel 1999 2/102 5/100 0.4 % 0.38 [ 0.07, 2.01 ]
Hahn 2006 0/24 1/21 0.1 % 0.28 [ 0.01, 7.22 ]
Ikeoka 2007 2/42 0/40 0.1 % 5.00 [ 0.23, 107.43 ]
Jablonowski 1997 1/341 7/341 0.2 % 0.14 [ 0.02, 1.15 ]
Jespersen 2006 212/2172 172/2200 12.3 % 1.28 [ 1.03, 1.57 ]
Joensen 2008 28/250 26/257 2.9 % 1.12 [ 0.64, 1.97 ]
Kaehler 2005 1/165 1/162 0.1 % 0.98 [ 0.06, 15.83 ]
Karlsson 2009 5/122 8/125 0.8 % 0.63 [ 0.20, 1.97 ]
Kaul 2004 1/230 2/236 0.2 % 0.51 [ 0.05, 5.67 ]
Keenan 2018 2404/97047 2616/93191 24.4 % 0.88 [ 0.83, 0.93 ]
Kim 2004 2/64 2/65 0.3 % 1.02 [ 0.14, 7.44 ]
Leowattana 2001 1/43 1/41 0.1 % 0.95 [ 0.06, 15.75 ]
Neumann 2001 16/506 13/504 1.7 % 1.23 [ 0.59, 2.59 ]
Ng 2007 2/91 4/91 0.3 % 0.49 [ 0.09, 2.74 ]
Nuntnarumit 2006 2/23 0/23 0.1 % 5.47 [ 0.25, 120.37 ]
Oei 2001 1/24 1/24 0.1 % 1.00 [ 0.06, 16.97 ]
Oldfield 1998 38/85 38/86 2.5 % 1.02 [ 0.56, 1.87 ]
Pierce 1996 107/333 137/334 7.3 % 0.68 [ 0.50, 0.93 ]
Robins-Browne 1983 1/39 1/39 0.1 % 1.00 [ 0.06, 16.58 ]
Sander 2002 4/136 5/136 0.6 % 0.79 [ 0.21, 3.02 ]
Seemungal 2008 0/53 1/56 0.1 % 0.35 [ 0.01, 8.68 ]
Shafuddin 2015 3/97 5/94 0.5 % 0.57 [ 0.13, 2.45 ]
Sinisalo 2002 4/74 1/74 0.2 % 4.17 [ 0.46, 38.24 ]
Uzun 2014 0/47 2/45 0.1 % 0.18 [ 0.01, 3.92 ]
Vainas 2005 20/257 25/252 2.4 % 0.77 [ 0.41, 1.42 ]
Vammen 2001 3/43 2/49 0.3 % 1.76 [ 0.28, 11.08 ]
Van den Broek 2009 7/1149 3/1148 0.5 % 2.34 [ 0.60, 9.07 ]
Vos 2011 5/15 8/13 0.4 % 0.31 [ 0.07, 1.47 ]
Wiesli 2002 1/20 2/20 0.2 % 0.47 [ 0.04, 5.69 ]
Zahn 2003 28/431 26/437 3.0 % 1.10 [ 0.63, 1.91 ]
Subtotal (95% CI) 108686 104855 88.2 % 0.98 [ 0.88, 1.10 ]
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
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(. . . Continued)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 3222 (Macrolide), 3406 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 49.26, df = 42 (P = 0.21); I2 =15%
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 109355 105520 100.0 % 0.96 [ 0.87, 1.06 ]
Total events: 3360 (Macrolide), 3562 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 56.66, df = 50 (P = 0.24); I2 =12%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 1.19, df = 1 (P = 0.28), I2 =16%
0.01 0.1 1 10 100
More AEs in placebo More AEs in macrolide
A D D I T I O N A L T A B L E S
Table 1. Rarely reported adverse events classified according to System Organ Classes
System Organ Class1 Adverse event2 Participants with an event P value
Macrolide N (%) Placebo N (%)
Blood and lymphatic
system disorders
Anaemia
(Garcia-Burguillo 1996)
2 (7) 3 (10) 0.640
Gastrointestinal
disorders
Dental disorder NOS (
Cameron 2013)
0 2 (5) 0.147
Rectal disorder (Pierce
1996)
27 (8) 10 (3) 0.004
Dry mouth (Ogrendik
2011)
3 (6) 2 (4) 0.646
Dyspepsia (Lanza 1998) 0 2 (7) 0.040
Flatulence (Jespersen
2006)
99 (5) 29 (1) 0.000
Frequent bowel move-
ment (Frossard 2002)
3 (6) 0 0.071
Upset stomach
(Jespersen 2006)
232 (11) 146 (7) 0.000
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Table 1. Rarely reported adverse events classified according to System Organ Classes (Continued)
Haemorrhoids
(Cameron 2013)
0 2 (5) 0.147
Heartburn (Hodgson
2016)
1 (5) 1 (5) 1.000
Necrotising enterocolitis
(Aly 2007)
3 (10) 4 (13) 0.688
Necrotising enterocolitis
(Nuntnarumit 2006)
1 (4) 3 (13) 0.295
Pancreatic fistula3 (Yeo
1993)
5 (9) 10 (17) 0.190
General disorders and
administration site con-
ditions
Infusion site pain (
Giamarellos-Bourboulis
2014)
26 (9) 1 (0) 0.000
Swelling (Hahn 2012) 0 2 (5) 0.146
General disorders
(Johnston 2016)
16 (16) 19 (19) 0.693
Generally unwell
(Saiman 2003)
1 (5) 1 (5) 1.000
Malaise (Cameron
2013)
1 (3) 2 (5) 0.541
Fatigue (Saiman 2003) 24 (28) 36 (37) 0.185
Fatigue (Saiman 2010) 9 (7) 13 (10) 0.353
Immune system disor-
ders
Allergic reaction (Hyde
2001)
4 (5) 0 0.041
Infections and infesta-
tions
Puerperal pyrexia (Tita
2016)
51 (5) 81 (8) 0.001
Gastroenteritis
(Cameron 2013)
7 (18) 0 (0) 0.006
Bacterial infection
(Haxel 2015)
13 (45) 9 (31) 0.279
Infection NOS (Roca
2016a)
15 (4) 38 (9) 0.001
312Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Rarely reported adverse events classified according to System Organ Classes (Continued)
Viral infection
(Cameron 2013)
0 (0) 2 (5) 0.147
Chorioamnionitis
(Garcia-Burguillo 1996)
3 (10) 1 (3) 0.301
Endometritis
(Garcia-Burguillo 1996)
3 (10) 2 (7) 0.640
Urinary tract infection (
Berne 2002)
4 (13) 8 (22) 0.294
Vaginal candidiasis
(Hahn 2012)
4 (11) 3 (8) 0.719
Otitis (Cameron 2013) 0 (0) 7 (18) 0.005
Injury,
poisoning, and procedu-
ral complications
Accident4 (Valery 2013) 2 (4) 2 (5) 0.982
Drug dosage error (
Valery 2013)
3 (7) 1 (2) 0.317
Fall (Hodgson 2016) 0 (0) 1 (5) 0.312
Investigations Blood urea nitrogen in-
creased (Uzun 2014)
4 (9) 10 (22) 0.067
Gastric residuals
(Reignier 2002)
7 (35) 11 (55) 0.204
Decreased lung function
(Saiman 2003)
13 (15) 7 (7) 0.088
Decreased lung function
(Saiman 2010)
8 (6) 16 (12) 0.080
Hearing test abnormal (
Ballard 2011)
20 (18) 24 (22) 0.458
Heart rate irregular (
Mandhane 2017)
10 (7) 4 (3) 0.103
Laboratory test abnor-
malities5 (Currier 2000)
82 (25) 104 (32) 0.053
Metabolism and nutri-
tion disorders
Hypochloraemia (Uzun
2014)
6 (13) 5 (11) 0.807
313Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Rarely reported adverse events classified according to System Organ Classes (Continued)
Musculoskele-
tal and connective tissue
disorders
Back pain (Cameron
2013)
2 (5) 6 (16) 0.125
Back pain (Hodgson
2016)
0 1 (5) 0.312
Knee pain (Cameron
2013)
2 (5) 0 0.157
Myalgia (Heppner
2005)
51 (30) 30 (32) 0.747
Rib pain (Hodgson
2016)
0 1 (5) 0.312
Nervous system disor-
ders
Nervous system disorder
NOS (Johnston 2016)
14 (14) 13 (13) 0.728
Impaired concentration
(Peterson 1996)
0 (0) 2 (6) 0.069
Sleepiness (Sampaio
2011)
3 (15) 3 (15) 1.000
Psychiatric disorders Psychiatric symptom
NOS (Cameron 2013)
4 (10) 2 (5) 0.414
Renal and urinary disor-
ders
Urine colour abnormal6
(McCormack 1987)
21 (6) 23 (6) 0.977
Reproductive system
and breast disorders
Vaginal itching7
(Eschenbach 1991)
55 (9) 48 (9) 0.714
Skin and subcutaneous
tissues disorders
Allergic skin reaction8 (
Petersen 1997)
7 (8) 7 (8) 1.000
Cutaneous symptom (
Kvien 2004)
5 (6) 3 (4) 0.592
Dermatitis (Cameron
2013)
1 (3) 2 (5) 0.541
Hives (Mandhane 2017) 10 (7) 16 (12) 0.210
Skin ulcer (Heppner
2005)
13 (8) 14 (15) 0.063
Surgical and medical
procedures
Sinus operation NOS (
Altenburg 2013)
1 (2) 2 (5) 0.514
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Table 1. Rarely reported adverse events classified according to System Organ Classes (Continued)
Surgery9 (Valery 2013) 3 (7) 3 (7) 0.977
Abbreviations:
MedDRA: Medical Dictionary for Regulatory Activities.
NOS: not otherwise specified.
1System Organ Classes are groupings by aetiology, manifestation site, or purpose defined by MedDRA 2018.
2Best matching term identified in MedDRA 2018.
3Reported as a postoperative complication.
4Reported as accident, fracture, or foreign body.
5Participants who developed a severe or life-threatening laboratory toxicity.
6Treated with erythromycin estolate or erythromycin stearate.
7Reported as “vaginal or rectal itching” - coded as vaginal itching.
8Adverse events reported at day 3.
9Type of surgery not specified.
Table 2. Deaths
Indication for
treatment
Study ID Follow-up period
(days)
Participants who died P value
Macrolide
N (%)
Placebo
N (%)
Acute respiratory
tract infection
Van Delden 2012 71 9 (19) 6 (13) 0.450
Cancer Barkhordar 20182 n/a 11 (23) 10 (21) 0.804
Bergeron 20173 730 95 (41) 66 (29) 0.006
Cardiovascular dis-
ease
Anderson 19994 730 5 (3) 4 (3) 0.720
Berg 2005 730 10 (4) 9 (4) 0.837
Cercek 2003 n/a 23 (3) 29 (4) 0.417
Grayston 2005 1424 143 (7) 132 (7) 0.481
Gupta 19975 n/a 1 (3) 1 (5) 0.611
Gurfinkel 1999 30 0 2 (2) 0.151
Gurfinkel 1999 90 0 4 (4) 0.041
Gurfinkel 1999 180 2 (2) 5 (5) 0.238
Ikeoka 20076 183 2 (5) 0 0.162
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Table 2. Deaths (Continued)
Jespersen 20067 949 212 (10) 172 (8) 0.023
Jespersen 20068 2190 497 (23) 426 (19) 0.004
Jespersen 20069 3650 866 (40) 815 (37) 0.055
Joensen 2008 767 28 (11) 26 (10) 0.693
Kaehler 2005 365 1 (1) 1 (1) 0.990
Karlsson 2009 548 5 (4) 8 (6) 0.418
Kim 200410 365 2 (3) 2 (3) 0.987
Leowattana 200111 90 1 (2) 1 (2) 0.973
Neumann 2001 365 16 (3) 13 (3) 0.579
Sander 200212 730 4 (3) 5 (4) 0.735
Sinisalo 200213 555 4 (5) 1 (1) 0.172
Vainas 2005 730 20 (8) 25 (10) 0.396
Vammen 2001 767 3 (7) 2 (4) 0.541
Wiesli 2002 986 1 (5) 2 (10) 0.548
Zahn 2003 365 28 (6) 26 (6) 0.739
Chronic respiratory
disease
Albert 201114 344 18 (3) 21 (4) 0.629
Anthony 201415 168 2 (5) 0 0.152
Ballard 201116 n/a17 20 (18) 24 (22) 0.458
Hahn 200618 n/a 0 1 (5) 0.280
Ozdemir 201119 n/a 2 (5) 4 (11) 0.394
Seemungal 2008 365 0 1 (2) 0.328
Shafuddin 2015 420 3 (3) 5 (5) 0.443
Uzun 201420 365 0 2 (4) 0.144
Vos 201121 2555 5 (33) 8 (62) 0.136
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Table 2. Deaths (Continued)
Gastrointestinal
condition
Aly 2007 n/a 5 (17) 6 (20) 0.739
Berne 2002 n/a 2 (6) 2 (6) 0.903
Ehsani 2013 n/a 0 1 (5) 0.311
Gokmen 2012 14 0 1 (4) 0.302
Ng 2007 n/a 2 (2) 4 (4) 0.406
Nuntnarumit 2006
22
n/a 2 (9) 0 0.148
Oei 200123 n/a 1 (4) 1 (4) 1.000
Reignier 2002 n/a 6 (30) 8 (40) 0.507
Robins-Browne
1983
7 1 (3) 1 (3) 1.000
HIV Currier 2000 483 3 (1) 7 (2) 0.201
El-Sadr 200024 386 5 (2) 5 (2) 0.980
Jablonowski 1997 n/a 1 (< 1) 7 (2) 0.033
Oldfield 1998 n/a 38 (45) 38 (44) 0.946
Pierce 1996 427/40225 107 (32) 137 (41) 0.017
Prevention of child-
hood mortality
Keenan 2018 726 4 (< 1) 1 (< 1) 0.195
Keenan 2018 62127 2404 (2) 2616 (3) 0.000
Sepsis Giamarellos-
Bourboulis 2008
28 31 (31) 28 (28) 0.642
Giamarellos-
Bourboulis 2008
90 43 (43) 60 (60) 0.016
Giamarellos-
Bourboulis 2014
28 56 (19) 51 (17) 0.648
Skin and soft tissue
complaints
Schwameis 2017 30 0 1 (< 1) 0.318
Urogynaecological
conditions
Kaul 200428 801/76429 1 (< 1) 2 (1) 0.578
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Table 2. Deaths (Continued)
Van denBroek 2009 n/a30 1 (< 1) 2 (< 1) 0.563
Van denBroek 2009 4231 7 (1) 3 (< 1) 0.205
Abbreviation:
HIV: human immunodeficiency virus.
n/a: not available.
1Post-treatment.
2Death caused by relapse, infection, and other reasons. Relapse caused five and seven deaths in the macrolide and placebo groups,
respectively.
3Relapse caused 52 and 23 deaths in the macrolide and placebo groups, respectively.
4Cardiovascular death.
5Cardiovascular death.
6Death caused by respiratory complications of chronic obstructive pulmonary disease or sepsis after limb revascularising surgery.
7All-cause mortality.
8All-cause mortality.
9All-cause mortality. Data obtained by e-mail correspondence with authors (Winkel 2017 [pers comm]).
10Cardiac death.
11Cardiac death.
12Incomplete reporting of death at 4-year follow-up. We contacted the authors but received no reply.
13Death caused by ischaemic heart disease or cancer.
14Death caused by chronic obstructive pulmonary disease, cardiovascular attacks, neoplasm, or other/unknown causes. Report on data
from Sadatsafavi 2016, a secondary study of Albert 2011.
15Death caused by bronchopneumonia with underlying coronary artery disease.
16Death caused by hypoxic respiratory failure, confirmed sepsis and/or necrotising enterocolitis, pulmonary haemorrhage, or withdrawal
of life support due to intraventricular haemorrhage.
17Data collected at days 3, 5, 7, then weekly for the duration of the study, and at discharge.
18Death caused by asthma-related cause.
19Death caused by sepsis or necrotising enterocolitis.
20Death caused by respiratory failure due to exacerbation in chronic obstructive pulmonary disease.
21Report on patients that never received open-label azithromycin. Report on data from Ruttens 2015, a secondary study of Vos 2011.
22Death caused by severe bronchopulmonary dysplasia or from necrotising enterocolitis.
23Death caused by necrotising enterocolitis and septicaemia.
24Death caused by liver failure, cardiovascular disease, cancer, an overdose of methadone, or wasting.
25Follow-up reported separately for clarithromycin and placebo group.
26Deaths reported within one week of study drug administration.
27Follow-up period estimated as person-years (N = 323,302)/total number of children randomised (N = 190,238).
28Deaths caused by trauma.
29Follow-up period reported separately for azithromycin and placebo groups.
30During pregnancy.
31During six weeks after delivery.
318Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Participants with macrolide-resistant bacteria
Participants with macrolide-resistant bacteria1 : 13 studies
Study ID Type of
macrolide
(days of
treatment)
Time for
follow-up
swabs
Macrolide-resistant
bacteria at baseline
N (%)
Macrolide-resistant
bacteria after treatment
2N (%)
Abso-
lute increase in
resistance
with antibiotic
(%)
Rela-
tive increase in
resistance
with antibiotic
(%)
Macrolide Placebo Macrolide Placebo
Bacharier
20153
AZM (5) ≥ 14
days postin-
tervention
5 (12) 4 (9) 8 (20) 7 (17) 0 1
Berg 20054 CLM (16*) Week 2 50 (34) 50 (34) 102 (69) 46 (31) 38 N/A
Week 8 96 (65) 55 (37) 28 N/A
Berkhof
20135
AZM (84) Week 12 0 1 (2) 1 (3) 0 1 -2
Brusselle
20136
AZM (182) Week 26 11 (48) 9 (39) 20 (87) 8 (35) 43 6
Gibson
20177
AZM (336) Week 48 14 (22) 18 (26) 20 (51) 17 (41) 6 -3
McCallum
20157,8
AZM (21) Day 23 8 (8) 13 (12) 7 (7) 13 (12) 1 1
Pierce 1996
8,9
CLM
(315*)
Not
specified
N/A N/A 11 (58) 0 N/A N/A
Roca 2016a
9,10
AZM (1) Day 3 12 (3) 11 (3) 19 (5) 9 (2) 3 N/A
Day 6 25 (6) 17 (4) 2 N/A
Day 14 41 (11) 15 (4) 7 N/A
Day 28 56 (15) 13 (3) 12 N/A
Saiman
201010,11
AZM (168) Day 168 38 (29) 50 (39) 43 (N/A) 9 (N/A) N/A N/A
Sirinavin
200311,12
AZM (5) Day 7 5 (5) 4 (4) 1 (33) 5 (24) 8 9
Day 30 3 (18) 0 17 18
Day 60 1 (4) 3 (14) 9 -10
319Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Participants with macrolide-resistant bacteria (Continued)
Day 90 10 (42) 7 (37) 4 5
Uzun 2014
12,13
AZM (365) 1 year 5 (23) 4 (20) 3 (12) 11 (41) 26 -10
Valery 2013
13,14
AZM
(621*)
End of study 10 (24) 8 (22) 19 (46) 4 (11) 33 18
> 30 days
and
≤
12 months
postinter-
vention14,15
6 (17) 3 (12) 3 3
Wilson
1977
ERY (7) Post-
treatment
0 1 (4) 0 1 (4) 0 1
Brill 2016 [pers comm] reported via email correspondence on both number of participants with resistant bacteria and the number of
resistant isolates (unpublished data). We contacted the author again for information on what type of resistant bacteria they report
on (macrolide-resistant or ‘others’), and are awaiting author reply.
Smith 2002 present the mean number of colony forming units of azithromycin-resistant streptococci per sample, and state that the
number of streptococci resistant to 2 mg/L azithromycin was significantly higher in people who had taken azithromycin compared to
placebo even at 22 weeks (data from Sefton 1996, a secondary study of Smith 2002). We contacted the author, but did not receive any
reply.
Wallwork 2006 report on nasal swabs from participants treated with roxithromycin and state that no macrolide-resistant organisms
were noted to have developed. Data not given for placebo group.
Wong 2012 state that macrolide resistance testing was not routinely undertaken, but two (4%) participants in the azithromycin group
developed macrolide-resistant Streptococcus pneumoniae at six months.
Abbreviations:
AZM: azithromycin.
CLM: clarithromycin.
ERY: erythromycin.
N/A: not available.
*Mean duration of treatment.
1Bacterial isolates tested vary between studies. The most common ones were: Streptococcus pneumoniae,Haemophilus influenza,Moraxella
catarrhalis,Pseudomonas aeruginosa, and Staphylococcus aureus.
2Some studies report on macrolide-resistant bacteria during treatment.
3A subsample of participants (14%) was tested for resistant bacteria. The authors also report on the number of participants acquiring
azithromycin-resistant bacteria (6 in AZM group versus 4 in placebo group).
4Data from Figure 2 in Berg 2005. Only the percentages of participants with macrolide-resistant bacteria are reported. We used the
number of participants randomised and screened for culture of pathogens (N = 148 in both groups) to calculate the number of
participants in each group.
5Data from Table 4 in Berkhof 2013.
6A subsample of participants (42%) was tested for resistant bacteria.
7Data from Table S8 and Table S9 in Gibson 2017. We only present data from nose swabs, as the same bacteria may be identified in
the various samples (sputum, throat, nose). A subsample of participants was tested for resistant bacteria.
8Data from Table 3 in McCallum 2015. We have reported on any of the macrolide-resistant bacteria.
9Report on people who contracted Mycobacterium avium complex infections.
10Data on mothers from Table 3 in Roca 2016a. We only present data from mothers’ nasopharyngeal swabs, as the same bacteria may
be identified in the various samples (nasopharynx, milk, vagina).
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11Data from Table 4 in Saiman 2010. Report on treatment-emergent bacteria at day 168. Not possible to calculate the percentage of
resistant bacteria at day 168, as the given denominator varies for each reported micro-organism.
12Data from Table 4 in Sirinavin 2003. Report on participants with a Salmonella isolate. The denominator (number with available
data) varied significantly (range 3 to 98) at days 7, 30, 60, and 90.
13Data from supplementary Table 2 in Uzun 2014. Number of participants with sputum samples used as denominator.
14Data from Table 4 in Valery 2013.
15Data on post-intervention macrolide-resistant bacteria are from Table 3 in Hare 2015, a secondary study of Valery 2013.
Table 4. Isolates with macrolide-resistant bacteria
Isolates with macrolide-resistant bacteria1 : 8 studies
Study ID Type of
macrolide
(days of
treatment)
Time for
follow-up
swabs
Macrolide-resistant
bacteria at baseline
N (%)
Macrolide-resistant
bacteria after treatment
2N (%)
Abso-
lute increase in
resistance
with antibiotic
(%)
Rela-
tive increase in
resistance
with antibiotic
(%)
Macrolide Placebo Macrolide Placebo
Albert 2011
3
AZM (365) At en-
rolment and
every 3
months
23 (52) 28 (57) 38 (81) 44 (41) 35 -8
Altenburg
20134
AZM (365) Week 12
and 64 + ex-
acerbations
7 (35) 8 (28) 53 (88) 29 (26) 55 9
Berg 20055 CLM (16*) “After ther-
apy”
27 (35) 33 (38) 51 (66) 40 (45) 18 -7
Lildholdt
20036
AZM (183) Week 26 1 (2) 0 2 (14) 0 12 7
Week 43 1 (6) 0 6 3
Week 60 1 (9) 0 9 5
Week 78 0 0 0 0
Seemungal
20087
ERY (365) 12 months 0 0 1 (4) 0 4 N/A
Tita 2016 AZM (1) Postpartum N/A N/A 3 4 N/A N/A
Videler
2011
AZM (84) Day 84 2 (4) 1 (2) 1 (2) 3 (7) 3 -3
Wilson
1979
ERY (7) “Post-
treatment”
0 0 0 0 0 N/A
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Brill 2016 [pers comm] report via email correspondence on both the number of participants with resistant bacteria and the number of
resistant isolates (unpublished data). We contacted the author again for information on what type of resistant bacteria they report
on (macrolide-resistant or ‘others’), and are awaiting author reply.
VanDelden 2012 state that azithromycin exposure did not lead to anMIC increase comparing the initial and last Pseudomonas aeruginosa
isolates. Data not shown.
Abbreviations:
AZM: azithromycin.
CLM: clarithromycin.
ERY: erythromycin.
MIC: minimum inhibitory concentration.
N/A: not available.
*Mean duration of treatment.
1Bacterial isolates tested vary between studies. The most common ones were: Staphylococcus aureus,Streptococcus pneumoniae,Moraxella
catarrhalis, andHaemophilus influenzae.
2Some studies report on macrolide-resistant bacteria during treatment.
3The denominator varies. At baseline: cultures from participants who had selected respiratory pathogens cultured at enrolment. During
course: cultures from participants who became colonised with selected respiratory pathogens during the course of the study. Note: a
much larger number of participants were colonised in the placebo group compared to the azithromycin group during the course of
treatment (range: 44 to 108).
4Data from supplementary online content, eResults from Altenburg 2013. Number of pathogens tested is used as denominator.
5Data from Table 3 in Berg 2005. Denominator: total number of oropharyngeal Haemophilus parainfluenzae strains (sensitive, inter-
mediate, resistant).
6Data from Table 2 in Lildholdt 2003. Denominator: number of positive cultures (range: 6 to 47).
7Report on one resistant Streptococcus pneumoniae, and state that all Haemophilus influenzae were resistant or assumed constitutionally
resistant to erythromycin.
Table 5. Proportion of macrolide-resistant streptococci
Proportion of macrolide-resistant streptococci1 isolates: 3 studies
Study ID Type of
macrolide
(days of
treatment)
Time for
follow-up
swabs
Proportion of resis-
tant
streptococci at base-
line
Proportion of resistant
streptococci after treat-
ment
Abso-
lute increase in
resistance
with antibiotic
(%)
Rela-
tive increase in
resistance
with antibiotic
(%)
Macrolide Placebo Macrolide Placebo
Brusselle
20132
AZM (182) Day 30 18 11 52 10 35 6
Day 180 74 18 49 8
Day 210 44 12 25 5
Malhotra-
Kumar
2007a3
AZM (3) Day 4 26 28 87 33 52 -27
Day 8 83 34 47 -25
Day 14 83 34 47 -25
Day 28 80 33 45 -24
322Adverse events in people taking macrolide antibiotics versus placebo for any indication (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 5. Proportion of macrolide-resistant streptococci (Continued)
Day 42 67 36 29 -16
Day 180 46 23 21 -12
Malhotra-
Kumar
2007b4
CLM (7) Day 8 30 25 81 31 45 10
Day 14 71 31 35 8
Day 28 63 30 28 7
Day 42 59 28 26 6
Day 180 43 21 17 4
Serisier
20135
ERY (336) Week 48 N/A N/A 29 0 N/A N/A
Abbreviations:
AZM: azithromycin.
CLM: clarithromycin.
ERY: erythromycin.
N/A: not available.
1Denominator: number of streptococci.
2Data from Figure S3 in Brusselle 2013. A subsample of participants (42%) was tested for resistant bacteria.
3Data from Figure 2 in Malhotra-Kumar 2007a. Note that only about 47% of participants attended follow-up on day 180.
4Data from Figure 2 in Malhotra-Kumar 2007b. Note that only about 47% of participants attended follow-up on day 180.
5Data from eTable 2 in Serisier 2013. Results are presented for the intention-to-treat population. Report on median change in the
proportion of macrolide-resistant streptococci.
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) and Cochrane Central Register of Controlled Trials (CENTRAL)
search strategy
1 exp Macrolides/
2 macrolide*.tw,nm,ot.
3 (azithromycin* or clarithromycin* or erythromycin* or roxithromycin*).tw,nm,ot.
4 or/1-3
5 exp Placebos/
6 placebo*.tw,nm,ot.
7 5 or 6
8 4 and 7
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Appendix 2. Embase (Elsevier) search strategy
#13 #8 AND #11 AND [1-1-2010]/sd NOT [22-8-2015]/sd (690)
#12 #8 AND #11 (2,267)
#11 #9 OR #10 (1,401,271)
#10 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR factorial:ab,ti OR volunteer*:ab,ti OR allocat*:ab,ti
OR assign*:ab,ti OR ((singl* OR doubl*) NEAR/2 blind*):ab,ti AND [embase]/lim (1,246,381)
#9 ’single blind procedure’/de OR ’double blind procedure’/de OR ’crossover procedure’/exp OR ’randomized controlled trial’/de
(421,654)
#8 #4 AND #7 (5,008)
#7 #5 OR #6 (328,717)
#6 placebo*:ab,ti AND [embase]/lim (204,119)
#5 ’placebo’/de AND [embase]/lim (263,844)
#4 #1 OR #2 OR #3 (129,809)
#3 azithromycin*:ab,ti OR clarithromycin*:ab,ti OR erythromycin*:ab,ti OR roxithromycin*:ab,ti AND [embase]/lim (31,108)
#2 macrolide*:ab,ti AND [embase]/lim (14,020)
#1 ’macrolide’/exp AND [embase]/lim (126,714)
Appendix 3. CINAHL (EBSCO) search strategy
S19 S8 AND S18
S18 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17
S17 (MH “Quantitative Studies”)
S16 TI placebo* OR AB placebo*
S15 (MH “Placebos”)
S14 (MH “Random Assignment”)
S13 TI random* OR AB random*
S12 TI ( (singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*) ) OR AB ( (singl* or doubl* or tripl* or trebl*) W1 (blind* or
mask*) )
S11 TI clinic* trial* OR AB clinic* trial*
S10 PT clinical trial
S9 (MH “Clinical Trials+”)
S8 S4 AND S7
S7 S5 OR S6
S6 TI placebo* OR AB placebo*
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(Continued)
S5 (MH “Placebos”)
S4 S1 OR S2 OR S3
S3 TI ( azithromycin* or clarithromycin* or erythromycin* or roxithromycin* ) OR AB ( azithromycin* or clarithromycin* or
erythromycin* or roxithromycin* )
S2 TI macrolide* OR AB macrolide*
S1 (MH “Antibiotics, Macrolide+”)
Appendix 4. LILACS (BIREME) search strategy
(mh:macrolides OR macrolide* OR macrólidos OR macrolídeos or mh:d02.540.505* OR mh:d02.540.576.500* OR mh:
d04.345.674.500* OR mh:azithromycin OR azithromycin* OR azitromicina OR mh:d02.540.505.250.050* OR mh:clarithromycin
OR clarithromycin* OR mh:claritromicina* OR mh:d02.540.505.250.100* OR mh:erythromycin OR erythromycin* OR eritromic-
ina or mh:d02.540.505.250* OR mh:roxithromycin OR roxithromycin* OR roxitromicina OR mh:d02.540.505.250.630*) AND
(mh:placebos OR placebo*)
Appendix 5. Web of Science (Clarivate Analytics) search strategy
#6 71 #4 AND #3
Refined by: publication years: (2015 OR 2016 )
Indexes = SCI-EXPANDED, SSCI,A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
#5 1254 #4 AND #3
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
#4 1,797,642 TOPIC: (random* or placebo* or crossover* or “cross over” or allocat* or ((doubl* or singl*) NEAR/1 blind*))
OR TITLE: (trial)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
#3 1254 #2 AND #1
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
#2 198,122 TOPIC: (placebo*)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
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(Continued)
#1 40,012 TOPIC: (macrolide* or azithromycin* or clarithromycin* or erythromycin* or roxithromycin*)
Indexes = SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EX-
PANDED, IC Timespan = 1985-2016
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The review differs from the protocol, Hansen 2015, in the following ways.
Objectives and Types of outcome measures: while conducting this review we realised that it would be most appropriate to present
each of the specific reported adverse events separately. Consequently, instead of handling the adverse events as adverse effects, adverse
reactions, and serious adverse events, as stated in the protocol, we have presented each of the adverse events separately.We have reported
on adverse events that occurred in≥ 5% in any of the groups (macrolide or placebo) (Zarin 2016). However, all reported adverse events
are available: adverse events by System Organ Classes: threshold ≥ 5%, Hansen 2018a, and adverse events by System Organ Classes <
5%, Hansen 2018b.
Trial authors very seldom referred to a specific definition of how they classified severe adverse events, and consequently we did not find
it appropriate to report these as a composite outcome labelled ’severe adverse events’. However, every single adverse event reported in
all of the included studies, regardless of how it was labelled by the trial authors, was extracted, and data are available (Hansen 2018a;
Hansen 2018b).
’Subsequent carriage of resistant bacteria’ has been refined to ’subsequent carriage of macrolide-resistant bacteria’.
Types of studies: we clarified that we included trials with more than two intervention arms, if it was possible to identify a macrolide arm
and a placebo arm. After the protocol was published, we decided to exclude purely pharmacodynamic and pharmacokinetic studies,
unless they also reported clinical parameters. We also excluded studies with fewer than 20 participants randomised to each arm. We
made these decisions after starting the title and abstract screening, when we realised that many of these small pharmacodynamic or
pharmacokinetic studies posed a high risk of reporting drug-drug interactions of macrolides or non-macrolide-related adverse events.
Searching other resources and Dealing with missing data: in the protocol we stated that we would contact authors of trials if adverse
events data were not published. However, as this evolved into an unexpectedly large review with generally very poor reporting of
adverse events, we contacted only trial authors if adverse events were incompletely reported and an e-mail address was available in the
publication.
Data collection and analysis: we stated in the protocol that MPH and ST would assess all studies identified by the searches, extract data,
and assess risk of bias for each of the included studies. However, the size of the review necessitated involvement of additional authors.
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ST participated in the process of selecting studies, while both AMcC and AMS participated in the selection of studies, data extraction,
and ’Risk of bias’ assessments. Uniform data collection was ensured by the participation of MPH at all stages and by having CDM as
the third review author in resolving any discrepancies.
Measures of treatment effect: in the protocol we planned to express all outcomes as Peto odds ratios (OR) as we expected that the
included trials would report on few adverse events. However, Peto OR mandates fixed-effect models, which would not be appropriate
to apply to our data as several sources of heterogeneity that might undermine the use of a fixed-effect approach exist in this review.
Unit of analysis issues: we deviated from the protocol by including both participants and bacterial isolates as units of analysis when
reporting subsequent carriage of macrolide-resistant bacteria.
Data synthesis: as trial authors used a wide range of terms when reporting adverse events, we categorised the reported adverse events
using a clinically validated, standardised medical classification system, the Medical Dictionary for Regulatory Activities (MedDRA).
We added a section describing the classification system to the review and how we analysed adverse events. To deal with an enormous
long tail of (mostly irrelevant) adverse events described in tiny numbers, we decided that we would undertake a meta-analysis when ≥
3 studies reported a specific adverse event.
Subgroup analysis and investigation of heterogeneity: as in the case of meta-analyses of the primary outcomes, at least three studies
were required for subgroup analyses.
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